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Abstract 
Studies in our laboratory have established that the route of vaccination, viral 
vector and the cytokine milieu, specifically IL-13 can critically impact the vaccine-
specific adaptive immune outcomes. Recent efforts in understanding which cells 
at the vaccination site produced IL-13 revealed that innate lymphoid cells (ILC)2 
were the major source of this cytokine at the vaccination site 24h post delivery. 
Knowing that manipulating IL-13 levels at the vaccination site also significantly 
altered resident lung dendritic cell (DC) recruitment, this study focused on 
dissecting the underlying mechanisms by which ILCs and DCs regulated vaccine-
specific immunity at the lung mucosae following intranasal vaccination. 
 
Poxviral and non-poxviral vaccine vectors induced uniquely different ILC-derived 
cytokine and DC profiles at the lung mucosae, 24 h post vaccination. For 
example, rFPV priming known to induce high avidity T cells, exhibited low ILC2-
derived IL-13, high ILC1/ILC3-derived IFN-g and enhanced recruitment of 
CD11b+ CD103- conventional DCs (cDC). Whereas, rMVA, rVV and Influenza A 
vector priming, linked to low avidity T cells, induced opposing ILC-derived 
cytokine profiles, together with enhanced CD11b- CD103+ cross-presenting DCs 
and reduced cDCs. Interestingly, Rhinovirus (RV) and Adenovius type 5 (Ad5) 
vectors, also showed different ILC-derived cytokine profiles and predominant 
recruitment of CD11b- B220+ plasmacytoid DCs (pDC). Knowing that cDCs are 
associated with high avidity CD8 T cell priming and pDCs are involved in antibody 
differentiation, these findings showed that vaccine derived early ILC/DC profiles 
directly impact the downstream adaptive immune outcomes. 
 
  X 
When trying to unravel how IL-13 signalling modulated these vaccine-specific 
adaptive immune outcomes, unlike IL-13Ra1, IL-13Ra2 was found to be the 
major sensor and regulator of early IL-13 mediated DC activity. For the first time 
a dual role of IL-13Ra2 was unraveled on lung cDC, where low IL-13 was 
associated with IL-13Ra2 signalling via STAT3 activating TGF-b1, whilst, high IL-
13 triggered sequestration by the same receptor. Interestingly, in this study 
differential IL-13 receptor mediated STAT3/STAT6 paradigms were observed, 
regulated collaboratively or independently by TGF-b1 and IFN-g. Low IL-13 driven 
early IL-13Ra2/STAT3 responses were regulated primarily by TGF-b1, whereas, 
high IL-13 driven IL-13Ra1/STAT6 responses were associated with IFN-gR 
expression bias. Moreover, inherent properties of viral vaccine vectors (host 
tropism, replication status and presence or absence of immunomodulatory 
genes), were also found to significantly alter the IL-4/IL-13 receptor regulation on 
lung DCs, in a time dependent manner. Specifically, the generation of a balanced 
adaptive immune outcome was associated with early regulation of IL-13Ra2, 
succeeded by IL-13Ra1/ IL-4Ra on lung DCs, as observed with rFPV vaccination 
unlike the other poxviral vectors tested.  
 
Collectively, findings of this thesis for the first time demonstrated the importance 
of understanding the mechanisms of IL-13 mediated DC regulation, at the 
vaccination site. Therefore, knowing these innate mechanisms associated with 
ILC/DC regulation may help design more efficacious vaccines and therapeutics 
against IL-13 related disease conditions. 
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Chapter 1 
 
General Introduction 
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 3 
1.1 The immune system  
The immune system is mainly comprised of two compartments, the innate and 
the adaptive systems. The innate immune system contains physical, chemical 
barriers, and immune cells which serve as the first line of defence against 
invading pathogens. Skin and mucous membranes are strategically placed 
externally on the body to prevent entry of pathogens or toxins 1, whereas mucus, 
digestive enzymes, antimicrobial peptides and complement proteins have the 
ability to prevent microbes from establishing infection 2. Whilst innate immune 
system initiates non-pathogen-specific defence, the adaptive immune system 
(comprising of specialized cells such as lymphocytes), initiates pathogen-specific 
or antigen-specific memory T and B cell immunity.  
 
1.2 Innate immune cells 
Cells of the innate immune system can be of both haematopoietic as well as non-
haematopoietic origin. Haematopoietic cells include mast cells, macrophages, 
neutrophils, eosinophils, natural killer (NK) cells, NKT cells, innate lymphoid cells 
(ILCs) and dendritic cells (DCs). Non-haematopoietic immune cells comprise of 
epithelial cells on various tissues like the skin and the gastrointestinal tract 3. 
Innate immune cells use germline-encoded broadly specific pattern recognition 
receptors (PRRs) such as Toll-like receptors (TLRs) and NOD-Like receptors 
(NLRs) to recognize conserved and invariant surface molecules called pathogen 
associated molecular patterns (PAMPs) on pathogens 4-6, and activation of these 
cells can induce various inflammatory immune responses. Cells such as 
macrophages, neutrophils and DCs can employ phagocytosis by which 
pathogen-derived particles are engulfed by phagocytes to cause degradation and 
antigen processing and subsequent presentation to T and B lymphocytes 7. Other 
 4 
cells such as NK cells can also employ cytotoxic lytic granules to kill recognized 
pathogens or infected target cells 8. Most PRR activated innate immune cells also 
lead to secretion of pro-inflammatory cytokines/ chemokines and antimicrobial 
proteins to orchestrate the local and systemic inflammatory responses such as 
recruitment of macrophages to secrete antimicrobial proteins and peptides or 
activate complement factors for opsonization of the pathogen 5. These innate 
immune responses perform as the first line of defence and also subsequent 
activation of the adaptive immune system.  
 
1.3 Mucosal immune system 
The mucosal immune system is comprised of sensory organs (eyes, nose, mouth 
and throat), lungs, gastrointestinal tract, genito-rectal tract (Figure 1.1) and is the 
first line of defence against pathogens. The mucosal immune system can employ 
both physical barriers and specialized immune responses to combat infection. 
Mucous produced by mucosal epithelial cells forms a protective layer, whilst 
epithelial cilia use beating movement to prevent pathogen infection 9,10. Chemical 
agents such as defensins and antimicrobial peptides are also secreted by the 
mucosal epithelium to degrade pathogenic particles 9,11,12. Interestingly, 
according to the site of pathogen encounter the immunity generated at the local 
and distal mucosal compartments can be vastly different (eg. nasal vs oral or 
rectal) 13.  
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The mucosal immune system is perceived as a holistic global organ called the 
common mucosal immune system containing a complex network of epithelial 
cells, innate and adaptive immune cells including an extensive microbiota. The 
mucosa-associated lymphoid tissue (MALT) is mainly comprised of the nasal-
associated lymphoid tissue (NALT), bronchus-associated lymphoid tissue 
(BALT), gut-associated lymphoid tissue (GALT), and the uro-genital-associated 
lymphoid tissue 9,14. Functionally, MALT is divided into inductive sites, comprising 
of naïve lymphocytes and antigen presenting cells and effector sites, which 
consists of activated T and B cells. Principally the inductive sites, such as Peyer’s 
patches in the gut, are fortified by specialised epithelial cells called microfold (M) 
cells, unique to mucosal surfaces. M cells have a unique ability to uptake and 
transport pathogen-derived antigens from the apical surface to the basolateral 
surface of the epithelium causing antigen uptake by antigen presenting cells 
(APCs), specifically DCs (Figure 1.2), which then present antigen to naïve 
lymphocytes at the inductive sites. Activated DCs can also migrate to draining 
lymph nodes, initiate activation and migration of lymphocytes to effector sites 
(such as lamina propria in the gut) via lymph vessels to initiate pathogen 
clearance (Figure 1.2) 15-17.  
 
In the context of lungs, antigenic exposure triggers tertiary lymphoid tissue 
organized into inducible bronchus-associated lymohid tissue (iBALT) (Figure 
1.3). iBALT is commonly formed in the lower airway lung parenchyma, specifically 
areas underlying the bronchial epithelium 18,19. Similar to conventional secondary 
lymphoid structures, iBALT is also compartmentalized into distinct B and T cell 
follicles where lymphocyte differentiation and maturation occur 20. However, 
interestingly, unlike in rats, iBALT areas in  
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humans and mice rarely exhibit presence of M cells 21,22. In these areas, 
lymphocyte trafficking majorly occurs via the lymphatics. Specifically, antigen 
uptake and transport of naïve lymphocytes into iBALT from the blood 
compartment is carried out by the afferent lymphatics, especially the high 
endothelial venules (HEVs) 23,24. Transport of antigen expressing DCs as well as 
primed T and B cells into the circulation is performed by the efferent lymphatics 
25,26. 
 
1.4. Dendritic cells 
Dendritic cells are professional APCs, which play a central role in linking the 
innate and adaptive arms of the immune system by activating pathogen-specific 
adaptive immune responses. Immature or semi-mature DCs are strategically 
located at the first line of defence (skin, lungs, gut, genito-rectal tract and all 
mucous membranes) as well as the circulatory system 27. Pathogen encounter 
activates immature DCs to take-up/process antigens and migrate to the 
respective lymphoid tissues (e.g. Gut-associated DC to mesenteric lymph nodes, 
lung-associated DCs to mediastinal lymph nodes). Mature DCs then present 
processed antigens to CD8+ or CD4+ T cells via the Major Histocompatibility 
Complex MHC-I or MHC-II respectively 28-30. The cytokines and chemokines 
expressed by the different DCs, macrophages and other innate immune cells 
govern T cell polarization and differentiation. For example, in general IL-12 and 
IFN-g have been established to polarize the type I (Th1) phenotype; IL-4 and IL-
13 are associated with type II (Th2) responses 31-34 and IL-6 and TGF-b1 are 
known to induce Th17 cell differentiation 35. Interestingly, DCs can have both 
myeloid or lymphoid origins, which lead to two principle populations of DCs, 
classical or conventional DCs (cDCs) and plasmacytoid DCs (pDCs) (Figure 1.4) 
 10 
36. cDCs are further classified into migratory DCs such as Langerhans cells, 
dermal DCs and resident DCs which perform antigen uptake either from the 
periphery or the lymph nodes and present antigens in the draining lymph nodes 
37. Whilst, pDCs retain an immature phenotype at steady-state which upon 
activation can induce inflammatory factors including type 1 interferons (IFN) 38,39.  
 
1.4.1 Mucosal dendritic cells  
Mucosal DCs are found either in MALTs or in the mucosal surfaces 40-45. These 
DCs also have the unique ability to directly sample antigens by extending 
dendrites through the epithelium 46 or indirectly via M cells, goblet cells or in some 
cases via neonatal Fc receptors 47-49. DCs in the mucosae are mainly classified 
into two groups non-migratory DCs which are tissue resident, or migratory DCs 
which sample antigens and migrate to the draining lymph nodes 50,51. For 
example, in one of the most studied mucosal organs, the small intestine, tissue 
resident DCs co-expressing CX3CR1 and CD11b sample local circulatory or 
luminal antigens to activate intraepithelial lymphocytes. Whilst migratory 
CD11blow CD103+ CD8+ or CD11b+ CD103+ DCs are responsible for generation 
of other T cell responses like differentiation of Th1 immunity and activation of 
regulatory T cells respectively. Other major DC subsets found in the small 
intestine include TLR5+ DCs which activate Th1 and Th17 cells, and 
plasmacytoid DCs (pDCs) both of which generate IgA responses 52. Mucosal DCs 
have the unique ability to imprint T cells with tissue-specific homing markers. 
Specifically, during T cell priming, mucosal dendritic cells induce tissue-specific 
‘homing markers’ (for example a4b7 and CCR9 for gut homing 53 and CCR5, 
CXCR3, a4b1 and CCR4 for lung homing 54-56) on T cells 24,57,58. 
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These T cell homing markers (integrins and chemokines) have the unique ability 
to bind to their tissue-specific ligands/adhesion molecules expressed on mucosal 
sites to initiate tissue-specific homing of effector and memory T cells. For 
example, a4b7 can bind to mucosal addressin cell adhesion molecule-1 
(MAdCAM-1) present in gut, whereas, a4b1, can bind to VCAM-1 in lung or BALT 
55,59. More and more studies are showing that when designing vaccines against 
chronic mucosal pathogens such as HIV, TB or chlamydia, it is imperative to 
induce effective mucosal T cell homing to the site of first pathogen encounter 60-
66. Hence, different routes of mucosal delivery are now being considered, when 
designing vaccines against these pathogens.  
 
1.4.2 Lung-specific dendritic cells: role in infection and immunity 
Four major DC subsets are found in the murine lung namely, CD11b- CD103+ 
cross-presenting DCs, CD11b+ CD103- conventional DCs (cDCs), (both of which 
constitute phagocytic classical DCs), plasmacytoid DCs (pDCs) and inflammatory 
monocyte-derived DCs (moDCs) (Figure 1.5) 67-70. For many years, immune 
activation and virus-specific DC activity have been studied using many viruses, 
such as Influenza, Herpes Simplex virus 1, Respiratory Syncytial Virus (RSV) and 
poxviruses 71,72. Interestingly, the precise roles of different DC subsets following 
different viral infections still remain controversial. 
 
1.4.2.1 Cross-presenting DCs 
Two major cross-presenting DCs, namely CD11b- CD103+ and CD11b- CD8a+, 
are found in mouse lung, which share common developmental origins as well as 
functions. Both these DCs require Batf3 (Basic Leucine Zipper ATF-Like 
Transcription Factor 3), ID2 (Inhibitor of DNA Binding 2), IRF8 (Interferon  
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Regulatory Factor 8) for activation 73, and functionally, have the unique ability to 
present exogenous antigens (normally presented via MHC-II molecules) to CD8+ 
T cells via MHC-I molecules 74. Specifically, in the context of acute viral infections 
such as Influenza and vaccinia virus infections, cross-presenting DCs have 
shown to efficiently activate cytotoxic CD8+ T cells, essential for viral clearance 
69,75-77. However, these two cross-presenting DCs, have unique structural and 
functional features. Specifically, CD11b- CD103+ cross-presenting DCs, more 
predominant in the lung, reside at the lung interface and sample exogenous 
antigens 78, as well as have the ability to process large quantities of apoptotic 
cells 79,80. In contrast, CD11b- CD8a+ cross-presenting DCs, which are lymph 
node resident 73, have the ability to extend dendrites to sample antigens from 
lymphatics or the blood compartment and also acquire transferred antigens from 
CD11b- CD103+ DCs at the draining lymph nodes using a process known as 
cross-dressing 81-83.  
 
1.4.2.2 Conventional DCs 
CD11b+ CD103- cDCs are normally located in the lung parenchyma, below the 
basement membrane. At steady state, compared to cross-presenting DCs, fewer 
cDCs are found in the lung tissue. Developmentally, CD11b+ CD103- cDCs are a 
heterogenous population, activated by major transcription factors IRF2 and IRF4 
74. In addition to enhanced expression of MHC-II, CD11c and CD11b, cDCs have 
also been shown to express CD24 and CD86 in mice 84,85. Despite having some 
overlapping functions with other classical DCs, some functions are unique to lung 
cDCs. Specifically, after resolution of respiratory viral infections, cDCs perform 
maintenance of iBALT function 86. Furthermore, cDCs are more adept at 
processing and presenting soluble antigens compared to other classical DCs 87. 
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Upon antigen uptake, cDCs majorly express antigens via MHC-II to CD4+ T cells 
88, although in some cases such as severe Influenza infection, CD11b+ cDCs 
have also been shown to potentiate CD8+ T cells 89 90.  
 
1.4.2.3 Plasmacytoid DCs 
pDCs, upon activation, infiltrate into the lung tissues and are distributed in the 
lung airways. In contrast to classical DCs, pDCs are pre-DCs and do not exhibit 
the classical ‘DC form’. pDCs specifically express TLR7 and TLR9 molecules, 
responding to a defined repertoire of PAMP signals. In addition to expressing low 
or no CD11b, pDCs also express surface markers B220, Ly6c, siglec-H along 
with low MHC-II in mice. pDCs are activated by transcription factors E2-2 
(belonging to the E protein family) and IRF8 70,91-93. Unique pDC properties 
include secretion of type I Interferons, specifically IFN-a in the context of 
Influenza and RSV infection 94-96. Type I IFN production by pDCs have also 
shown to activate virus mediated B cell differentiation and hence development of 
antibody responses 97. Studies using systemic Herpes Symplex Virus (HSV) 
infection have shown that in addition to being interferon producers, pDCs are 
important activators of NK cells and CD8+ T cells 98. 
 
Unlike in acute viral infection, in the context of recombinant viral vector-based 
vaccination, CD11b- CD103+ cross-presenting DCs have been associated with 
induction of low avidity vaccine-specific CD8+ T cells whereas CD11b+ CD103-
cDCs have been associated with high avidity T cell immunity 99. Knowing that 
pDCs are associated with effective antibody responses 97, understanding the 
regulation of these three lung DC subsets at the lung mucosae (vaccination site) 
immediately post intranasal vaccination forms the basis of this thesis.  
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1.5 Importance of Mucosal vaccination  
It is now well established that the route of vaccination can significantly influence 
the resulting local and distal immune responses. Both systemic and mucosal 
vaccination have been historically used against mucosal pathogens 100. 
Interestingly, although systemic vaccination can induce effective immunity at the 
blood compartment, it has shown to be ineffective at inducing long lasting 
mucosal immunity 101. For example, intramuscular vaccination has shown to 
promote mucosal immunity against certain mucosal pathogens such as Bovine 
respiratory syncytial virus, bovine rotavirus and H5N1 102-105, but have elicited 
poor immune outcomes against chronic mucosal pathogens such as HIV-1, 
tuberculosis and chlamydia 102. This has been mainly associated with poor T cell 
homing to the mucosae post systemic delivery, where the pathogen is first 
encountered 53,106. Thus, vaccine strategies that can induce immunity at the local 
and distal mucosae are important for control of these infections, specifically 
strategies that can induce effective long lasting mucosal T cell immunity as well 
as IgA responses 107-111. Different mucosal routes of vaccination for example 
intranasal, oral, intrarectal, intravaginal and intraocular have shown to induce 
immunity at different local and distal mucosae. Specifically, intranasal (i.n.) 
vaccination has been more successful at generating immunity in the upper 
respiratory tract, gut, as well as the genito-rectal mucosae 112-114 (Figure 1.6a). 
Whereas, oral vaccination has shown to induce immunity in the salivary glands, 
mammary glands, gut mucosae and in some instances at the rectal tract 113. 
Vaginal vaccination has shown to induce immunity in the local mucosae, 
whereas, rectal vaccination has shown to induce immunity at the local rectal as 
well and the gastro-intestinal mucosae 115-117. It is  
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now well established that these differential immune responses are mainly 
governed by the activation of unique tissue-specific mucosal DCs promoting 
tissue-specific T cell and B cell homing 24,57,58. 
 
1.5.1 HIV vaccines and mucosal immunity 
In the context of HIV, despite being a disease of the mucosae, no mucosal HIV 
vaccine strategy has yet been tested in humans. All the systemic vaccination 
approaches tested in human clinical trials have yielded poor outcomes 118-121, 
except the RV144 trial showing marginal efficacy with 31.2 % protection 121. Over 
two decades of work in animal models (both in mice and macaques) have shown 
that HIV mucosal vaccination strategies can induce promising long lasting 
protective immunity 122-124. Studies by Belyakov et al. and studies in our laboratory 
have shown that intrarectal vaccination approaches can induce effective HIV-
specific cytotoxic CD8+ T cells at the mucosae both in mice and non-human 
primates, and established the importance of mucosal cytotoxic CD8+ T cells in 
prevention of viral dissemination and protection against HIV 102,107,125-129. Several 
decades of work, trying to understand why systemic vaccines were failing in 
clinical trials, Ranasinghe et al. were the first to show that, compared to a purely 
systemic approach, a purely mucosal or mucosal/systemic prime-boost 
vaccination regimen (i.n./i.m. prime poxviral vector-based HIV vaccine approach) 
can induce high avidity HIV-specific T cell immunity 130. They showed that these 
responses were mainly associated with the expression of IL-4/IL-13 by cytotoxic 
CD8+ T cells, where systemic vaccination was shown to induce elevated IL-4/ IL-
13 production compared to mucosal delivery 130-132 (Figure 1.6b). Recent studies 
in the laboratory have shown that, HIV vaccines that transiently block IL-4/IL-13 
activity at the vaccination site can lead to high avidity/poly-functional cytotoxic T 
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cells in murine and macaque models 122-124 (Li et al. in preparation). Moreover, in 
addition to the route of delivery and cytokine cell milieu in a prime-boost vaccine 
modality, the choice of vaccine vector, specifically the priming vector was also 
shown to significantly impact avidity/poly-functionality of T cells 131,133. Thus, 
understanding how these factors (specifically, IL-3 levels and viral vectors) 
influence adaptive immune outcomes at the innate immune level forms the basis 
of this thesis.  
 
1.6 Viral vectors: poxviral vector-based vaccines 
For many decades, viral vectors such as poxviruses have been promising 
vaccine delivery vehicles 134-140. Their unique ability to contain large amounts of 
foreign genetic material without loss of viral function or host cell infectivity, and 
the ability to express these genes/antigens at high concentrations, enabling the 
induction of robust pathogen-specific cellular and humoral responses, have made 
these vectors popular vaccine candidates, specifically in prime-boost vaccine 
modalities 99,121,130,141-145. 
 
1.6.1 Recombinant vaccinia virus-vectored vaccines 
Vaccinia virus (VACV) has been the most studied poxvirus in the context of 
vaccine design. Historically, several VACV strains have been used as smallpox 
vaccines, which ultimately lead to smallpox eradication 146-148 149-151. Different 
VACV strains with improved safety, reduced pathogenicity and high 
immunogenicity have been used as recombinant vaccines for pathogens, for 
which effective vaccine strategies are not yet available, for example HIV-1, 
hepatitis, tuberculosis and malaria 152-157. In the context of HIV-1, recombinant 
Tiantan Vaccinia virus (rTV), Copenhagen derived New York Vaccinia Virus 
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(NYVAC) 158-162 and recombinant Modified Vaccinia Ankara (rMVA) have been 
tested in different prime-boost vaccine modalities (rDNA/viral; protein/viral; 
viral/protein). 148,163-166. Mucosal delivery of rTV, NYVAC and rMVA have also 
been tested and have shown some promising mucosal HIV-specific T cell 
outcomes 128,162,167,168.  
 
1.6.2 Recombinant MVA-based vaccines 
MVA was first derived from the Chorioallantoic Vaccinia Ankara (CVA) strain after 
extensive serial passaging of the virus in cell culture 164,165. The resultant MVA 
was known to be replication deficient and non-pathogenic in most mammalian 
cells rendering the virus extremely safe in humans as a vaccine vector 169,170. 
Additionally, due to its intrinsic adjuvant abilities and capacity to induce robust 
cellular and humoral immune responses, recombinant MVA (rMVA) vector-based 
vaccines were extensively studied against many pathogens such as HIV-1, 
Mycobacterium tuberculosis, Malaria and Hepatitis B 148,154,171,172. Interestingly, 
i.m. rDNA prime/i.m. rMVA booster vaccination strategies were one of the first to 
be tested against HIV. Although these vaccines were found to be effective in 
animals models 173-176, due to the poor uptake of rDNA, as well as inability to 
induce long lasting mucosal immunity 177,178, rDNA vaccine strategies resulted in 
poor immune outcomes in Phase I clinical trials, similar to other systemic rDNA-
based vaccine strategies in the early 2000s 129,144,163,179-181. In later studies, even 
though mucosal delivery of rMVA-based HIV vaccines has yielded some 
promising outcomes in mice and macaques 167,182, rMVA mucosal vaccine 
strategy has not yet been trialed in humans. Additionally, Esteban et al. were the 
first to design a range of rMVA deletions mutants, rendering the vaccine more 
effective and safe by removing vector-specific immune evasive genes 137, such 
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as IL-1b receptor, IL-18 binding protein, C6L (genes associated with type I IFN 
signaling), or F1L, (involved in apoptosis). Interestingly, these mutants were 
shown to induce HIV-specific immune outcomes in animal models compared to 
parental rMVA 183-186.  
 
1.6.3 Recombinant avipoxvirus vector-based vaccines 
Avipoxvirus vectors, such as canarypox and fowlpox, which cannot replicate in 
mammalian hosts, rendering them extremely safe in humans, have also been 
studied as recombinant vaccine vectors 187-189. In the context of HIV vaccine 
design, recombinant canarypoxvirus (known as ALVAC,) and the close relative 
recombinant fowlpox virus (rFPV) vaccine strategies have been well studied 190-
196. Interestingly, the only HIV vaccine trial that have been partially successful in 
humans, the RV144 trial (31.2% reduction in HIV-1 infections in vaccine 
recipients), used an ALVAC prime followed by HIV gp120 protein booster strategy 
121. This partial protection was correlated with antibody dependent cell mediated 
cytotoxicity (ADCC) and HIV envelope-specific non-neutralizing antibody 
responses elicited by this vaccination approach 197-201. This partial success 
renewed the interest in recombinant poxviral vector-based approaches as 
potential HIV vaccine candidates.  
 
FPV was first used as a vaccine against fowlpox in chickens and was later used 
as a vehicle to deliver antigens against other poultry diseases such as avian 
influenza, Newcastle disease and infectious bronchitis 202. Boyle et al. were the 
first to use rFPV vectors as a vaccine strategy against HIV 135,193,203. The initial 
prime-boost vaccination strategy, using pure intramuscular (i.m.) rDNA prime/ 
rFPV booster, although showed promising immune outcomes in mice and 
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macaques 129,191,193,204,205, unfortunately failed in Phase I clinical trials 144. 
However, these trials clearly established that rFPV was extremely safe in humans 
144,204. Later rDNA prime followed by rFPV co-expressing HIV antigens together 
with co-stimulatory molecules or cytokines including IFN-g,  IL-12, 4-1BBL), 
although were found to enhance immunogenicity/vaccine efficacy in murine and 
macaque models 131,206-213, co-expression of IFN-g  and  IL-12 were later found to 
be ineffective in humans 204,214. Interestingly, despite disappointing outcomes 
with i.m. rDNA/i.m. rFPV systemic vaccination strategy in human clinical trials 144, 
i.m. rDNA/i.n. or rectal rFPV strategies were found to induce better protective 
efficacy in non-human primates compared to pure systemic delivery 129. These, 
together with later studies revealed that rFPV was an excellent mucosal delivery 
vector 131,205. These studies also demonstrated that compared to rDNA/viral 
vector-based vaccine strategies viral/viral prime-boost modalities could induce 
better poly-functional long lasting T cell immunity 215-218. Specifically, i.n. rFPV 
prime followed by i.m. rVV or rMVA booster strategies were shown to generate 
sustained mucosal and systemic HIV-specific high avidity/poly-functional CD8+ T 
cells both in mice and macaques 123,130,131, unlike the inverse strategies 131,133 
(Ranasinghe, personal communication) (Figure 1.7) eliciting, not only the route 
of delivery 130,131,205, but also the order in which these viral vectors are delivered 
in a prime-boost modality, played an important role in modulating the final 
vaccine-specific adaptive immune outcomes 133. 
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1.7 Non-poxviral vector-based vaccines 
Apart from poxviruses, many other viruses have also been used as vectors to 
deliver vaccine antigens. Among the non-poxvirus recombinant vector-based 
vaccines, Cytomegalovirus, Sendai virus, Lentiviruses, Polio-virus, different 
retroviruses, adenoviruses, Influenza virus, Human Rhinoviruses have been used 
in many major pre-clinical and clinical vaccine trials 136,138,219-222.  
 
1.7.1 Recombinant Adenovirus vector-based vaccines 
In the context of HIV vaccine design, several recombinant Adenovirus (Ad) 
vectors have also been found to induce high immunogenicity in animal models 
140,219,222,223. Recombinant Adenovirus serotype 5 (rAd5) was used in the STEP/ 
Phambili HIV clinical trials with great anticipation of success in 2008 118,119. Even 
though the vaccine strategy induced robust HIV-specific cellular and neutralizing 
antibody responses in mice and non-human primate models 224-227, Phase I 
STEP/Phambili trials had to be unexpectedly hauled due to vector-specific 
immunity in humans leading to increased HIV acquisition 118,228. Since then, 
several other non-human related and modified rAd vectors, for example Ad26, 
Ad35 and Chimpanzee Ad vectors, have been tested 223,229,230. In clinical trials, 
these modified rAd vectors have shown better safety profiles (reduced liver 
toxicity and anti-vector immunity) with promising cross-clade antibody responses 
231. Recent clinical trials by Barouch and colleagues using rAd26 HIV vaccination 
strategy in human clinical trials, although have shown ADCC and broad epitope-
specific Env antibody responses, have shown limited breadth of HIV-specific T 
cell immunity 232,233. Interestingly, using these rAd vectors, efforts are now being 
made to induce unique innate immune cell profiles to improve breadth and cross-
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reactivity of T cell response as well as Env-specific neutralizing antibody 
responses 225,234-238.  
  
1.7.2 Recombinant Influenza vector-based vaccines 
Influenza A has a broad host range inducing immune responses in many different 
animals and known to induce both Th1 and Th2 immunity, essentially eliciting 
both cellular and humoral immunity 239. Due to these properties, various live and 
inactivated recombinant Influenza A-based vaccine strategies have been tested 
against several pathogens, including HIV-1 138,239-242. Recombinant Influenza A 
expressing HIV Nef antigens used in an i.n. H1N1 prime/ i.n. H3N2 booster 
vaccination strategy in mice have shown to induce elevated Nef-specific systemic 
as well as mucosal CD8+ T cells (in the genito-rectal nodes) 242. Similarly, 
recombinant Influenza expressing HIV Env or Gag in a heterologous Influenza 
prime/ rVV booster modality have also shown enhanced antigen-specific CD8+T 
cells both in mice and macaques 138,243,244. Gherardi et al. have also shown that 
i.n. Influenza/i.n. or intraperitoneal (i.p.) rMVA or rVV booster strategy, can not 
only induce env-specific CD8+ T cells expressing IFN-g, but also env-specific 
IgG2a responses in mice 138. Moreover, Tan et al. have shown that compared to 
i.n. rFPV/ i.n. Influenza HIV prime-boost vaccine strategy, the inverse strategy 
can induce low avidity mucosal and systemic HIV-specific CD8+ T cells (Tan, 
Derose et al. personal communication), once again eliciting the importance of the 
choice of priming vector in prime-boost modalities.  
 
1.7.3 Recombinant rhinovirus vector-based vaccines 
Recently, recombinant human rhinovirus (rHRV)-based HIV prime-boost vaccine 
strategy was also tested in mice, specifically with the intention of inducing 
 28 
effective immunity at the first line of defence at the genito-rectal and gut mucosae. 
220. i.n.rHRV/ i.m. rDNA booster vaccination strategy expressing HIV Gag and Tat 
antigens was shown to induce enhanced poly-functional Gag- and Tat-specific 
systemic and mucosal (mesenteric lymph nodes) CD8+ T cell responses and also 
Tat-specific mucosal IgA and serum IgG antibodies in vaginal lavage and blood 
220,245.  
 
While the appetite to design new vaccine strategies using different recombinant 
viral vector-based vaccines are growing, how different recombinant viral vectors, 
expressing similar pathogen-specific genes/antigens induce vastly different 
adaptive immune outcomes still remains unanswered. Surprisingly, the 
mechanisms underpinning how these different vectors induce different vaccine-
specific immune outcomes, especially at the innate immune level, still remains 
poorly characterised, which this forms the main basis of this thesis.  
 
1.8. Role of cytokines in viral infection and immunity 
Activation of TLRs following an infection commonly signal in Myd88 dependent 
or independent pathways to activate downstream elements such as the 
Interleukin-1 receptor associated kinase (IRAK), Tumor necrosis factor receptor 
associated factor 6 (TRAF6), Interferon regulatory factor (IRF) and/or nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFkB), which in turn 
induce production of a plethora of pro-inflammatory cytokines such as type I IFN, 
Tumor necrosis factor (TNF)-a, Interleukin (IL)-1, IL-6, IL-8, depending on the 
pathogen encountered 246. Whilst the IFNs employ direct antiviral activities such 
as inhibiting replication of the virus, enhancing lysis of infected cells or activation 
of other pro-inflammatory cells such as macrophages 247,248, TNFs can enhance 
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vascular adhesion of inflammatory cells to promote antiviral responses 249. 
Furthermore, interleukins can promote both pro- and anti-inflammatory properties 
following binding specific receptors 250. Traditionally, whilst Th1 immune 
responses have been responsible for defence against intracellular pathogens 
such as viruses and bacteria, Th2 responses have known to be associated with 
extracellular infections, such as, helminths and also parasitic infections. In 
addition to Th1 and Th2 immunity, Th17 cells are also known to secrete IL-17 
and IL-22 in response to extracellular bacterial and fungal infections 251. Individual 
roles as well as inter-regulation between Th1 and Th2 immunity has been well-
documented in allergy/asthma, helminth infections as well as viral infections 252-
263. In the context of poxviral vector-based vaccination, IL-4 and IL-13 expression 
by antigen-specific CD8+ T cells have been directly linked to T cell avidity and 
protective efficacy 122-124,130-132 (Li et al. in preparation). 
 
1.8.1 IL-4 and IL-13 in disease and viral vector-based vaccine efficacy 
Th2 cytokines IL-4 and IL-13 have been extensively studied in disorders involving 
Th2 immunity including inflammatory conditions such as allergy and asthma, 
fibrosis, atopic dermatitis, tumor progression as well as parasitic infections 
255,257,264-269. In the context of allergic asthma, although IL-4 and IL-13 have shown 
overlapping functions such as IgE associated pathogenesis and eosinophil 
recruitment to the lung parenchyma, the two cytokines have also been associated 
with unique functions. Over-expression of IL-4 associated humoral immunity has 
been linked to Th2 inflammation 256,270, whilst IL-13 mediated activation of 
fibroblasts, goblet cell differentiation, smooth muscle contraction, mucous 
production and bronchial hyperresponsiveness has been associated with airway 
hyperreactivity and pathogenesis in allergic asthma 254. In the context of different 
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infections, IL-4 and IL-13 have also shown opposing as well as unique functions. 
For example, following N. brasiliensis infection, whilst IL-4 has been involved in 
promoting disease progression, IL-13 is essential for parasite clearance 259,271,272. 
During, Streptococcus infection in mice, IL-4 has shown to exacerbate the 
bacterial infection 273. Interestingly, during Klebsiella pneumonia infection, IL-13 
has shown to promote host protection, whilst, in the context of Chlamydia 
trachomatis infection, IL-13 has been associated with susceptibility to infection 
252,274-276. Additionally, in acute and primary viral infections (Ectromelia virus and 
respiratory syncytial virus) IL-13 has been associated with improved antiviral 
immunity 263,277, whilst in the context of viral vector-based vaccination, presence 
of IL-4 and IL-13 have shown to dampen effective T cell immunity 131,132. 
Interestingly, Ranasinghe et al. have shown that novel poxviral vector-based 
vaccines, that transiently inhibit IL-14 and/or IL-13 at the vaccination site can 
differentially regulate HIV-specific T and B cell immunity 122,124.  
 
1.8.2 IL-4/IL-13 signalling 
IL-4/ IL-13 functions via a common receptor system comprising of Type I (IL-
4Ra/gc) and Type II (IL-4Ra/IL-13Ra1) receptor complexes (Figure 1.8) 278. IL-4 
binds IL-4Ra with high affinity, which heterodimerises with gc subunit and forms 
the Type I IL-4R complex. Membrane bound IL-13Ra1 is the low affinity receptor 
for IL-13 (Kd ~30 nM) which heterodimerises with IL-4Ra to form the high affinity 
functional Type II IL-4R complex 279. Once activated, both IL-4R Type I and Type 
II complexes activate the JAK/STAT6 signalling pathway 280. In allergic asthma, 
IL-4 type I and type II receptor complexes play a central role in   
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promoting inflammation. Whilst IL-4Ra signalling activates Th2 responses via 
alternatively activated macrophages 281, IL-13Ra1 signalling mediates lung 
pathology by promoting lung fibrosis, mucous production and airway 
hypersensitivity 262,282. In the context of eosinophilic esophagitis and cardiac 
homeostasis, the association of IL-13Ra1/IL-4Ra with STAT3 signalling has also 
been proposed 108,283.  
 
IL-13Ra2 is the high affinity receptor for IL-13 (Kd ~440 pM), which exists as a 
membrane bound, as well as a soluble form (Figure 1.8). Interestingly, IL-13Ra2 
first discovered in mouse urine 284, was long thought to be a decoy receptor in 
mice, functioning to only sequester IL-13 from the milieu 285-287. However, IL-
13Ra2 is now known to be a functional receptor in humans and has been 
associated with certain cancers (of the brain, breasts, ovaries, liver) and disease 
conditions 288-292. Hence, in the recent years IL-13Ra2 has been targeted as an 
anti-cancer treatment 293. In the context of chronic inflammatory diseases such 
as inflammatory bowel disease (IBD), expression of IL-13Ra2 has been 
associated with disease promotion/progression 294, and up-regulation of IL-
13Ra2 in the airway inflammation has also shown to negatively regulate IL-13 
mediated pathogenicity in mice and humans 295,296. Furthermore, in helminth 
infection (schistosomiasis), IL-13Ra2 expression has been linked to down-
regulation of inflammation causing disease protection 297. Although the exact 
mechanism is not well understood, studies have reported that IL-13Ra2 can 
signal via STAT3 298,299. Interestingly, other studies have also shown the 
association of IL-13Ra2 to downstream activation of transforming growth factor 
beta 1 (TGF-b1) 300,301. Recent studies in our laboratory using poxviral vector-
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based vaccination that transiently inhibited STAT6 and IL-13 activity at the 
vaccination site 122,124 have shown the involvement of an STAT6 independent 
pathway, (likely linked to IL-13Ra2 pathway), associated with antibody 
differentiation 122,302.  
 
1.9 Impact of IL-13 levels on lung resident ILCs and DCs at the 
vaccination site 
Over a decade of work in our laboratory using poxviral vector-based mucosal and 
systemic vaccine strategies, it was established that more than IL-4, IL-13 was 
detrimental for the induction of high avidity/poorly poly-functional HIV-specific T 
cells 130,132. Subsequently, vaccines that co-expressed HIV antigens together with 
IL-4/IL-13 inhibitors were developed in the laboratory as described before, that 
transiently inhibited IL-4 and IL-13 activity at the vaccination site; namely, IL-4R 
antagonist and IL-13Ra2 adjuvanted vaccines. Specifically, IL-4R antagonist 
adjuvanted vaccine transiently inhibited IL-4/IL-13 signalling via STAT6 by 
binding IL-4Ra 122,123, whereas IL-13Ra2 adjuvanted vaccine transiently 
sequestered IL-13 at the vaccination site, reducing IL-13 activity 124 (Figure 1.9). 
In an HIV i.n. rFPV/i.m. rMVA prime-boost modality both these vaccines were 
shown to induce high avidity poly-functional (ability to express IFN-g, TNF-a and 
IL-2 and cytotoxic markers) mucosal and systemic T cells with better protective 
efficacy in both mice and macaques 122-124. In addition to effective T cell immunity, 
unlike the IL-13Ra2 adjuvanted vaccine strategy, IL-4R antagonist adjuvanted 
HIV vaccine strategy was also shown to induce IgG1 and IgG2a antibodies in 
mice, showing that IL-13 was necessary for effective antibody differentiation 
122,302. Interestingly, presence of high avidity poly-functional T cells and effective 
antibody differentiation have been hallmarks of   
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protective immunity observed in a rare cohort of people who naturally control HIV 
infection, known as elite controllers 303-305.  
 
Hence, when trying to unravel how these novel IL-4/IL-13 inhibitor viral vector-
based vaccines modulated vaccine-specific immunity at the innate and adaptive 
compartments, recent studies for the first time demonstrated that, innate 
lymphoid cell type 2 (ILC2), were the major source of IL-13 at the vaccination site, 
post 24 h delivery 306 and ILC2-derived IL-13 also modulated the ILC1/ILC3-
derived IFN-g and IL-17 production at the vaccination site 306. Using i.n. delivery 
of these novel vaccines it was also established that IL-13 levels at the lung 
mucosae could significantly alter the lung DC recruitment, 24 h post delivery 
(during the peak antigen expression) 99,307. Specifically, transient inhibition of IL-
13 enhanced recruitment of CD11b+ cDCs to the lung mucosae, which was 
associated with high avidity T cell induction 99,124. Moreover, adoptive transfer 
studies revealed that lung CD103+ cross-presenting DCs were responsible for 
induction of low avidity CD8 T cells 99. These studies clearly established that the 
level of IL-13 at the vaccination site as well as different DC subsets induce 
uniquely different downstream HIV-specific adaptive immune outcomes 
(specifically, IL-13 was detrimental for induction of high avidity poly-functional T 
cells, whereas IL-13 was necessary for effective antibody differentiation) (Figure 
1.10). However, whether different viral vectors induced different ILC2-derived IL-
13 at the vaccination site that impacted the recruitment of different DC subsets 
were not established, which forms the basis of this study.  
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1.10 Scope of the thesis 
1.10.1 Hypotheses 
1. Different viral vector-based vaccines induce uniquely different adaptive 
immune outcomes by differential DC recruitment, mainly associated with ILC2-
derived IL-13 levels at the vaccination site. 
2. Level of IL-13 at the vaccination site differentially regulates IL-13Ra2 and IL-
13Ra1 on lung cDCs, which is co-regulated by transcription factors STAT3 
and STAT6. 
3. Differential regulation of IL-4/IL-13 receptors on lung DCs 24-72 h post 
delivery, governs the unique vaccine-specific adaptive immune outcomes 
induced by different recombinant poxviral vector-based vaccines (expressing 
the same vaccine antigen). 
 
1.10.2 Aims 
1. Study the influence of lung ILC2-derived IL-13 levels on lung DC 
recruitment, 24 h post intranasal poxviral and non-poxviral vector-based 
vaccination. 
2. Assess how IL-4/IL-13 receptors and related downstream molecules are 
regulated on lung cDCs 24 h post recombinant viral vector-based 
vaccination. 
3. Using four different poxviral vector-based vaccines, assess how IL-4/IL-13 
receptors are regulated on different lung DC subsets, 24 - 72 h post 
vaccination. 
 
In this thesis, the results section is divided into three chapters:  
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Chapter 3: Recent studies by Li et al, using transient inhibition of IL-13 and 
STAT6 signalling at the vaccination site have shown that ILC2 were the major 
source of IL-13 at the vaccination site, 24 h post rFPV vaccination 306, responsible 
for modulating downstream adaptive immune outcomes both in mice and 
macaques (specifically modulating T cell avidity and B cell immunity) 122-124. 
Trivedi et al. also showed that manipulating IL-13 levels at the vaccination site 
significantly altered resident lung cDC recruitment and downstream T cell 
outcomes 308. Knowing that route of delivery and different viral vector-based 
vaccines can induce vastly different antigen-specific immune outcomes 
130,131,133,308, this study attempted to dissect the underlying mechanisms by which 
innate immune cells, notably ILC and DC regulated vaccine-specific immune 
outcomes. Specifically, assess whether there was any association between the 
level of ILC2-derived IL-13 and the DCs recruited to the vaccination site, 24 h 
post delivery, using 7 different viral vector-based vaccines (4 poxviral and 3 non-
poxviral).  
 
Chapter 4: Knowing that IL-13 can promote chronic inflammatory conditions as 
well as certain infections 259,271,272, and studies in our laboratory have shown that 
IL-13 levels at the vaccination site can differentially regulate/recruit lung cDCs to 
the lung mucosae 24 h post vaccination 99, this study evaluated the mechanisms 
by which viral vector-induced ILC2-derived IL-13 levels regulate the lung cDC 
response following intranasal vaccination. Specifically, 24 h post intranasal 
poxviral vector-based vaccination, this study evaluated the expression of IL-4/IL-
13 receptor and associated immunomodulatory molecules (STAT3, STAT6, TGF-
b1 and IFN- gR) on lung cDCs.  
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Chapter 5: Dysregulation of IL-13 receptors have shown to promote several 
disease conditions associated with different IL-13 conditions. Whilst IL-13Ra1 is 
the low affinity receptor, IL-13Ra2 is the high affinity receptor for IL-13. 
Interestingly, under high IL-13 conditions, IL-13Ra1 has been central in mediating 
allergic asthma and chronic inflammation 262,282, and the lesser understood IL-
13Ra2 has been deemed instrumental in promoting certain diseases conditions, 
309-311. In contrast, under low IL-13 conditions, IL-13Ra1 has also been shown to 
promote homeostasis and induce tissue repair 310,312. Hence, these studies 
clearly demonstrate that IL-13 receptors can be differentially regulated under 
different IL-13 conditions. Therefore, given that post viral vector vaccination, level 
of IL-13 at the vaccination site were found to differentially regulate DC responses 
(chapters 3 & 4), in this chapter, regulatory patterns of IL-13Ra1 and IL-13Ra2 
were evaluated on lung DCs, 24 to 72h post four different recombinant HIV 
poxviral vector-based vaccines (which were found to induce different ILC2-
derived IL-13 levels at the vaccination site). 
  
 
 
 
 
 
 
 
  
 41 
 
 
 
 
 
Chapter 2 
 
General Materials1 
 
 
 
1 All methods used in the thesis have been mentioned in specific chapters which have 
been also compiled as journal articles. 
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Table 2.1 Medium 
Name  Component Company Catalogue 
no. 
Complete RPMI 
medium  
RPMI 1640 (500ml) 
HI-FCS (35ml) 
1M HEPES (10ml) 
Penicillin-Streptomycin 
(0.5ml) 
100mM sodium 
pyruvate  
b-mercaptoethanol  
Sigma  
GIBCO   
GIBCO 
JCSMR  
 
GIBCO 
GIBCO  
R8758 
10099-133 
15630-080 
N/A 
 
11360070 
M-6250 
Complete Essential 
Medium (MEM) 
MEM  
5% (v/v) FCS  
1mM HEPES  
30ug/ml penicillin-G  
50ug/ml streptomycin  
50ug/ml neomycin  
GIBCO/Sigma  
Invitrogen  
Invitrogen  
Sigma  
Sigma  
Sigma  
M-4655 
10437028 
15630-080 
021156065 
S6501 
N-6386 
RPMI medium (wash 
medium) 
RPMI 1640 (500ml) 
10 mM HEPES 
Sigma 
Invitrogen  
R8758 
15630-080 
 
Table 2.2 Buffers and solutions 
Name  Component Company Catalogue 
no. 
Lung Digestion Buffer  1 ml Complete RPMI  
1 mg/ml Collagenase  
Sigma  
Sigma  
R8758 
C2139 
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1.2 mg/ml Dispase  
5 Units/ml DNase 
GIBCO  
Calbiochem  
17105-041 
26095 
Red Blood Cell Lysis 
Buffer (RBC-LB) 
0.16 mM NH4Cl  
0.17M Tris HCL (pH 
7.6) 
Sigma  A0171 
FACS buffer  PBS  
 
2% FCS 
Sigma  
 
GIBCO   
D8537-
500ML 
10099-133 
Intracellular Fixation 
Buffer (IC-Fix) 
IC-Fix Biolegend 420801 
Intracellular 
Permeabilisation 
buffer (IC-Perm) 
10% 10X IC-PERM  
90% dH2O 
eBioscience 
JCSMR 
00-8333-56 
N/A 
Paraformaldehyde 
(PFA) 
0.5% (w/v) PFA in PBS  Sigma  P-6148 
Brefeldin A (BFA) 1:1000 working dilution 
in complete RPMI 
medium  
eBioScience 00-4506-51 
Phosphate Buffer 
Saline (PBS) 
1X PBS  Sigma D8537 
Poly-L-Lysine 
solution 
0.1% (w/v) in H20 Sigma  P1274 
Antifade Vectashield 
mounting medium for 
fluorescence with 
10μl per slide Vector 
Laboratories, 
USA 
H-1200 
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4′,6-diamidino-2-
phenylindole (DAPI) 
Antifade Vectashield 
mounting medium for 
fluorescence 
10μl per slide Vector 
Laboratories, 
USA 
H-1000 
 
Table 2.3 Anti-mouse antibodies used for flow cytometry 
Antibody 
 
Fluorochrome Working 
dilution 
Company Clone 
CD3 FITC 1:200 BioLegend 17A2 
CD19 FITC 1:100 BioLegend 6D5 
CD11b  FITC 1:200 BioLegend M1/70 
CD11c FITC 1:100 BioLegend N418 
CD49b FITC 1:200 BioLegend HMa2 
FceRI FITC 1:100 BioLegend MAR-1 
CD45 APC/Cy7 1:200 BioLegend 30-F11 
ST2 PE 1:100 BioLegend DIH9 
IL-25R APC 1:100 BioLegend 9B10 
NKp46 Brilliant Violet 
421 
1:100 BioLegend 29A1.4 
IFN-g Brillian Violet 
510 
1:100 BioLegend XMG1.2 
IL-17A Alexa Fluor 
700 
1:100 BioLegend TC11-
18H10.1 
IL-13 PE-eFLuor 610 1:100 eBioscience eBio13A 
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TSLPR APC 1:100 R&D FAB5461A 
MHC-II I-Ad APC 1:1600 eBioscience M5/114.15.2 
CD11c Biotin  1:200 BioLegend N418 
Streptavidin  Brilliant Violet 
421 
1:400 BioLegend N/A 
CD8 APC-
eFluor780 
1:300 eBiosceince 53-6.7 
B220 PerCPCy5.5 1:300 eBioscience RA3-6B2 
CD11b  Alexa Fluor 
700 
1:300 BioLegend M1170 
CD103 FITC 1:200 eBioscience 2E7 
7-amino-
actinomycin 
D viability 
staining 
solution 
(7AAD) 
N/A 1:100 BioLegend N/A 
IL-4Ra PE 1:100 BioLegend I015F8 
IL-13Ra1 PE 1:100 eBioscience 13MOKA 
IL-13Ra2 Biotin 1:100 R&D 110815 
Streptavidin PE 1:100 BioLegend N/A 
IFN-gRa Biotin 1:400 BioLegend 2E2 
Streptavidin  APC 1:100 BioLegend N/A 
gc PE 1:100 BioLegend TUGm2 
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p-Stat3 Biotin 1:100 Santa Cruz 
Biotechnology 
Tyr 705 
p-Stat6 Biotin 1:100 Santa Cruz 
Biotechnology 
Tyr 641 
TGF-b1 PE 1:100 BioLegend Tw7-16B4 
Fc block N/A 1:200 BD 
Biosciences 
2.4G2 
 
Table 2.4 Viral vector based vaccines and doses used to immunize mice 
Virus Dose (pfu/mouse) Family 
Recombinant fowlpox 
virus expressing HIV-1 
(rFPV) 
2 x 107 Poxviridae 
Recombinant Vaccinia 
Virus expressing HIV-1  
(rVV) 
2 x 107 Poxviridae 
Recombinant Modified 
Vaccinia Ankara 
expressing HIV-1 
(rMVA) 
2 x 107 Poxviridae 
IL-1bR deletion variant 
of rMVA expressing HIV-
1 (rMVA-ΔIL-1bR) 
2 x 107 Poxviridae 
Influenza A vector 500 Orthomyxoviridae 
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Recombinant human 
Rhinovirus serotype 1A 
(RV) 
5x106 TCID50 Picornaviridae 
Adenovirus 5 (Ad5) 2 x 107 Adenoviridae 
 
 
 
Table 2.5 Reagents for Fluidigm 48.48 Biomark Assay 
Preamplification mix 
(single cell) per 
reaction (5ul)  
Cells Direct 2x 
reaction buffer  
2.5 µL Invitrogen  
SuperScript® III 
RT/Platinum® 
Taq Mix* 
0.1 µL Invitrogen  
0.2x pooled 
assays  
1.25 µL Invitrogen  
SUPERase• 
In™ RNase 
Inhibitor 
0.05 µL Invitrogen 
DEPC treated 
water 
1.1 µL Ambion 
Preamplification mix 
(100 cell) per reaction 
(20 ul) 
Cells Direct 2x 
reaction buffer 
10 µL Invitrogen  
SuperScript® III 
RT/Platinum® 
Taq Mix* 
0.4 µL Invitrogen  
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0.2x pooled 
assays  
0.5 µL per assay 
diluted in DEPC 
treated water in a 
total volume of 5 µL 
Invitrogen  
SUPERase• 
In™ RNase 
Inhibitor 
0.2 µL Invitrogen 
DEPC treated 
water 
4.4 µL Ambion 
Preamplification mix 
(100 cell) per reaction 
(25 ul) 
Cells Direct 2x 
reaction buffer 
12.5 µL Invitrogen  
SuperScript® III 
RT/Platinum® 
Taq Mix* 
0.5 µL Invitrogen  
0.2x pooled 
assays  
0.5 µL per assay 
diluted in DEPC 
treated water in a 
total volume of 6.25 
µL 
Invitrogen  
SUPERase• 
In™ RNase 
Inhibitor 
0.25 µL Invitrogen 
DEPC treated 
water 
5.5 µL Ambion 
Taqman qPCR mix 20X Taqman 0.5 µL  Thermofisher  
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per reaction (10 µL)  gene expression 
assay  
2X Taqman 
PCR universal 
mastermix  
5 µL  Applied 
Biosystems  
Diluted cDNA 
template  
1 µL  See section 
2.3.5  
DEPC treated 
water  
3.5 µL  Ambion  
Fluidigm sample 
premix per inlet (5 µL)  
2X Taqman 
PCR universal 
mastermix  
2.5 µL  Applied 
Biosystems  
20X GE sample 
loading reagent  
0.25 µL  Millennium 
Biosciences  
cDNA  2.25 µL   
Fluidigm assay 
premix per inlet (5 µL)  
20X Taqman 
gene expression 
assay  
2.5 µL  Thermofisher  
Assay loading 
reagent  
2.5 µL  Millennium 
Biosciences  
 
Table 2.6. Primer probe sets used for Fluidigm Biomark 48.48 gene 
expression assay 
Gene symbol Encoded protein Assay ID Reference 
sequence 
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Ifngr1 IFN-γ receptor 
subunit 1 
Mm00599890_m1 NM_010511.2 
Icos Inducible T-cell 
costimulatory 
(ICOS) 
Mm00497600_m1 NM_017480.2 
Tgfb1 Transforming 
growth factor beta 
1 
Mm01178820_m1 NM_011577.2 
Stat6 Signal transducer 
and activator 
(STAT) 6 
Mm01160477_m1 NM_009284.2 
Stat3 STAT3 Mm01219775_m1 NM_213660.3 
NM_011486.5 
NM_213659.3 
Cd86 T-lymphocyte 
activation antigen 
Mm00444543_m1 NM_019388.3 
Siglech Sialic acid binding 
Ig-like lectin H 
(SiglecH) 
Mm00618627_m1 NM_178706.5 
NM_001310738.1 
NM_001310740.1 
Rpl32 Ribosomal 
protein L32 
Mm02528467_g1 NM_172086.2 
Ywhas Stratifin Mm02524691_s1 NM_018754.2 
Eef2 Eukaryote 
elongation factor 
2 
Mm01171435_gH NM_007907.2 
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Chapter 3 
 
Viral vector and route of administration determine the 
ILC and DC profiles responsible for downstream 
vaccine-specific immune outcomes2 
 
This chapter is published as: Roy, S., Jaeson, M.I., Li, Z., Mahboob, S., Jackson, 
R.J., Grubor-Bauk, B., Wijesundara, D.K., Gowans E.J., and Ranasinghe, C. Viral 
vector and route of administration determine the ILC and DC profiles responsible 
for downstream vaccine-specific immune outcomes. Vaccine 2019.  
 
 
 
2 The chapter related ILC experiments were performed by Ms. Shaaerah Mahboob, Mr. 
Irwan Jaeson and Dr. Zheyi Li. 
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3.1 Abstract 
This study demonstrates that route and viral vector can significantly influence the 
innate lymphoid cells (ILC) and dendritic cells (DC) recruited to the vaccination 
site, 24 hours post delivery. Intranasal (i.n.) vaccination induced ST2/IL-33R+ 
ILC2, whilst intramuscular (i.m.) induced IL-25R+ and TSLPR+ (Thymic stromal 
lymphopoietin protein receptor) ILC2 subsets. However, in muscle a novel ILC 
subset devoid of the known ILC2 markers (IL-25R- IL-33R- TSLPR-) were found 
to express IL-13, unlike in lung. Different viral vectors also influenced the ILC-
derived cytokines and the DC profiles at the respective vaccination sites. Both 
i.n. and i.m. recombinant fowlpox virus (rFPV) priming, which has been 
associated with induction of high avidity T cells and effective antibody 
differentiation exhibited low ILC2-derived IL-13, high NKp46+ ILC1/ILC3 derived 
IFN-g and low IL-17A, together with enhanced CD11b+ CD103- conventional DCs 
(cDC). In contrast, recombinant Modified Vaccinia Ankara (rMVA) and Influenza 
A vector priming, which has been linked to low avidity T cells, induced opposing 
ILC derived-cytokine profiles and enhanced cross-presenting DCs. These 
observations suggested that the former ILC/DC profiles could be a predictor of a 
balanced cellular and humoral immune outcome. In addition, following i.n. 
delivery Rhinovirus (RV) and Adenovius type 5 (Ad5) vectors that induced 
elevated ILC2-derived IL-13, NKp46+ ILC1/ILC3-derived-IFN-g and no IL-17A, 
predominantly recruited CD11b- B220+ plasmacytoid DCs (pDC). Knowing that 
pDC are involved in antibody differentiation, we postulate that i.n. priming with 
these vectors may favour induction of effective humoral immunity. Our data also 
revealed that vector-specific replication status and/or presence or absence of 
immune evasive genes can significantly alter the ILC and DC activity. 
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Collectively, our findings suggest that understanding the route- and vector-
specific ILC and DC profiles at the vaccination site may help tailor/design more 
efficacious viral vector-based vaccines, according to the pathogen of interest. 
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3.2 Introduction  
In the last two decades, inactivated, live attenuated, replication-competent or -
defective viruses have been extensively tested as viral vector-based vaccines. 
Interestingly, poxviruses such as Modified Vaccinia Ankara (MVA), New York 
strain of vaccinia virus (NYVAC), which are attenuated versions of vaccinia virus 
(VV), and Avipoxvirus; canarypox and fowlpox (FPV) viruses, used in prime-boost 
modalities have yielded uniquely different immune outcomes, dependent upon 
the route of delivery and/or the vaccine vector combination 121,131,159,313. For 
example, heterologous rFPV/rVV compared to rVV/rFPV vaccination has shown 
to induce highly poly-functional/ high avidity T cells 131,133,205,314, moreover, rMVA 
used as a booster, as opposed to a prime has shown to induce more effective T 
cell immunity 138,143,315.  Similarly, both replication-competent and -defective 
recombinant Adenovirus-based vaccines have also shown to induce T cell 
responses associated with immune protection in animal models 118,140,316. 
Moreover, viruses such as, Influenza A, Human RV, Cytomegalovirus, and 
Vesicular stomatitis virus, have also been assessed as promising vaccine 
delivery vehicles 220,315,317,318. In a recent prime-boost vaccination study, mucosal 
RV prime vaccination was shown to induce HIV-specific T cell responses 
associated with protection in mice 245. To improve vaccine-specific immunity, 
variants of viral vectors, such as IL-1βR and/or IL18 binding protein (IL-18bp) 
deletion mutants of MVA and Adenoviral vectors have also been recently tested 
229,319,320. Despite the knowledge of different viral vector-based vaccines 
conferring different adaptive immune outcomes, the underlying innate immune 
mechanisms governing these processes at the vaccination site still remains 
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elusive, specifically the role of innate lymphoid cells (ILCs) and dendritic cells 
(DCs).  
 
ILCs, although derived from a common progenitor are lineage negative in nature 
and according to the transcription factors, receptors and cytokines they express, 
are broadly classified into three main categories (ILC1, ILC2 and ILC3) 321. ILC2, 
due to their ability to express IL-13, have been heavily studied under chronic 
inflammation, allergic asthma and helminth infections 322. During intracellular 
pathogen infection, ILC1 have shown to express IFN-g and tumour necrosis factor 
(TNF)-α 323, whilst during extracellular bacterial and fungal infections, ILC3 have 
been associated with interleukin (IL)-17A and IL-22 expression 324,325. Although 
ILCs have three distinct phenotypes, studies have shown that they have the 
ability to interconvert between the phenotypes, according to the external stimuli, 
and thus thought to be highly plastic 326,327. It is postulated that ILCs can polarize 
the immune response, according to the immune cell milieu or pathogen 
encountered, towards Th1, Th2 or Th17 immunity. However, the role of ILCs in 
viral vector-based vaccination is not well characterised.  
 
DCs sample antigens at various body surfaces; skin, gastrointestinal tract and 
lungs, and are among the first line of defence against many pathogens. Based 
on the anatomical location and the invading pathogen, distinct DC subsets carry 
out differential functions 328. For example; lung DCs have been extensively 
studied under respiratory infections. Lung conventional CD11b+ CD103- DCs 
(cDCs) and cross-presenting CD11b- CD103+ DCs have been associated with 
CD8 T cell priming 329,330. Although conflicting evidence suggest that cDCs are 
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functionally more important in mounting an effective antiviral response 75,331, 
there is growing evidence to support the notion that the activity of a particular DC 
subset is determined by the specific infection. For example: control of acute 
influenza virus infection is associated with CD11b- CD103+ DCs cross 
presentation to CD8 T cells 332, whilst, CD11b- CD8+ DCs, which share a common 
developmental origin with CD11b- CD103+ DCs, have been associated with 
activation of cytotoxic CD8 T cells against non-respiratory pathogens such as 
West Nile Virus 333. In the context of respiratory syncytial virus (RSV) infection, 
CD11b+ and CD103+ DC subsets have been involved in antigen presentation to 
both CD4 and CD8 T cells 72. In addition, during Influenza A infection, CD11b+ 
DCs have also been associated with humoral immunity 86. Furthermore, 
plasmacytoid DCs (pDCs) also have been associated with distinct functions 
during viral infections 334,335. 
 
It is now well established that the route of delivery, cytokine milieu, viral vectors 
and the order in which they are administered can yield vastly different adaptive 
immune outcomes 128,131,133,205,336. We have previously shown that i) IL-13, 
although detrimental for high avidity/poly-functional CD8 T cell immunity, was 
necessary for effective antibody differentiation 122,124,337. ii) Using rFPV 
adjuvanted vaccines that transiently inhibited IL-13 activity at the vaccination site, 
we have recently established that ILC2 (not other lineage+ cells) were the major 
source of IL-13 at the vaccination site 24 h post vaccination 338. iii) Furthermore, 
using the same vaccines we have also shown that elevated IL-13 in the milieu 
recruited CD11b- CD103+ cross-presenting DCs, associated with low avidity CD8 
T cells 99,124. Therefore, in this study to further understand which specific innate 
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immune cell subsets play a predominant role in shaping the downstream adaptive 
immune outcomes, replicating and non-replicating viral vectors were delivered 
intranasally and intramuscularly and subsequent ILC-derived cytokine profiles 
and DCs subsets were assessed 24 h post vaccination. 
 
3.3 Materials and Methods 
 
3.3.1 Mice.  
Pathogen-free 6–8 weeks old female BALB/c mice were purchased from the 
Australian Phenomics Facility, The Australian National University. All animals 
were maintained, monitored daily and cervically dislocated at the endpoint 
according to the Australian NHMRC guidelines within the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes and in 
accordance with guidelines approved by the ANU Animal Experimentation and 
Ethics Committee (AEEC), protocol number A2014/14 and A2017/15.  
 
3.3.2 Viral vector-based Vaccines.  
Recombinant FPV, VV and MVA expressing HIV antigens described previously 
were used in this study 190,338. The rMVADIL-1bR was constructed and kindly 
provided by Dr. Jackson. Influenza A and Adenovirus 5 (Ad5) vectors were kindly 
provided by Prof. Arno Mullbacher, JCSMR, ANU. Recombinant Human 
Rhinovirus serotype 1A (RV) was kindly provided by Prof. Gowans and Dr. 
Wijesundara, Basil Hetzel Institute, University of Adelaide 220.  
 
3.3.3 Immunisation.  
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BALB/c mice were intranasally or intramuscularly immunised with 1x107 plaque 
forming units (pfu) of each of the poxviruses rFPV, rVV, rMVA, rMVA-ΔIL-1bR; 
2x107 pfu (i.n.) or 2.5x107 pfu (i.m.) of Ad5, 5x106 TCID50 of RV or 500 pfu of 
Influenza A. Note that, doses used were comparable to those used in previous 
studies, optimal to induce adaptive immune outcomes. Mice were vaccinated with 
10 µl per nostril (i.n.) or 50 μL per leg (i.m.) under mild isofluorane anaesthetic. 
rFPV, rVV, rMVA, rMVA-ΔIL-1bR were sonicated three times for 15 seconds on 
ice at 50% capacity using Branson Sonifier 450 immediately prior to vaccination.  
 
3.3.4 Preparation of lung lymphocytes.  
Lung tissues were collected 24 h post vaccination in complete RPMI for ILC 
studies as described previously 338. For DC studies, lungs were harvested at 12, 
24 and 48 hours post vaccination. Lung tissues were prepared as described 
previously 338. Briefly, tissues were cut into small pieces, and enzymatically 
digested for 45 min at 37°C in digestion buffer containing 1 mg/ml collagenase 
(Sigma-Aldrich, St Louis, MO), 1.2 mg/ml Dispase (Gibco, Auckland, NZ), 5 
Units/ml DNase (Calbiochem, La Jolla, CA) in complete RPMI. Samples were 
crushed and passed through a 100µm falcon cell strainer and resulting lung cell 
suspensions were then treated with red cell lysis buffer followed by extensive 
washing to remove the lysis buffer. Samples were then passed through gauze to 
remove debris, cells were re-suspended in complete RPMI, rested overnight at 
37°C under 5% CO2 as per our previous studies prior to staining 124,205.  
 
3.3.5 Preparation of muscle lymphocytes.  
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Muscle tissues were harvested 24 h post vaccination in complete RPMI and 
prepared as previously indicated 338. Briefly, tissues were, homogenised and 
enzymatically digested for 45 min at 37oC in a digestion buffer containing 2 
mg/mL collagenase, 2.4 mg/mL dispase and 5 Units/mL of DNAse in complete 
RPMI. Subsequently, samples were very gently pushed through a 70 μM Falcon 
cell strainer, to avoid debris. Resulting cell suspension was then washed, 
resuspended in complete RPMI and rested overnight as per lung prior to staining 
124,205 
 
3.3.6 Evaluation of lung and muscle ILCs using flow cytometry.  
Monoclonal antibodies FITC-conjugated anti-mouse CD3 (T cells) clone 17A2, 
CD19 (B cells) clone 6D5, CD11b (macrophages and dendritic cells) clone 
M1/70, CD11c (dendritic cells) clone N418, CD49b (NK, NKT, T cells) clone 
HMα2, FcεRIα (Mast cells and Basophils) clone MAR-1 (all linage positive 
markers were selected as FITC), PE-conjugated anti-mouse ST2/IL-33R (clone 
DIH9), APC-conjugated IL-25R (clone 9B10), APC/Cy7-conjugated anti-mouse 
CD45 (clone 30-F11), Brilliant Violet 421-conjugated anti-mouse CD335 (NKp46) 
(clone 29A1.4), Brilliant Violet 510-conjugated anti-mouse IFN-g (clone XMG1.2), 
Alexa Fluor 700-conjugated IL-17A (clone TC11-18H10.1) were obtained from 
BioLegend. PE-eFluor 610-conjugated anti-mouse IL-13 (clone eBio13A) was 
purchased from eBioscience and APC- conjugated anti-mouse TSLPR R&D 
systems. ILC2 and ILC1/3s were stained separately to avoid fluorochrome 
overlap. Specifically, FITC-conjugated lineage cocktail antibodies and APC/Cy7-
conjugated anti-mouse CD45 were used in both ILC2 and ILC1/ILC3 staining. For 
lung and muscle ILC2 staining, PE-conjugated anti-mouse ST2/IL-33R, and PE-
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eFluor 610-conjugated anti-mouse IL-13 were used and for muscle ILC2 staining, 
additionally APC-conjugated IL-25R and APC-conjugated anti-mouse TSLPR 
were used. Brilliant Violet 421-conjugated anti-mouse NKp46, Brilliant Violet 510-
conjugated anti-mouse IFN-g, Alexa Fluor 700-conjugated IL-17A were only used 
in ILC1/3s staining. Briefly, for intracellular staining, samples were treated with 
Brefeldin A for 5 hours, washed, cell surface staining was performed followed by 
and intracellular staining after fixing and permeabilising the cells as per our 
previous protocols124. Once the staining was completed all samples were fixed 
with 0.5% paraformaldehyde, 1.4 x 106 events from each lung sample were 
acquired and 3.0 x 106 events were acquired for muscle on a BD LSR Fortessa. 
Data were analysed using Tree Star FlowJo software (version 10.0.7) using 
gating strategies indicated in Chapter 3 Appendix Figures 1 and 2. 
 
3.3.7 Evaluation of lung DCs using Flow cytometry. 
2x106 cells were blocked with anti-mouse CD16/CD32 Fc Block antibody (BD 
Biosciences, USA) for 20 min at 4°C and cells were surface stained with APC 
conjugated MHCII I-Ad (e-Biosciences, USA), biotin conjugated CD11c (N418 
clone, Biolegend, USA), followed by streptavidin Brilliant violet 421 (Biolegend, 
USA) and other DC markers CD8 APC-eFluor780 (53–6.7 clone, ebiosciences, 
USA), B220 PercpCy5.5 (RA3-6B2 clone, e-Biosciences, USA), CD11b 
AlexaFluor 700 (M1170 clone, Biolegend, USA) and CD103 FITC (2E7 clone, e-
Biosciences, USA) for 30 min on ice. Cells were resuspended in PBS and 
analysed using BD LSRII flow cytometer Becton Dickinson, San Diego, CA). 
5x105 events per sample were collected and results were analyzed using FlowJo 
software version 10.0.7, as described in Figures 3.1 – 3.3. Note that, live/dead 
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staining was also performed using viability dye 7-amino-actinomycin D (7-AAD 
Biolegend, USA) (Figures 3.1). 
 
3.3.8 Statistical analysis.  
Cytokine expression by ILCs was calculated as a percentage of the parent ILC 
subset. To depict the differences in IL-13 expression, following i.n. vs i.m. 
vaccinations, number of ILC2 expressing IL-13 were also back calculated to 
CD45+ population and normalized to 1x106. The muscle ILC2 subset percentages 
were calculated as (subset of interest/Lin- population x 100%). The DC subsets 
were represented as a percentage of total MHC-II+ CD11c+ DCs. The p-values 
were calculated using two-tailed paired parametric student’s t-test, unpaired 
parametric student’s t-test or Ordinary One-way ANOVA with Tukey’s multiple 
comparison post-test. All experiments were repeated minimum 2-3 times.  
 
3.4 Results 
3.4.1 Different viral vector-based vaccines can induce uniquely different 
ILC2-derived 13 profiles following intranasal and intramuscular 
vaccination. 
BALB/c mice were vaccinated intranasally or intramuscularly with four different 
poxviral vectors rFPV, rMVA, rVV and rMVAΔIL-1βR and three non-poxviral 
vectors Influenza A, Human rhinovirus (RV) and Adenovirus type 5 (Ad5). 
Percentage of lung and muscle ILC2 and their corresponding IL-13 expression 
were assessed 24 h post vaccination. ILC2 were gated as CD45+ FSClow, SSClow, 
lineage- ST2/IL-33R+ cells for lung (Chapter 3 Appendix Figure 1) or lineage- 
IL-25R+, TSLPR+ and ST2/IL-33R+ for  
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muscle (Chapter 3 Appendix Figure 2), as indicated in Materials and Methods 
and Li et al 2018 338. Among all the vectors tested, following i.n. delivery, Influenza 
A vector recruited the highest percentage of Lin- ST2/IL-33R+ ILC2 to the 
vaccination site (lung mucosae). In contrast, RV and Ad5 recruited the lowest 
percentage of ILC2, which was much lower than unimmunized control (p=0.0014 
and p=0.0011 respectively) (Figures 3.4a and Chapter 3 Appendix Figure 3). 
However, despite this, RV and Ad5 expressed elevated IL-13 levels, which were 
similar to rMVA and Influenza A (Figures 3.4b and c). Among the three poxviral 
vectors tested, the highest IL-13 level was detected in rMVA (rFPV vs rMVA 
p<0.0001, rMVAΔIL-1βR vs rMVA p<0.0001), whilst rMVAΔIL-1βR showed the 
lowest (rFPV vs rMVAΔIL-1βR p=0.4159) (Figures 3.4b and c). It is also 
noteworthy that, all the vectors showed significantly elevated IL-13 expression by 
Lin- ST2/IL-33R+ ILC2 compared to the unimmunized control (rFPV p=0.0028; 
rMVA p<0.0001; rMVAΔIL-1βR p=0.0412; Influenza A p<0.0001; RV p<0.0001; 
Ad5 p<0.0001) (Figures 3.4a-c). 
 
Following i.m. vaccination, mainly IL-25R+ ILC2s and TSLPR+ ILC2, ranging from 
0.25% to 2% were detected. In the context of IL-25R+ ILC2, rMVA and Ad5 vector 
vaccination showed significantly elevated numbers compared to unimmunised 
control (p=0.0183 and p=0.0178 respectively). Furthermore, Ad5 vaccination also 
showed higher proportion of IL-25R+ ILC2s compared to influenza A (p=0.0004) 
(Chapter 3 Appendix Figure 4). Interestingly, rMVAΔIL-1βR (1.8% average) 
showed a significantly elevated proportion of TSLPR+ ILC2 compared to rFPV 
and rMVA vaccination (p<0.0001 and p=0.0240 respectively) (Chapter 3 
Appendix Figure 4). Ad5 also showed elevated TSLPR+ ILC2s compared to 
rFPV and influenza A vaccination (p=0.0103 and p=0.0006 respectively) 
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(Chapter 3 Appendix Figure 4). Following i.m. vaccination, similar to our 
previous studies extremely low or no ST2/IL-33R+ ILC2 were detected with all 
vaccine groups tested (Chapter 3 Appendix Figure 4). 
 
Surprisingly, following i.m. delivery, canonical ILC2 subsets (IL-25R+, TSLPR+) 
were found to express marginal IL-13. In contrast, compared to the unimmunised 
control, a not yet defined ILC2 subset that lacked IL-25R, ST2/IL-33R and TSLPR 
were found to express IL-13 (Chapter 3 Appendix Figures 5 and 6). Out of the 
vectors tested, Ad5 showed remarkably higher proportion (2 to 3-fold) of IL-25R- 
IL-33R- TSLPR- cells expressing IL-13 (p<0.0001) (Chapter 3 Appendix Figure 
5), which was comparatively lower than i.n. Ad5 vaccination (Figure 3.4b). It is 
noteworthy that, the ILC2-derived IL-13 expression by each vector was 
significantly higher following i.m. delivery compared to i.n. delivery. (Note that: 
The parent ILC2 population in the i.m. groups were much greater than the i.n. 
ST2+/IL-33R+ ILC2s. Thus, the difference in IL-13 expression by these two ILC 
subsets were also represented normalised to the CD45+ subset, described in 
materials and methods (Chapter 3 Appendix Figure 4d).  
 
3.4.2 Poxviral and non-poxviral vectors showed significantly different 
ILC1/ILC3- derived IFN-g and IL-17A expression profiles. 
Our recent intranasal rFPV vaccination studies have shown that the transient 
inhibition of ILC2-derived IL-13 at the vaccination site can directly impact the level 
of IFN-g and IL-17A expression by NKp46+ and NKp46- ILC1/ILC3s at the 
vaccination site 24h post vaccination 338. Hence, we next investigated the 
induction of IFN-g and IL-17A expression by ILC1/ILC3s by different viral vaccine 
vectors as per indicated in Materials and Methods using flow cytometry gating 
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strategies described in Chapter 3 Appendix Figure 1. Following i.n. vaccination, 
although no significant differences in the percentages of NKp46+ ILC1/ILC3s 
were detected compared to the unimmunized control (Figure 3.5a), compared to 
Influenza A, Ad5 showed significantly reduced numbers of NKp46+ ILC1/ILC3s 
(p=0.042). Whist rMVAΔIL-1βR recruited NKp46+ ILC1/ILC3s similar to rFPV, 
rMVA recruited significantly lower numbers of NKp46+ ILC1/ILC3s compared to 
rFPV (p=0.036) (Figure 3.5a). In the context of IFN-g expression by NKp46+ 
ILC1/ILC3s, RV induced the highest (average 14.5%), followed by Ad5 (average 
5%) and rFPV (average 2.9%) (Figure 3.5b and c). Unlike rFPV, the deletion 
mutant rMVAΔIL-1βR and rMVA showed significantly lower IFN-g expression  
(p=0.0187, and 0.0011 respectively), which was also lower than the unimmunized  
control (p=0.0086 respectively) (Figure 3.5b and c). Expression of IFN-g by 
Influenza A was similar to that of the unimmunized control.  
 
Interestingly, following i.n. delivery 95-98% ILC1/ILC3s were found to be NKp46- 
(Figure 3.6a). Although there were no differences observed between the 
numbers of NKp46- ILC1/ILC3s recruited by any of poxvirus vectors (Figure 
3.6a), IFN-g expression was vastly different. rFPV was amongst the highest 
inducers of IFN-g expression by NKp46- ILCs (Figure 3.6b and c), whilst showing 
modest IFN-g expression also by NKp46+ ILCs (Figure 3.6b and c). Out of all the 
vaccine vectors tested, rMVAΔIL-1βR showed the lowest IFN-g expression by 
NKp46- ILC1/ILC3s (Figure 3.6b and c). Although Influenza A recruited 
significantly lower numbers of NKp46- ILC1/ILC3s compared to RV and Ad5 
(p=0.0004, p<0.0001 respectively), it induced the highest IFN-g expression 
among the non-poxviral vectors (Figure 3.6b and c). Interestingly, the IFN-g 
expression by NKp46- ILC1/ILC3s was very similar between Influenza A and   
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rFPV vaccinated groups (Figure 3.6b and c). It is noteworthy that, although the 
unimmunized control showed elevated NKp46- ILC1/ILC3 numbers, low or no 
expression of IFN-g was observed (Figures 3.6a-b and Chapter 3 Appendix 
Figure 3). Remarkably, rMVAΔIL-1βR induced the highest IL-17A expression by 
both NKp46+ (Figures 3.7a and c) and NKp46- ILC1/ILC3 subsets (Figures 3.7b 
and d). rMVA and Influenza A vectors induced modest IL-17A expression by both 
these subsets (Figure 3.7), whilst rFPV, Ad5 and RV showed no IL-17A 
expression, similar to the unimmunized control (Figures 3.7 and Chapter 3 
Appendix Figure 3. 
 
Unlike i.n., following i.m. delivery, the proportion of NKp46+ ILC1/ILC3 in the 
muscle was very minimal (0-0.8%) across all vaccine vectors (Chapter 3 
Appendix Figure 7a), with significant differences observed between rMVA 
compared to rFPV, rMVAΔIL-1βR and Ad5 (p=0.0087 p=0.0049, and p=0.0397 
respectively). Additionally, only rFPV and Influenza A vaccinated groups showed 
any expression of IFN-g by NKp46+ ILC1/ILC3 (Chapter 3 Appendix Figure 7b). 
Interestingly, IFN-g expression by these subsets was much greater following i.m 
versus i.n. vaccination (rFPV i.m. ~12.06% i.n. 2.5% and influenza A i.m. ~4.67% 
i.n.~1.5%) (Chapter 3 Appendix Figure 7b and 3.2). In the context of IL-17A 
expression by NKp46+ ILC1/ILC3, only Influenza A vaccinated animals showed 
any significant expression (average 8.39%, p<0.0001 influenza A vs. all vaccine 
vectors) (Chapter 3 Appendix Figure 7c). Of the poxviral vectors tested, 
rMVAΔIL-1βR vaccinated group also showed an increase in the proportion of 
NKp46+ ILC1/ILC3 expressing IL-17A (average 0.89%) although not significant 
and was similar to what was observed with i.n. delivery (average 1.0%). 
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Moreover, following i.m. delivery, different IFN-g and IL-17A expression profiles 
were detected by NKp46- ILC1/ILC3 (Chapter 3 Appendix Figure 7e and f). 
Unlike i.n. delivery, very low IFN-g expression was detected following i.m. 
vaccination, and only influenza A (~0.01%) and Ad5 (~0.03%) showed any IFN-g 
expression (Chapter 3 Appendix Figure 7e and f).  All vectors showed different 
NKp46- ILC1/ILC3-derived IL-17A expression profiles. Specifically, out of the 
vectors tested, Ad5 and rMVAΔIL-1βR showed the highest expression (~0.58% 
and ~0.84% respectively) (Chapter 3 Appendix Figure 7f). Interestingly, the 
NKp46- ILC1/ILC3-derived IL-17A expression by the rMVAΔIL-1βR group was 
significantly elevated compared to unimmunised, rFPV, rMVA and influenza A 
(p<0.0001, p=0.0064, p<0.0001, and p<0.0001 respectively) (Chapter 3 
Appendix Figures 6 and 7f). Whilst, Ad5 showed significant differences 
compared to unimmunised, rMVA, and influenza A vaccinated groups (p=0.0048, 
p=0.0172 and p=0.0219 respectively) (Chapter 3 Appendix Figure 7e and f).   
 
3.4.3 rFPV and rMVAΔIL-1βR lead to preferential recruitment of CD11b+ 
CD103- conventional DCs to the lung mucosae, 24h post intranasal 
vaccination.  
Our previous studies have shown that transient inhibition of IL-13 at the 
vaccination site can significantly modulate DC recruitment and resulting avidity of 
CD8+ T cells, including B cell immunity 99,122,124. Since we have shown that ILC2 
are the major source of IL-13 at the vaccination site and this is also viral vector-
dependent 338, in this study we have also assessed the influence of viral vector 
on lung DC recruitment  24h post i.n. vaccination as indicated in Figures 31.-3.3. 
In this study, four different lung DC subsets was assessed (CD11b+ CD103- cDC, 
CD11b- CD103+ cross-presenting DC, CD11b- CD8+ cross-presenting DC and 
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CD11b- B220+ pDC (not other immune cell infiltrates)). Percentage of each DC 
subset, for a given viral vector was calculated as a proportion of total MHC-II+ 
CD11c+ DCs, as described in Materials and Methods.  
 
In agreement with Trivedi et al 2014, these studies also showed that rFPV 
recruited significantly elevated proportions of CD11b+ CD103- cDCs compared to 
rMVA and rVV (p=0.0062, p=0.0322 respectively). Additionally, the deletion 
mutant rMVAΔIL-1βR recruited the highest percentage of CD11b+ CD103- cDCs, 
whilst Ad5 recruited the lowest (Figures 3.8a and b). Furthermore, CD11b+ 
CD103- cDC recruitment by Influenza A was similar to that of rFPV, rMVA, rVV 
and RV (Figures 3.8a and b). Compared to the unimmunized control, rFPV, 
rMVAΔIL-1βR and Influenza A showed significant elevated CD11b+ CD103- cDC 
recruitment (p=0.0069, p<0.0001 and p=0.0077 respectively). 
 
3.4.4. Intranasal rVV vaccination recruited elevated numbers of CD11b- 
CD103+ and CD11b- CD8+ cross-presenting DCs to the lung mucosae 24 h 
post vaccination.  
Unlike CD11b+ CD103- cDC recruitment, rFPV induced significantly lower CD11b- 
CD103+ cross-presenting DCs compared to that of the unimmunized control 
(p=0.0224), and these values were significantly lower than that of rVV, Influenza 
A and RV vectors (p<0.0001, p=0.0065 and p<0.0001 respectively) (Figures 
3.8a and c). Interestingly, compared to all viral vectors tested, rVV recruited the 
highest percentage of CD11b- CD103+ cross-presenting DCs to the lung 
mucosae 24 h post vaccination (Figures 3.8a and c). Whilst, rFPV recruited the 
lowest number similar to rMVA, rMVAΔIL-1βR and Ad5 (Figures 3.8a and c). 
Furthermore, the proportion of CD11b- CD8+ cross-presenting DCs recruited by 
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all the vaccine vectors showed a comparable profile to that of the CD11b- CD103+ 
cross-presenting DCs, where rVV showed the highest proportion of CD11b- CD8+ 
cross-presenting DCs (Figures 3.8a,c, 3.9). It is noteworthy that the cross-
presenting CD11b- CD103+ DCs recruited by rVV, Influenza A and RV were 
significantly higher than unimmunized control (p<0.0001, p=0.0067 and p=0.0113 
respectively) (Figures 3.8a and c). Whereas, cross-presenting CD11b- CD8+ 
DCs recruited by rVV and Influenza A although were significantly higher than 
unimmunized control (p<0.0001, p=0.0498 respectively), Ad5 recruitment was 
significantly lower (p=0.0164) (Figures 3.9).  
 
3.4.5. Compared to the other viral vectors, RV and Ad5 recruited elevated 
CD11b- B220+ plasmacytoid DCs to the lung mucosae 24h post intranasal 
vaccination. 
Next when the CD11b- B220+ pDC recruitment profile was assessed, these DCs 
showed a unique profile compared to the other three DC subsets examined. At 
24 h post vaccination, RV and Ad5 recruited the highest percentage of CD11b- 
B220+ pDCs to the lung mucosae, whilst Influenza A, rFPV and rMVAΔIL-1βR 
showed the lowest (Figure 3.10). Among the poxviral vectors, rVV recruited the 
highest proportion of CD11b- B220+ pDCs whilst rFPV recruited the lowest, and 
rMVA and rMVAΔIL-1βR showed a similar pDC profile. Compared to the 
unimmunised control, rVV, RV and Ad5 vectors showed significant differences in 
pDC recruitment 24h post vaccination (p=0.0025, p<0.0001 and p<0.0001 
respectively) (Figure 3.10). 
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3.4.6. Following intranasal vaccination different viral vectors showed 
different kinetic profiles 0 to 48h post vaccination. 
Next, we also evaluated the DC recruitment kinetics 0 to 48 hours post 
vaccination. Distinct DC kinetic profiles for each of the vectors were detected over 
time. rFPV showed significant regulation of CD11b+ CD103- cDCs, which was 
similar to the cDC profile induced by the rMVA deletion variant (rMVAΔIL-1βR), 
unlike the parental rMVA (Figures 3.11a and 3.12a-b). The replication 
competent rVV showed regulation of all DC subsets, with significant modulation 
of cross-presenting DCs. Interestingly, cDC recruitment kinetics between rVV, 
rMVA and Influenza were very similar (Figures 3.11b, 3.12a and c). Ad5 
recruited a pDC profile similar to RV and a CD11b- CD8+ profile similar to rVV 
(Figures 3.11b, c and 3.12d).  
 
3.5. Discussion 
This study has clearly demonstrated that not only the route of vaccination, but 
also different viral vector-based vaccines can induce significantly different ILC 
subsets at the respective vaccination sites 24 h post delivery. In the context of 
ILC2, Lin- ST2/IL-33R+ ILC2 were predominant in lung, whilst Lin- IL-25R+ or/and 
Lin- TSLPR+ ILC2 were found in muscle 24 h post viral vector vaccination. This 
was not entirely surprising as Lin- IL-25R+ ILC2 has been associated with 
circulation 339,340, whilst Lin- TSLPR+ ILC2 is known to be skin-resident 341. 
Although, Lin- ST2/IL-33R+ ILC2 was the major source of IL-13 in lung, Lin- IL-
25R- TSLPR- ST2/IL-33R- ILC2s were the predominant source of IL-13 in muscle. 
Interestingly, recently we have also found that following viral vector vaccination 
IL-5 expression was specific to lung ILC2, not muscle (Jaeson et al. submitted), 
reaffirming that ILCs can be highly plastic under different conditions (specifically 
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chronic inflammatory conditions versus vaccination or infection) 326,342, and why 
different routes of delivery may yield uniquely different innate and adaptive 
immune outcomes.  
 
In addition to ILC2, i.n. versus i.m. vaccinations induced different proportions of 
NKp46+ ILC1/ILC3s unlike NKp46- ILC1/ILC3s. Specifically, significantly lower 
numbers of NKp46+ ILC1/ILC3s were detected in muscle compared to the lung 
(~ 1% vs 4-8%), confirming that circulatory ILC1/ILC3s are scarce as opposed to 
tissue resident ILCs 343. Both NKp46+ and NKp46- ILC1/ILC3s were able to 
express different levels of IFN-g, that were vaccine route- and vector-dependent. 
Specifically, whilst both NKp46+/- ILC1/ILC3 subsets were able to express IFN-g 
in lung, only the NKp46+ ILCs in muscle expressed IFN-g,  albeit by two 
vaccination groups, where the expression was in the order of rFPV > Influenza 
A. Moreover, muscle NKp46- cells expressed extremely low IFN-g following 
Influenza and Ad5 vaccination.  Majority of i.m. delivered vectors induced 
elevated ILC2-driven IL-13 and minimal ILC1/ILC3-driven IFN-g expression 
compared to i.n. delivery. Additionally, our previous studies with pox-viral vectors 
have shown that, compared to i.m., i.n. delivery can induce T cells of higher 
avidity, associated with low IL-13 at the vaccination site 205,314,338. Furthermore, 
i.n. rFPV priming has shown to induce high avidity T cells compared to i.n. rVV 
and Influenza priming vaccination 131,133,344, (Tan, Derose et al. personal 
communication). In agreement with our current study, i.n. Ad5 vaccination has 
also shown comparable ILC2 gene expression profiles to i.n. rFPV, unlike i.m. 
Ad5 delivery (Jaeson et al. submitted). Taken together, these findings may 
explain why systemic vaccination with some viral vectors may lead to suboptimal 
antiviral immunity, compared to mucosal vaccination 133,314,345,346.   
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Besides the route of delivery, each viral vector also induced a uniquely different 
ILC2-driven IL-13 and ILC1/ILC3-driven IFN-g expression profiles. Specifically, 
both i.n. and i.m. rFPV vaccination induced low ILC2-derived IL-13, and high 
NKp46+ or NKp46- ILC1/ILC3-derived IFN-g. In contrast, i.m. rMVA vaccination 
induced lower ILC2-derived IL-13 compared to i.n. delivery. Knowing that, low IL-
13 is associated with improved T cell immunity, our current data may explain why 
previously rMVA has been found to be more efficacious as an i.m. delivery vector 
than a mucosal delivery vector 138,315. Moreover, whilst i.n. delivery of rMVA, 
Influenza A, RV and Ad5 induced elevated ILC2-derived IL-13, the expression of 
IFN-g was lower in NKp46+ ILC1/ILC3s following rMVA, Influenza A; and NKp46- 
ILC1/ILC3s following RV and Ad5 vaccinations. Interestingly, we have previously 
shown that IL-4R antagonist adjuvanted vaccination that transiently inhibited IL-
13 signalling via STAT6, induced low ILC2-derived IL-13 expression associated 
with elevated expression of NKp46- ILC1/ILC3-derived IFN-g  338. Additionally, 
enhanced IfngR gene expression on ILC2 was also recently associated with low 
ILC2-derived IL-13 (Jaeson et al. submitted). Taken together, these observations 
suggest that enhanced ILC1/ILC3-derived IFN-g expression regulates ILC2-
derived IL-13 at the vaccination site, similar to the Th1/Th2 paradigm. Hence, we 
propose that ILC-derived IL-13 and IFN-g balance at the vaccination site crucially 
impacts the downstream vaccine-specific immunity.  
 
Different vectors also lead to differential expression of IL-17A by NKp46+ and 
NKp46- ILC1/ILC3. Specifically, i.n. rMVA, rMVAΔIL-1βR and Influenza A vectors 
induced elevated IL-17A by both ILC1/ILC3 subsets at the lung mucosae 24h 
post vaccination.  However, majority of the vectors induced different levels of IL-
17A by NKp46- ILC1/ILC3 subsets in the muscle. In asthma studies the 
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importance of maintaining IL-13 and IL-17 balance has been well documented 
347. Similarly, our vaccination studies have also shown that IL-13 can regulate IL-
17A expression at the transcriptional and translational level, which plays an 
important role in determining the quality of T cell immunity 348. Knowing that i) rVV 
and its derivatives (rMVA) perform better as a booster vaccine than a prime 133,138 
ii) Influenza A prime yield poor adaptive immune outcomes (Tan, Derose et al. 
personal communication) 344 and iii) systemic Ad5  immunization have shown to 
induce less effective antiviral T cell responses 118,349-351, collectively our data 
suggest that the early onset of high ILC1/ILC3-derived IL-17A together with low 
IFN-g and high ILC2-derived IL-13 could be detrimental for inducing effective 
cellular immunity.  
 
Our study demonstrated that in addition to different ILC profiles, mucosal 
vaccination with different viral vectors yielded uniquely different lung DC profiles 
at the vaccination site 24 h post vaccination. We have previously shown that IL-
13 levels at the vaccination site can significantly alter DC phenotype, specifically, 
inhibition of IL-13 can recruit elevated CD11b+ CD103- cDCs associated with high 
avidity T cells 99. This study further substantiated our previous findings of 
enhanced recruitment of CD11b+ CD103- cDCs as opposed to CD11b- CD103+ 
cross-presenting DCs following i.n. rFPV vaccination. Moreover, moderate 
proportions of CD11b- B220+ pDCs were also observed with rFPV vaccination. 
pDCs are known to induce antibody differentiation via IFN-g production 336 and 
their clustering with cDCs have shown to induce efficient T cell mediated antiviral 
immunity 335. We have already established that rFPV priming can induce robust 
high avidity T cells and differentiated antibodies, involved in protective immunity 
against viral pathogens such as HIV 122,133. Thus, our current findings suggest 
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that although in the context of certain viral vectors, the cDC/pDC balance may 
govern the quality of T and B cell immunity, replicating vectors such as Influenza 
A may employ other mechanisms (as Influenza A showed similar cDC/pDC profile 
to rFPV associated with poor quality T cells).  
 
In contrast to rFPV vaccination, rMVA lead to elevated ILC2-derived IL-13, similar 
to rVV (data not shown), and both vectors significantly enhanced recruitment of 
CD11b- CD103+ cross-presenting DCs to the lung mucosae, as shown previously 
99. This may explain why rMVA and rVV priming lead to low avidity T cells 
following recombinant HIV vaccination 131,133. Moreover, intranasal Influenza A, 
RV and Ad5 vaccination which also lead to high ILC2-derived IL-13, preferentially 
induced CD11b- CD103+ cross-presenting DCs as opposed to cDCs. In a prime-
boost vaccine modality, recombinant Influenza A priming has shown to induce 
enhanced magnitude of vaccine-specific T cells, however, are of low avidity 
unlike rFPV priming (Tan, Derose et al. personal communication). Similarly, 
recombinant Ad5 vaccination has also shown to induce high magnitude of 
vaccine-specific CD8 T cells 140. Therefore, these observations suggest that 
these vectors although lead to enhanced magnitude of vaccine-specific T cell 
immunity (IFN-g production by T cells), may lead to low avidity T cells against 
chronic infections such as HIV-1. Despite low cDCs, Ad5 and RV exhibited a bias 
towards pDC recruitment. Knowing that pDC-driven IFN-g can induce effective 
antibody responses, we postulate that Ad5- and RV-based vaccines could be 
more efficacious in inducing humoral immunity. Similar to CD11b- CD103+ cross-
presenting DCs, rVV additionally induced elevated CD11b- CD8+ cross-
presenting DCs to the lung mucosa. These observations suggested that, early 
induction of CD11b- CD8+ cross-presenting DCs, could also be associated with 
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induction of low avidity T cells. However, in the context of some pathogens, (for 
example, Leishmania, and also some viruses, Influenza and HSV-1 infections), 
induction of cross-presenting DCs have been associated with protective immunity 
330,352,353. Thus, when designing recombinant viral vector-based vaccines, careful 
selection of the vector, according to the pathogen of interest may be of great 
importance. 
 
rMVAΔIL-1βR is known to induce effective memory T cell responses compared 
to parental rMVA vaccination 354. Unlike rMVA, rMVAΔIL-1βR induced low ILC2-
derived IL-13 and elevated cDCs similar to rFPV, which has shown to induce high 
avidity T cells with better protective immunity. These findings indicated that 
removal of a single immune evasive gene from the viral vector can significantly 
alter the innate immune outcomes, specifically the ILCs and DCs, associated with 
effective protective immunity. However, compared to rFPV (which showed 
elevated IFN-g and no IL-17A expression), rMVAΔIL-1βR vaccination induced 
suboptimal ILC1/ILC3-derived IFN-g and high IL-17A expression at the 
vaccination site. It is well established that IFN-g is crucial for antiviral immunity, 
and overexpression of IL-17A can lead to immune imbalance 355. It is also known 
that viral IL-18bp neutralize host IL-18 and prevent IFN-g production 356. Thus, 
the residual IL-18bp in the rMVAΔIL-1βR vector could be responsible for the 
observed ILC1/ILC3-derived IFN-g profile. Thus, we postulate that rMVA vector 
lacking both IL-1βR and IL-18bp genes may lead to ILC/DC profiles similar to 
rFPV and balanced T and B cell outcomes. 
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Furthermore, rVV, rMVA and rMVAΔIL-1βR data clearly demonstrated that the 
attenuation status of a viral vector and the presence or absence of virokines 
significantly modulated the ILC cytokine expression and DC profile. The rFPV 
and rMVAΔIL-1βR data indicated that viral vectors that do not interfere with the 
host immune system could be more efficacious at inducing vaccine-specific 
immunity in humans (e.g.- Avipoxvirus compared to Orthopoxvirus). These 
observations strongly highlight the notion that when designing viral vector-based 
vaccines, in addition to the safety and genetic stability, inherent properties of the 
viruses themselves need serious consideration (in this case, its replicative ability 
within the mammalian host). 
 
We have previously shown that ILC2s are the only source of IL-13 at the 
vaccination site, 24 h post vaccination and IL-13 level in the milieu can crucially 
impact the DC recruitment at the lung mucosae 99,124,338. Hence, collectively our 
findings suggest that, early ILC2-derived IL-13, together with ILC1/ILC3-derived 
IFN-g and IL-17A, differentially impact DC recruitment/regulation at the 
vaccination site (Figure 3.13), associated with adaptive immune outcomes and 
this warrants further investigation. Therefore, we postulate that i) following 
vaccination, ILC and DC profiles may act as predictors of downstream vaccine-
specific immunity and ii) selection of viral vector according to the pathogen of 
interest (eg: virus, bacteria or parasites) may help tailor/design effective viral-
vector based vaccines against chronic pathogens.  
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Chapter 4 
 
Post viral vector-based vaccination IL-13Ra2 functions 
as a master sensor on conventional dendritic cells to 
regulate IL-13 in a STAT3 dependent manner. 3 
 
This work is now published as: Roy, S., Liu, HY., Jaeson, M.I., Deimel, L.P., 
and Ranasinghe, C. Unique IL-13Ra2/STAT3 mediated IL-13 regulation 
detected in lung conventional dendritic cells, 24 h post viral vector vaccination. 
Scientific Reports 2020. 
 
 
 
3 Experiments related to Figures 4.14 and 4.15 were performed by Ho-Ying Liu; and 4.16 
was performed by Lachlan Deimel. 
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4.1 Abstract 
This study demonstrates that 24 h following viral vector-based vaccination IL-
13Ra2 functions as a master sensor on conventional dendritic cells (cDCs), 
abetted by high protein stability coupled with minimal mRNA expression, to 
rapidly regulate DC mediated IL-13 responses at the lung mucosae, unlike IL-
13Ra1. Under low IL-13, IL-13Ra2 performs as a primary signalling receptor, 
whilst under high IL-13, acts to sequester IL-13 to maintain homeostasis, both in 
a STAT3-dependent manner. Likewise, we show that viral vector-derived IL-13 
levels at the vaccination site can induce differential STAT3/STAT6 paradigms in 
lung cDC, that can get regulated collaboratively or independently by TGF-b1 and 
IFN-g. Specifically, low IL-13 responses associated with recombinant Fowlpox 
virus (rFPV) is regulated by early IL-13Ra2, correlated with STAT3/TGF-b1 
expression. Whilst, high IL-13 responses, associated with recombinant Modified 
Vaccinia Ankara (rMVA) is regulated in an IL-13Ra1/STAT6 dependent manner 
associated with IFN-gR expression bias. Different viral vaccine vectors have 
previously been shown to induce unique adaptive immune outcomes. Taken 
together current observations suggest that IL-13Ra2-driven STAT3/STAT6 
equilibrium at the cDC level may play an important role in governing the efficacy 
of vector-based vaccines. These new insights have high potential to be exploited 
to improve recombinant viral vector-based vaccine design, according to the 
pathogen of interest and/or therapies against IL-13 associated disease 
conditions. 
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4.2 Introduction  
IL-13 and IL-4 share a common signalling receptor system and are known to have 
overlapping as well as distinct functions 278. These two cytokines have been 
extensively studied under allergy, asthma, helminth and parasitic infections 
309,357-359. IL-13 is produced by various immune cell types, specifically innate 
lymphoid cells (ILC2s), CD4 and CD8 T cells 130,360 and can directly impact the 
function of eosinophils, basophils and dendritic cells (DCs) 361,362. Recent allergy 
and asthma studies have shown that ILC2-derived IL-13 can stimulate the 
migration of lung DCs to promote Th2 immunity 363. Interestingly, whilst 
overproduction of IL-13 is associated with tissue pathology 364, deficiency of IL-
13 has been associated with increased susceptibility to certain skin cancers 365. 
Moreover, mounting evidence has also suggested the importance of IL-13 
regulation in infection and immunity. 
 
We have previously demonstrated that the vaccine route, viral vector combination 
and cytokine milieu (level of IL-13) can significantly alter the adaptive immune 
outcomes 130,132,133. Pox viral vector-based HIV vaccine strategies that transiently 
inhibited IL-13 activity at the vaccination site, can induce high avidity/poly-
functional T cells both in mice and macaques 122-124 (Li et. al in preparation). 
Interestingly, 24h post delivery of these vaccines, whilst ILC2s were found to be 
the major source of IL-13 at the vaccination site 366, elevated recruitment of 
CD11b+ CD103- conventional DCs (cDC) to the lung mucosae were associated 
with the observed adaptive immune outcomes 99. Moreover, recently we have 
shown that different viral vector-based vaccines can induce unique ILC2-derived 
IL-13 profiles and recruitment of different DC subsets to the vaccination site, 24 
h post delivery 367. Specifically, i.n. rFPV vaccination associated with low ILC2-
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derived IL-13 recruited  CD11b+ CD103- conventional DC (cDC) 99, whilst 
high/medium ILC2-derived IL-13 producers, rMVA and Ad5 vaccinations 
recruited enhanced cross-presenting DCs and plasmacytoid DCs (pDCs) to the 
lung mucosae, respectively. Using adoptive transfer of different DC subsets to 
the lung mucosae, we have also shown that cross-presenting DCs induced low 
avidity HIV-specific T cells, whilst cDC were associated with high avidity T cells 
99  
 
IL-13 can bind to IL-13Ra1 with low affinity (KD = 30 nM) and, heterodimerize with 
IL-4Ra subunit to form the Type II IL-4 receptor complex to activate downstream 
JAK1- or JAK2-/TYK2- induced STAT6 signalling 358. Cheng et al. have also 
proposed that activation of IL-13Ra1/IL-4Ra could induce STAT3 signalling 
under certain IL-13 conditions 108 and a recent study has shown an association 
of IL-13Ra1 with STAT3 in relation to cardiac homeostasis 368. Interestingly, IL-
13Ra2, known to be the high affinity receptor for IL-13 (KD = 440 pM) 278,369, 
initially thought to be a decoy receptor in mice has now been established as a 
functional receptor in humans 370. Overexpression of IL-13Ra2 has been 
associated with various cancers and targeted as an anti-cancer therapeutic 
291,293. Although the exact signalling mechanism of IL-13Ra2 is not yet well-
characterised, in malignant glioma, IL-13Ra2 has shown to regulate activation of 
STAT3 299 and initiate signalling via activation protein 1 (AP-1). Furthermore IL-
13Ra2 has also shown to induce transforming growth factor beta 1 (TGF-b1) 
under certain chronic infections and autoimmune disease conditions 309. 
Recently, we have also shown that in the context of viral vector-based 
vaccination, the STAT6 independent pathway (likely associated with IL-13Ra2) 
was involved in antibody differentiation 302. Therefore, knowing that both STAT3 
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and STAT6 are involved in IL-13 regulation and that IFN-g  can also modulate IL-
13 activity 286,311,371, this study focused on deciphering the IL-13 signalling 
mechanisms lung cDCs employ under different IL-13 conditions (different viral 
vector-based vaccination conditions), to induce vastly different adaptive immune 
outcomes.  
 
4.3 Materials and Methods 
 
4.3.1 Mice.  
Pathogen-free 6–8 weeks old female wild type BALB/c, IL-13-/- and STAT6-/- mice 
on a BALB/c background were purchased from the Australian Phenomics Facility, 
The Australian National University (ANU). All animals were maintained, 
monitored daily, euthanized by cervical dislocation and experiments were 
performed in accordance with the Australian NHMRC guidelines within the 
Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes and in accordance with guidelines approved by the ANU Animal 
Experimentation and Ethics Committee (AEEC), protocol number A2014/14 and 
A2017/15. 
 
4.3.2 Immunisation.  
BALB/c mice were intranasally immunised with 1 X 107 plaque forming units (pfu) 
of rFPV, rMVA, or 2 X 107 pfu of Ad5. Mice were vaccinated with a volume of 10 
µl per nostril (total 20 µl) under mild isofluorane anaesthetic. rFPV and rMVA 
were sonicated thrice for 15 seconds in ice at 50% capacity using Branson 
Sonifier 450 immediately prior to vaccination.  
 
 110 
4.3.3 Evaluation of lung DCs and IL-4/IL-13 and IFN-g receptors using Flow 
cytometry. 
Lung tissues were collected 24 h post vaccination as described in Li et al. 2018 
366. 2 X 106 cells from each sample were blocked with anti-mouse CD16/CD32 
antibody (BD Biosciences, USA) for 20 min at 4°C and cells were surface stained 
with APC-conjugated anti-mouse MHCII I-Ad (e-Biosciences, USA), biotin-
conjugated anti- mouse CD11c (N418 clone, Biolegend, USA), followed by 
streptavidin Brilliant violet 421 (Biolegend, USA), anti-mouse CD11b AlexaFluor 
700 (M1170 clone, Biolegend, USA) and anti-mouse CD103 FITC (2E7 clone, e-
Biosciences, USA) for 30 min on ice as previously described in 367. Cells were 
additionally extracellularly or intracellularly stained with anti-mouse IL-4Ra 
(CD124) PE (I015F8 clone, Biolegend, USA), anti-mouse IL-13Ra1 (CD213a) PE 
(13MOKA clone, e-Biosciences, USA), Biotin-conjugated anti-mouse IL-13Ra2 
(110815 clone, R&D systems, USA), followed by streptavidin PE (Biolegend, 
USA), anti-mouse gc (CD132) PE (TUGm2 clone, Biolegend, USA) and biotin-
conjugated anti-mouse IFN-gRa chain (CDw119) (2E2 clone, Biolegend, USA), 
followed by streptavidin PE (Biolegend, USA). For intracellular staining, cells 
were fixed using Fixation buffer (Biolegend, USA) for 10 minutes at 4°C followed 
by permeabilisation using 1x Intracellular staining permeabilisation wash buffer 
(Biolegend, USA) for 10 minutes at 4°C prior to intracellular staining. Cells were 
fixed using 1.5% paraformaldehyde followed by resuspension in PBS and 
analysed using BD LSRII flow cytometer Becton Dickinson, San Diego, CA). 5 
x105 events per sample were acquired and results were analyzed using FlowJo 
software v10.0.7.  
 
4.3.4 In vitro STAT3 and STAT6 inhibition assays.  
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Unimmunised BALB/c lung suspensions were treated with either 100 nM of small 
molecule STAT6 inhibitor (Axon Medchem) or 20 µM Stattic (small molecule 
STAT3 inhibitor) in PBS overnight followed by low (100 pg/ml) or high (10,000 
pg/ml) IL-13 stimulation for 3 h or 0.5 h (as mentioned in specific figures) before 
evaluation of IL-4 and IL-13 receptor expression on lung DCs using flow 
cytometry as described above. Biologically relevant inhibitor concentrations were 
used in this study as reported previously 302,372. 
 
4.3.5 Immunofluorescence assays. 
Single cell suspensions of lungs were washed to remove media and blocked with 
anti-mouse CD16/CD32 Fc Block antibody (BD Biosciences, USA) for 20 min at 
4°C and cells were surface stained with FITC- conjugated anti-mouse CD11c 
(N418 clone, Merck, Germany), anti-mouse IL-4Ra (CD124) PE (I015F8 clone, 
Biolegend), anti-mouse IL-13Ra1 (CD213a) PE (13MOKA clone, e-Biosciences, 
USA), Biotin-conjugated anti-mouse IL-13Ra2 (110815 clone, R&D systems, 
USA), followed by streptavidin APC (Biolegend, USA) and biotin-conjugated anti-
mouse IFN-gRa chain (CDw119) (2E2 clone, Biolegend, USA), followed by 
streptavidin PE (Biolegend, USA). Cells were fixed using 1.5% Paraformaldehyde 
(Biolegend, USA) and suspension cells were centrifuged onto Poly-L-Lysin 
(Sigma, USA) coated glass cover slips. Cover slip containing cell pellet was 
covered with 10 µl of Antifade Vectashield mounting medium with or without 4′,6-
diamidino-2-phenylindole (DAPI) from Vector Laboratories, USA and mounted 
onto a clean glass slide. Slides were imaged and analysed using Leica TCS SP5 
confocal microscope (Leica, Germany) at 60x magnification. DAPIlow CD11c+ 
cells were identified as viable lung DCs for receptor expression. To quantify 
receptor co-expression, each CD11c+ DC double positive for a given receptor 
 112 
combination (IL-13Ra1 and IL-13Ra2, IL-4Ra and IL-13Ra2, or IL-13Ra2 and 
IFN-gR) was identified and quantified per imaged area as described in Figure 
4.1. Proportion of each receptor combination was calculated as a percentage of 
the total number of viable DCs per imaged area. Data were represented as an 
average of 5 imaged areas from each experiment. To quantify IL-13/IL-4 receptor 
intensity, ImageJ software v 1.52e (for Windows) was used. During this process, 
DAPIlow CD11c+ cells expressing the receptor of interest were identified (Figure 
4.2). Next, each cell was identified as a region of interest (ROI) and the software 
generated integrated density of the ROI was used to calculate receptor intensity 
as; IL-13/IL-4 receptor intensity = (Integreated density of ROI/ Area of ROI).  
 
4.3.6 cDC sorting for Fluidigm 48.48 Biomark and qPCR assays. 
Single (n=48 per vaccine group) or 500 cDCs were sorted into 5 µl or 25 µl pre-
amplification mixture respectively using a BD FACS Aria II cell sorter, using the 
gating strategy as described in Figure 4.12. The pre-amplification mixture 
contained 2x reaction buffer, SuperScript® III RT/Platinum® Taq Mix, 0.2x pooled 
assays, SUPERase• In™ RNase Inhibitor and DEPC treated water per well.  
 
Sorted cDCs in pre-amplification mixture were centrifuged at 1454 x g to release 
mRNA as previously described 308. The cDNA was synthesised using thermo-
cycling program: 1x cycle of 50o C for 15 minutes, 95o C for 2 minutes followed 
by 14- 20 cycles (for single or 500 cells) of 95o C for 15 seconds and 60o C for 4 
minutes, followed by storing samples at -20o C until use.  
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4.3.7 Real-time quantitative PCR (RT-qPCR) analysis of IL-4/IL-13 receptors. 
RT-qPCR for 500 cells was performed using TaqMan qPCR mix (containing 1 μL 
of each gene expression assay (primers listed in Table 2.6), 5 μL of 2X TaqMan 
Universal PCR master mix, 1 μL cDNA and 4.5 μL of DEPC treated water), using 
a 7900HT thermocycler program: 50oC for 2 minutes, 95oC for 10 minutes, and 
45 cycles of 95oC for 15 seconds and 60oC for 1 minute. The targeted primer-
probe FAM fluorescence was detected by normalising to ROX (6- carboxy-X-
rhodamine) intensity. SDS 2.4 for Windows software was used to obtain the cycle 
threshold (Ct) values (ranging from 0 to 45) and the mRNA amplification profiles. 
Ct values were subject to quality control using SDS 2.4 analysis software where, 
0 indicated a high expression and values closer to 45  
indicated low expression levels. 
 
4.3.8 Fluidigm 48.48 Biomark gene expression assay.  
Fluidigm 48.48 gene expression assay was performed as previously described 
308. Briefly, prior to loading the integrated fluidic chip (IFC) (Fluidigm), the cDNA 
was diluted 1:1 cDNA:DEPC treated water. Following chip priming, 2.5μL of 
diluted cDNA (in DEPC water) and 0.25 μL of 20X GE Sample Loading Reagent 
was loaded onto the sample side of the chip. Subsequently, 2.5 μL of each gene 
expression assay (Figure 4.3) and 2.5 μL of 20X GE Assay Loading Reagent 
was loaded onto the assay side of the IFC. Next, the IFC was loaded onto the 
IFC Controller MX and gene expression assay was performed and analysed 
using the GE 48.48 Standard.pcl program on the Fluidigm BiomarkTM. The 
fluorescence values obtained from the Fluidigm BiomarkTM were normalised to 
ROX (6- carboxy-X-rhodamine) intensity. Ct values (ranging from  
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0 to 40) were subject to quality control using the Biomark Real-time qPCR 
analysis software where, 0 indicated a high expression and values closer to 40 
indicated low expression levels. Binary analysis was performed to determine the 
proportion of cells expressing a certain gene using RStudio and Microsoft Excel 
2016 software and analysed using GraphPad Prism 7.0.  
 
4.3.9 Statistical analysis. 
Lung MHC-II+ CD11c+ CD11b+ CD103- cDC proportions were represented as a 
percentage of total MHC-II+ CD11c+ DCs and receptor proportions were 
calculated as a percentage of parent cDC population as described in 367. The p-
values were calculated using either two-tailed, paired parametric Student’s t-test 
or Ordinary One-way ANOVA with Tukey’s multiple comparison post-test. Gene  
expression was first analysed as percentage of cDCs expressing a gene of 
interest. For each gene of interest, the Ct value for the housekeeping gene (l32) 
was subtracted from each sample Ct value to determine DCt, and the gene 
expression level was calculated as 40–DCt or 45–DCt. All experiments were 
repeated minimum two times. Principal Component Analysis (PCA) was 
performed to analyse the relationship between the genes, using a correlation 
matrix created using Spearman’s rho (ρ) as described previously 308. To 
determine the co-expression profile with respect to only Stat3, Stat6, tgfb1 and 
Ifngr1, following PCA, a k-means clustering algorithm using RStudio was used to 
identify clusters. To determine statistical significance with respect to co-
expression studies, a Fisher’s exact test was implemented with False Discovery 
Rate (FDR) correction.  
 
4.4 Results 
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4.4.1 rFPV vaccination significantly up-regulated IL-13Ra2 expression on 
lung cDCs 24 h post i.n. vaccination  
Knowing that rFPV priming, which induced low ILC2-derived IL-13 and CD11b+ 
CD103- cDCs 367, was associated with high avidity T cells 99, this study aimed to 
unravel the underlying mechanisms by which IL-13 regulated cDC recruitment, 
following intranasal (i.n.) rFPV vaccination. Hence, IL-4/IL-13 receptor expression 
on lung cDCs (MHC-II+ CD11c+ CD11b+ CD103-) were evaluated 24 h post 
delivery using flow cytometry following gating strategy described in Figure 4.4. 
Data revealed that infiltrated lung cDCs in response to 24 h of i.n. rFPV 
vaccination exhibited significantly higher proportion of intracellular and 
extracellular expression of IL-13Ra2 compared to the unimmunised control 
(p<0.0001; Figure 4.5a and b). In the context of other IL-4/IL-13 associated 
receptors, IL-4Ra, IL-13Ra1 and gc were marginally or not expressed on cDCs 
(p<0.001; Figure 4.5a and b). Upon vaccination although intracellular IL-13Ra1 
expression was up-regulated compared to the unimmunised control (p=0.0019), 
no such difference was observed extracellularly (Figure 4.5a and b). Moreover, 
unlike the other receptors, significantly higher IL-13Ra2 density was also 
observed on vaccinated lung cDCs compared to the unimmunized control 
(p=0.0006) (Figure 4.5c and d). Note that to validate the specificity of IL-4/IL-13 
receptor antibodies, expression of these receptors was assessed on several 
different immune cells as well as tissue types. Interestingly, elevated IL-13Ra2 
expression was only observed on vaccinated lung DCs not splenic (systemic) 
DCs or other immune cells (CD4+ T cells, CD8+ T cells and B220+ B cells) tested 
from both tissue types (Figures 4.6 and 4.7), indicating that the IL-13Ra2 
expression pattern was lung DC-specific.  
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Interestingly, qPCR analysis of IL-4/IL-13 mRNA expression on lung cDCs at 24 
h post rFPV vaccination revealed that Il13ra2 mRNA expression was significantly 
lower (associated with high Ct) (Figure 4.5e and 4.8) compared to all the other 
receptors, where Il4ra and gC mRNA expression levels were much greater than 
Il13ra1 and Il13ra2 (Il13ra2 vs Il4ra p=0.0034, Il13ra2 vs gC p=0.0018), (Figure 
4.5e). However, in the context of IL-13Ra2, at 72 h post rFPV vaccination, 
elevated mRNA followed by reduced protein expression was observed (inverse 
to 24h) (Figure 4.5f and g), indicative of a non-linear mRNA-protein regulation 
of this receptor.  
 
To further confirm the expression profiles of IL-13Ra2, IL-13Ra1 and IL-4Ra 24 
h post rFPV vaccination on lung DCs, immunofluorescence staining was also 
performed as described in methods and Figure 4.9a. Data showed that elevated 
proportion of lung CD11c+ DCs expressed IL-13Ra2, compared to IL-13Ra1 or 
IL-4Ra,  (p<0.0001) in accordance with flow cytomtery data (Figure 4.10a and 
b).  
 
4.4.2 IL-13 stimulation conditions lead to differential expression of IL-13Ra1 
and IL-13Ra2 on CD11c+ lung DCs  
As different viral vector-based vaccines have shown to induce different levels of 
IL-13 at the lung mucosae, which influence DC activity 367, in vitro IL-13 
stimulation was performed to mimic these vaccination conditions in order to study 
the effect of IL-13 on IL-4/IL-13 receptors. Flow cytometric analysis showed that 
when unimmunized lung cells from BALB/c mice were stimulated with a range of 
IL-13 concentrations, at different time intervals, IL-13Ra1 and IL-13Ra2 were 
differentially expressed. Within 30 minutes of low IL-13 (100 
% of max
R
e
c
e
p
to
r
C
D
4
+
T
 c
e
ll
s
C
D
8
+
T
 c
e
ll
s
B
2
2
0
+
B
 c
e
ll
s
M
H
C
-I
I+
C
D
1
1
c
+
 
D
C
s
IL
-4
R
a
IL
-1
3
R
a
1
IL
-1
3
R
a
2
gC
SSC-A
F
S
C
-A
FSC-H
F
S
C
-A
B220
F
S
C
-A
CD3
F
S
C
-A
O
R
P
1
CD4
C
D
8
P
2
P
3
P
4
P
5
P
6
% of max
R
e
c
e
p
to
r
F
ig
u
re
4
.6
.
E
v
a
lu
a
ti
o
n
o
f
IL
-4
a
n
d
IL
-1
3
re
c
e
p
to
r
e
x
p
re
s
s
io
n
o
n
lu
n
g
ly
m
p
h
o
c
y
te
s
a
n
d
D
C
s
2
4
h
fo
ll
o
w
in
g
rF
P
V
v
a
c
c
in
a
ti
o
n
.
B
A
L
B
/c
m
ic
e
n
=
5
w
e
re
i.
n
.
v
a
c
c
in
a
te
d
w
it
h
rF
P
V
a
n
d
2
4
h
p
o
s
t
lu
n
g
s
w
e
re
p
re
p
a
re
d
a
s
d
e
s
c
ri
b
e
d
in
m
e
th
o
d
s
.
(L
e
ft
p
a
n
e
l)
B
2
2
0
+
B
c
e
lls
(P
3
)
w
e
re
g
a
te
d
fr
o
m
S
in
g
le
ly
m
p
h
o
c
y
te
s
(P
2
)
a
n
d
C
D
4
+
T
c
e
lls
(P
5
)
a
n
d
C
D
8
+
T
c
e
lls
(P
6
)
w
e
re
g
a
te
d
fr
o
m
C
D
3
+
T
c
e
lls
(P
3
),
fo
llo
w
in
g
g
a
ti
n
g
o
n
s
in
g
le
ly
m
p
h
o
c
y
te
s
(P
2
).
M
H
C
-I
I+
C
D
1
1
c
+
D
C
s
w
e
re
g
a
te
d
fo
llo
w
in
g
s
tr
a
te
g
y
d
e
s
c
ri
b
e
d
in
m
e
th
o
d
s
.
(R
ig
h
t
p
a
n
e
l)
F
lo
w
c
y
to
m
e
tr
y
a
n
a
ly
s
is
w
a
s
p
e
rf
o
rm
e
d
a
n
d
re
p
re
s
e
n
ta
ti
v
e
h
is
to
g
ra
m
p
lo
ts
s
h
o
w
g
e
o
m
e
tr
ic
m
e
a
n
in
te
n
s
it
ie
s
fo
r
IL
-4
R
a
,
IL
-1
3
R
a
1
,
gc
a
n
d
IL
-1
3
R
a
2
(r
e
d
lin
e
)
a
g
a
in
s
t
th
e
is
o
ty
p
e
c
o
n
tr
o
l
(s
o
lid
g
re
y
)
o
n
lu
n
g
C
D
4
+
T
c
e
lls
,
C
D
8
+
T
c
e
lls
,
B
2
2
0
+
B
c
e
lls
a
n
d
M
H
C
-I
I+
C
D
1
1
c
+
D
C
s
.
% of max
R
e
c
e
p
to
r
C
D
4
+
T
 c
e
ll
s
C
D
8
+
T
 c
e
ll
s
B
2
2
0
+
B
 c
e
ll
s
M
H
C
-I
I+
C
D
1
1
c
+
 
D
C
s
IL
-4
R
a
IL
-1
3
R
a
1
IL
-1
3
R
a
2
gC
F
ig
u
re
4
.7
.
E
v
a
lu
a
ti
o
n
o
f
IL
-4
a
n
d
IL
-1
3
re
c
e
p
to
r
e
x
p
re
s
s
io
n
o
n
s
p
le
n
ic
ly
m
p
h
o
c
y
te
s
a
n
d
D
C
s
.
U
n
im
m
u
n
is
e
d
B
A
L
B
/c
m
ic
e
n
=
5
w
e
re
u
s
e
d
to
o
b
ta
in
s
p
le
e
n
s
a
n
d
s
in
g
le
c
e
ll
s
u
s
p
e
n
s
io
n
s
w
e
re
p
re
p
a
re
d
to
s
ta
in
fo
r
ly
m
p
h
o
c
y
te
s
a
n
d
D
C
s
a
s
d
e
s
c
ri
b
e
d
in
m
e
th
o
d
s
.
C
D
4
+
T
c
e
lls
,
C
D
8
+
T
c
e
lls
a
n
d
B
2
2
0
+
B
c
e
lls
w
e
re
g
a
te
d
a
s
s
h
o
w
n
in
F
ig
u
re
4
.7
a
n
d
M
H
C
-I
I+
C
D
1
1
c
+
D
C
s
w
e
re
g
a
te
d
fo
llo
w
in
g
s
tr
a
te
g
y
d
e
s
c
ri
b
e
d
in
m
e
th
o
d
s
.
F
lo
w
c
y
to
m
e
tr
y
a
n
a
ly
s
is
w
a
s
p
e
rf
o
rm
e
d
a
n
d
re
p
re
s
e
n
ta
ti
v
e
h
is
to
g
ra
m
p
lo
ts
s
h
o
w
g
e
o
m
e
tr
ic
m
e
a
n
in
te
n
s
it
ie
s
fo
r
IL
-
4
R
a
,
IL
-1
3
R
a
1
,
gc
a
n
d
IL
-1
3
R
a
2
(r
e
d
lin
e
)
a
g
a
in
s
t
th
e
is
o
ty
p
e
c
o
n
tr
o
l
(s
o
lid
g
re
y
)
o
n
s
p
le
n
ic
C
D
4
+
T
c
e
lls
,
C
D
8
+
T
c
e
lls
,
B
2
2
0
+
B
c
e
lls
a
n
d
M
H
C
-I
I+
C
D
1
1
c
+
D
C
s
.
RawCtvalues
l3
2 I
l1
3r
a2
Il1
3r
a1
Il4
ra
gC
0
1
5
3
0
4
5
**
**
**
*
**
** *
*
F
ig
u
re
4
.8
.
E
v
a
lu
a
ti
o
n
o
f
IL
-4
/
IL
-1
3
re
c
e
p
to
r
m
R
N
A
e
x
p
re
s
s
io
n
o
n
lu
n
g
c
D
C
s
a
t
2
4
h
p
o
s
t
rF
P
V
v
a
c
c
in
a
ti
o
n
.
B
A
L
B
/c
m
ic
e
lu
n
g
s
(n
=
3
)
w
e
re
h
a
rv
e
s
te
d
a
t
2
4
h
p
o
s
t
rF
P
V
v
a
c
c
in
a
ti
o
n
a
n
d
s
in
g
le
c
e
ll
s
u
s
p
e
n
s
io
n
s
w
e
re
F
A
C
S
s
o
rt
e
d
fo
r
5
0
0
M
H
C
-
II
+
C
D
1
1
c
+
C
D
1
1
b
+
C
D
1
0
3
-
c
D
C
s
to
e
v
a
lu
a
te
IL
-4
a
n
d
IL
-1
3
re
c
e
p
to
rs
a
t
th
e
m
R
N
A
le
v
e
l
u
s
in
g
q
P
C
R
a
s
d
e
s
c
ri
b
e
d
in
m
e
th
o
d
s
.
B
a
r
g
ra
p
h
s
re
p
re
s
e
n
t
ra
w
C
t
v
a
lu
e
s
fo
r
a
ll
re
c
e
p
to
rs
a
n
d
h
o
u
s
e
-k
e
e
p
in
g
g
e
n
e
,
R
ib
o
s
o
m
a
l
p
ro
te
in
L
3
2
(l
3
2
).
N
o
te
th
a
t
h
ig
h
C
t
in
d
ic
a
te
s
lo
w
m
R
N
A
e
x
p
re
s
s
io
n
.
E
rr
o
r
b
a
rs
re
p
re
s
e
n
t
S
ta
n
d
a
rd
E
rr
o
r
o
f
m
e
a
n
(S
E
M
)
a
n
d
p
v
a
lu
e
s
w
e
re
c
a
lc
u
la
te
d
u
s
in
g
O
n
e
-w
a
y
A
N
O
V
A
fo
llo
w
e
d
b
y
T
u
k
e
y
’s
m
u
lt
ip
le
c
o
m
p
a
ri
s
o
n
te
s
t.
*p
<
0
.0
5
,
**
p
<
0
.0
1
,
**
*p
<
0
.0
0
1
,
**
**
p
<
0
.0
0
0
1
.
E
x
p
e
ri
m
e
n
ts
w
a
s
re
p
e
a
te
d
tw
o
ti
m
e
s
.
(a
)
R
e
p
re
s
e
n
ta
ti
v
e
 i
m
a
g
e
s
 f
o
r 
D
A
P
I 
o
n
ly
 b
a
c
k
g
ro
u
n
d
 c
o
n
tr
o
l 
fo
r 
c
o
n
fo
c
a
l 
m
ic
ro
s
c
o
p
y
 i
m
a
g
e
s
D
A
P
I
F
IT
C
P
E
A
P
C
D
A
P
I 
o
n
ly
 b
a
c
k
g
ro
u
n
d
 c
o
n
tr
o
l 
a
n
d
 u
n
s
ta
in
e
d
 c
o
n
tr
o
l 
fo
r 
in
 v
it
ro
 I
L
-1
3
 s
ti
m
u
la
ti
o
n
 s
tu
d
ie
s
(b
)
H
ig
h
 I
L
-1
3
 (
D
A
P
I)
L
o
w
 I
L
-1
3
 (
D
A
P
I)
F
ig
u
re
4
.9
.
Im
m
u
n
o
fl
u
o
re
s
c
e
n
c
e
im
a
g
in
g
o
f
lu
n
g
C
D
1
1
c
+
D
C
n
e
g
a
ti
v
e
c
o
n
tr
o
ls
fo
r
re
c
e
p
to
rs
u
s
in
g
c
o
n
fo
c
a
l
m
ic
ro
s
c
o
p
y.
(a
)
R
e
p
re
s
e
n
ta
ti
v
e
c
o
n
fo
c
a
l
m
ic
ro
s
c
o
p
y
im
a
g
e
s
o
f
lu
n
g
c
e
lls
s
ta
in
e
d
w
it
h
D
A
P
I
to
id
e
n
ti
fy
v
ia
b
le
c
e
lls
u
n
s
ta
in
e
d
fo
r
re
c
e
p
to
r
a
n
ti
b
o
d
ie
s
,
s
h
o
w
in
g
n
e
g
a
ti
v
e
c
o
n
tr
o
ls
fo
r
th
e
F
IT
C
,
P
E
a
n
d
A
P
C
c
h
a
n
n
e
ls
.
(b
)
U
n
im
m
u
n
is
e
d
lu
n
g
c
e
lls
s
h
o
w
in
g
D
A
P
Ilo
c
e
lls
s
ti
m
u
la
te
d
w
it
h
,
lo
w
(1
0
0
p
g
/m
l)
a
n
d
h
ig
h
(1
0
0
0
0
p
g
/m
l)
IL
-1
3
.
W
h
it
e
a
rr
o
w
s
in
d
ic
a
te
C
D
1
1
c
+
D
C
s
c
o
-e
x
p
re
s
s
in
g
IL
-1
3
R
a
2
a
n
d
IL
-1
3
R
a
1
,
w
h
ils
t
y
e
llo
w
a
rr
o
w
s
s
h
o
w
e
x
p
re
s
s
io
n
o
f
IL
-1
3
R
a
1
o
n
ly
.
D
A
P
I
C
D
1
1
c
-
F
IT
C
IL
-1
3
R
a
1
-P
E
IL
-1
3
R
a
2
-
A
P
C
D
A
P
I
C
D
1
1
c
-
F
IT
C
IL
-4
R
a
-P
E
IL
-1
3
R
a
2
-
A
P
C
(a
)
012345
2
0
4
0
6
0
8
0
1
0
0
**
**
**
**
% receptor+ CD11c+
DCs
(b
)
IL
-1
3
R
α
2
IL
-1
3
R
α
1
IL
-4
R
α
F
ig
u
re
4
.1
0
.
E
v
a
lu
a
ti
o
n
o
f
IL
-4
/I
L
-1
3
re
c
e
p
to
r
e
x
p
re
s
s
io
n
o
n
lu
n
g
C
D
1
1
c
+
D
C
s
2
4
h
fo
ll
o
w
in
g
rF
P
V
v
a
c
c
in
a
ti
o
n
u
s
in
g
c
o
n
fo
c
a
l
m
ic
ro
s
c
o
p
y.
(a
)
R
e
p
re
s
e
n
ta
ti
v
e
im
m
u
n
o
fl
u
o
re
s
c
e
n
c
e
im
a
g
e
s
s
h
o
w
lu
n
g
c
e
lls
fr
o
m
i.
n
.
rF
P
V
v
a
c
c
in
a
te
d
B
A
L
B
/c
m
ic
e
(n
=
5
)
2
4
h
p
o
s
t-
d
e
liv
e
ry
,
e
x
p
re
s
s
in
g
IL
-1
3
R
a
2
+
a
n
d
IL
-1
3
R
a
1
+
(t
o
p
p
a
n
e
l)
a
n
d
IL
-1
3
R
a
2
+
a
n
d
IL
-4
R
a
+
(b
o
tt
o
m
p
a
n
e
l)
a
t
m
a
g
n
if
ic
a
ti
o
n
x
6
0
,
a
s
d
e
s
c
ri
b
e
d
in
m
e
th
o
d
s
.
W
h
it
e
a
rr
o
w
s
in
d
ic
a
te
C
D
1
1
c
+
D
C
s
e
it
h
e
r
IL
-1
3
R
a
2
+
IL
-
1
3
R
a
1
+
o
r
IL
-1
3
R
a
2
+
IL
-4
R
a
+
.
(b
)
B
a
r
g
ra
p
h
s
h
o
w
s
th
e
s
ig
n
if
ic
a
n
t
d
if
fe
re
n
c
e
s
b
e
tw
e
e
n
p
e
rc
e
n
ta
g
e
o
f
c
D
C
s
e
x
p
re
s
s
in
g
IL
-1
3
R
a
2
+
,
IL
-1
3
R
a
1
+
,
o
r
IL
-4
R
a
+
.
E
rr
o
r
b
a
rs
re
p
re
s
e
n
t
S
ta
n
d
a
rd
E
rr
o
r
o
f
m
e
a
n
(S
E
M
)
a
n
d
p
v
a
lu
e
s
w
e
re
c
a
lc
u
la
te
d
u
s
in
g
O
n
e
-w
a
y
A
N
O
V
A
fo
llo
w
e
d
b
y
T
u
k
e
y’
s
m
u
lt
ip
le
c
o
m
p
a
ri
s
o
n
te
s
t.
*p
<
0
.0
5
,
**
p
<
0
.0
1
,
**
*p
<
0
.0
0
1
,
**
**
p
<
0
.0
0
0
1
.
A
ll
e
x
p
e
ri
m
e
n
ts
w
e
re
re
p
e
a
te
d
th
re
e
ti
m
e
s
.
% IL-13R2+ cDCs
0
1
2
3
4
5
6
7
5
8
0
8
5
9
0
9
5
1
0
0
0
1
2
3
4
5
6
05
1
0
1
5
% IL-13R1+ cDCs
(a
)
1
0
0
 p
g
/m
L
1
0
0
0
0
 p
g
/m
L
T
im
e
 (
h
)
T
im
e
 (
h
)
(b
)
F
ig
u
re
4
.1
1
(a
-b
).
E
v
a
lu
a
ti
o
n
o
f
re
la
ti
v
e
IL
-1
3
R
a
1
a
n
d
IL
-1
3
R
a
2
e
x
p
re
s
s
io
n
o
n
lu
n
g
D
C
s
fo
ll
o
w
in
g
lo
w
a
n
d
h
ig
h
IL
-1
3
s
ti
m
u
la
ti
o
n
in
v
it
ro
u
s
in
g
fl
o
w
c
y
to
m
e
tr
y.
L
u
n
g
c
e
lls
fr
o
m
u
n
im
m
u
n
is
e
d
B
A
L
B
/c
(n
=
5
p
e
r
g
ro
u
p
)
w
e
re
s
ti
m
u
la
te
d
w
it
h
1
0
0
p
g
/m
l
(l
o
w
)
o
r
1
0
0
0
0
p
g
/m
l
(h
ig
h
)
IL
-1
3
fo
r
0
.5
,
3
a
n
d
6
h
.
L
u
n
g
s
u
s
p
e
n
s
io
n
s
w
e
re
s
ta
in
e
d
fo
r
M
H
C
-I
I+
C
D
1
1
c
+
D
C
s
a
n
d
IL
-1
3
re
c
e
p
to
r
e
x
p
re
s
s
io
n
w
a
s
e
v
a
lu
a
te
d
u
s
in
g
fl
o
w
c
y
to
m
e
tr
y.
L
in
e
g
ra
p
h
s
s
h
o
w
p
e
rc
e
n
ta
g
e
o
f
lu
n
g
c
D
C
s
e
x
p
re
s
s
in
g
(a
)
IL
-1
3
R
a
2
a
n
d
(b
)
IL
-
1
3
R
a
1
in
re
s
p
o
n
s
e
to
lo
w
o
r
h
ig
h
IL
-1
3
c
o
n
c
e
n
tr
a
ti
o
n
s
o
v
e
r
ti
m
e
.
E
rr
o
r
b
a
rs
re
p
re
s
e
n
t
S
ta
n
d
a
rd
E
rr
o
r
o
f
m
e
a
n
(S
E
M
).
E
x
p
e
ri
m
e
n
ts
w
e
re
re
p
e
a
te
d
th
ri
c
e
.
 136 
pg/ml) stimulation, IL-13Ra2 was expressed, and was sustained even at 10000 
pg/ml (10 ng/ml) IL-13 concentration (Figure 4.11a). In contrast, only very high 
IL-13 concentrations, 10000 pg/ml (10 ng/ml) lead to the expression of IL-13Ra1 
and the expression was time dependent, where at 6h the expression level was 
similar to the baseline control, unlike IL-13Ra2 (Figure 4.11b). Confocal imaging 
as described in methods further confirmed that very high IL-13 10000 pg/ml (10 
ng/ml) can induce elevated expression of IL-13Ra1 on lung CD11c+ DCs 
compared to no or low IL-13 (100 pg/ml) conditions (p<0.0001) (Figure 4.11c top 
and bottom panels). In contrast, both high and low IL-13 conditions, showed no 
difference in IL-13Ra2 expression on lung CD11c+ DCs, consistent with flow 
cytometry (Figure 4.11c top and middle panels). Moreover, an average 77% and 
15% of lung CD11c+ DCs were found to co-express IL-13Ra2 and IL-13Ra1 
under high and low IL-13 conditions respectively (Figure 4.11d). Confocal 
microscopy also further confirmed that there was no IL-4Ra activity following IL-
13 stimulation (data not shown).  
 
4.4.3 STAT3 inhibition significantly up-regulated IL-13Ra2 and down-
regulated IL-13Ra1 on lung DCs  
IL-13Ra1 signalling is known to activate STAT6 278, and in some cases STAT3 
368,371, and IL-13Ra2 has shown to activate STAT3 and TGF-b1 299,309. 
Furthermore, our recent studies have shown Stat3, Stat6 and Tgfb1 gene 
expression on lung ILC2s, 24 h following viral vector vaccination (Jaeson et al. 
submitted). Knowing that ILC2-derived cytokines, especially IL-13, can impact 
DC recruitment 367, in this study, 12 regulatory genes were assessed by single  
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cell Fluidigm 48.48 assay as described in materials and methods and Figure 
4.12. Data revealed that, 40-60% of cDCs expressed Tgfb1, Stat3 and Stat6, 24 
h post rFPV vaccination (Figure 4.13a). Also, 15-20% of cDCs were found to 
express Ifngr1 and cd86. The cd86 expression as opposed to siglec-h further 
confirmed that the sorted single cells were cDCs and not pDCs (Figure 4.13a). 
Principal component Analysis (PCA) revealed that, the probability of co-
expression of Stat3 and Tgfb1 on cDCs was much greater (75%) than Tgfb1 and 
Stat6 (42%) (Figure 4.13b), and co-expression of Stat3 together with Stat6 was 
(53%), 24 h post rFPV vaccination (Figure 4.13b). Furthermore, the probability 
of co-expression of Ifngr1 with Stat3 whilst being 39%, Ifngr1 with Tgfb1 was 
22%, which were much lower than co-expression of Ifngr1 and Stat6 (46%) 
(Figure 4.13b). Note that in these studies, Ribosomal protein L32 (Rpl32), 
Stratifin (Ywhas) and Eukaryote elongation factor 2 (Eef2) were used as 
endogenous positive control genes to validate the mRNA data (Table 2.6). 
 
To understand the relationship between STAT3, STAT6 and IL-13Ra2 at the 
protein level (by mimicking low and high IL-13 conditions at the vaccination site 
post different viral vector-based vaccination), when lung cells were treated with 
small-molecule inhibitors of STAT3 or STAT6 in the presence of low (100 pg/ml) 
and high (10000 pg/ml or 10ng/ml) IL-13, differential regulation of IL-13Ra2 was 
detected on lung DCs. These results clearly demonstrated that under low IL-13 
stimulatory conditions, STAT3 inhibition caused significant up-regulation of IL-
13Ra2 compared to the uninhibited control (p<0.001) (Figure 4.14a-b). In 
contrast, under these conditions, although STAT6 inhibition showed some up-
regulation of IL-13Ra2 (Figure 4.14a-b), combined STAT3/STAT6 inhibition did 
 146 
not show any change in IL-13Ra2 expression compared to STAT6 inhibition 
alone, although there was some up-regulation compared to the control  
 (p=0.026) (Figure 4.14a-b). But surprisingly, under high IL-13, both STAT3 
inhibition and combined STAT3/STAT6 inhibition induced elevated IL-13Ra2 
expression on DCs (Figure 4.14c-d). Under all inhibitory conditions tested, the 
profiles of IL-13Ra1 and IL-4Ra expression mimicked each other (Figure 4.14a-
d). Specifically, STAT6 inhibition caused significant up-regulation of these two 
receptors on DCs compared to the uninhibited control. In contrast, STAT3 and 
combined STAT3/STAT6 inhibition showed a significant down-regulation of IL-
13Ra1 and IL-4Ra  compared to the uninhibited control  (Figure 4.14a-d). Note 
that, STAT6 inhibition induced IL-13Ra1 up-regulation, further confirming the 
association of IL-13Ra1 with STAT6. Therefore, following STAT3 inhibition up-
regulation of IL-13Ra2 was indicative of the IL-13Ra2 association with STAT3. It 
is also noteworthy that, IL-4 receptors (IL-4Ra and gc) were not regulated on DCs 
even upon IL-4 stimulation (Figure 4.15a-b). This confirmed that the observed 
receptor regulation was triggered by IL-13 not IL-4. 
 
4.4.4 STAT3 inhibition significantly down-regulated TGF-b1 on lung cDCs 
in vivo, associated with IL-13Ra2 
Since Fluidigm 48.48 Biomark analysis of rFPV vaccinated lung cDCs revealed 
that Stat3 and Tgfb1 gene expression were strongly correlated, next association 
of STAT3 activation/phosphorylation with TGF-b1 at the protein level was 
evaluated. In vitro inhibition studies under low IL-13 (100 pg/ml) stimulation 
revealed revealed that STAT3 inhibition significantly down-regulated TGF-b1 
expression in cDCs whilst STAT6 inhibition had no impact compared to the   
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uninhibited control (Figure 4.16a-b). To understand the relationship between IL-
13, IL-13Ra2, STAT3 and TGF-b1, when STAT6-/- mice were vaccinated i.n. with 
rFPV (which induced low IL-13 at the vaccination site and enhanced IL-13Ra2 
expression on lung cDCs, (Figure 4.5)) and lung cDCs were assessed 24 h post 
vaccination, phosphorylated STAT3 (pSTAT3) and TGF-b1 were both up-
regulated on STAT6-/- cDCs compared to the wild type counterpart (p=0.0038 and 
0.0003 respectively, (Figure 4.17c-d)), suggestive of IL-13Ra2 signalling. 
Moreover, significant up-regulation of IL-13Ra2 (Figure 4.18a-b) and down-
regulation of TGF-b1 (Figure 4.18c-d) were also observed in unimmunised IL-
13-/- cDCs compared to WT. Taken together these observations evoked the 
notion that the measured TGF-b1 and IL-13Ra2 expression profiles were linked 
to IL-13. 
 
4.4.5 IL-13Ra2 and IFN-gR were co-expressed on lung cDCs 24 h following 
i.n. rFPV vaccination 
Our previous studies have shown that 24 h post viral vector vaccination, 
ILC1/ILC3- derived IFN-g expression was inversely associated with ILC2-derived 
IL-13 at the vaccination site, which significantly impacted cDC recruitment 99,367. 
Knowing that IFN-g is a potent IL-13 inhibitor and can also mobilise IL-13Ra2 
from intracellular compartments to the cell surface 286,373,374, in this part of the 
study, the association of IFN-gR and IL-13Ra2 on lung cDCs, following i.n. rFPV 
vaccination was further investigated.  
 
Data revealed that following i.n. rFPV vaccination, differential IL-13Ra2 and IFN-
gR expression levels were observed on lung cDCs (Figure 4.19a-d). Specifically,   
p
S
T
A
T
3
T
G
F
-β
1
0
2
0
4
0
6
0
8
0
1
0
0
**
**
*
6
8
.8
%
5
4
.1
%
7
0
.8
%
4
2
.0
%
0
.5
6
%
F
M
O
C
o
n
tr
o
l
S
T
A
T
6
S
T
A
T
3
/ 
S
T
A
T
6
TGF-b1
F
S
C
-A
(a
)
(b
)
S
T
A
T
3
% TGF-b1+ cDCs 
(low IL-13)
p
S
T
A
T
3
T
G
F
-b
1
7
5
.0
%
5
0
.0
%
9
6
.0
%
7
0
.0
%
W
T
0
.8
4
%
Is
o
ty
p
e
pSTAT3/ TGF-b1
F
S
C
-A
(c
)
S
T
A
T
6
-/
-
(d
)
W
T
S
T
A
T
6
-/
-
% pSTAT3+or TGF-b1+cDCs
p
S
T
A
T
3
T
G
F
-b
1
C
on
tr
ol
S
TA
T3
 
 S
TA
T6
  S
TA
T3
/ S
TA
T6
05
1
0
1
5
2
0
4
0
6
0
8
0
1
0
0
*
*
F
ig
u
re
4
.1
7
.
E
v
a
lu
a
ti
o
n
o
f
p
S
T
A
T
3
a
n
d
T
G
F
-b
1
o
n
lu
n
g
c
D
C
s
u
p
o
n
IL
-1
3
s
ti
m
u
la
ti
o
n
in
v
it
ro
,
in
th
e
p
re
s
e
n
c
e
o
f
S
T
A
T
3
a
n
d
S
T
A
T
6
in
h
ib
it
o
rs
o
r
2
4
h
p
o
s
t
rF
P
V
v
a
c
c
in
a
ti
o
n
.
U
n
im
m
u
n
is
e
d
B
A
L
B
/c
lu
n
g
s
(n
=
4
)
w
e
re
tr
e
a
te
d
w
it
h
S
T
A
T
3
,
S
T
A
T
6
o
r
c
o
m
b
in
e
d
S
T
A
T
3
/S
T
A
T
6
in
h
ib
it
o
rs
o
v
e
rn
ig
h
t,
fo
llo
w
e
d
b
y
1
0
0
p
g
/m
l
o
f
lo
w
IL
-1
3
fo
r
3
h
o
u
rs
a
s
d
e
s
c
ri
b
e
d
in
m
e
th
o
d
s
.
(a
a
n
d
b
)
In
d
ic
a
te
re
p
re
s
e
n
ta
ti
v
e
F
A
C
S
p
lo
ts
a
n
d
g
ra
p
h
s
s
h
o
w
in
g
T
G
F
-b
1
e
x
p
re
s
s
io
n
in
lu
n
g
M
H
C
-I
I+
C
D
1
1
c
+
C
D
1
1
b
+
c
D
C
s
fo
llo
w
in
g
in
v
it
ro
S
T
A
T
3
a
n
d
S
T
A
T
6
in
h
ib
it
io
n
.
(c
a
n
d
d
)
In
d
ic
a
te
lu
n
g
c
D
C
s
e
x
p
re
s
s
in
g
p
S
T
A
T
3
a
n
d
T
G
F
-
b
1
2
4
h
p
o
s
t
i.
n
.
rF
P
V
v
a
c
c
in
a
ti
o
n
o
f
S
T
A
T
6
-/
-
a
n
d
W
T
B
A
L
B
/c
m
ic
e
(n
=
5
).
E
rr
o
r
b
a
rs
re
p
re
s
e
n
t
S
ta
n
d
a
rd
E
rr
o
r
o
f
m
e
a
n
(S
E
M
)
a
n
d
p
v
a
lu
e
s
w
e
re
c
a
lc
u
la
te
d
u
s
in
g
p
a
ir
e
d
S
tu
d
e
n
t’s
t-
te
s
t.
*p
<
0
.0
5
,
**
p
<
0
.0
1
,
**
*p
<
0
.0
0
1
,
**
**
p
<
0
.0
0
0
1
.
T
h
e
s
e
e
x
p
e
ri
m
e
n
ts
w
e
re
re
p
e
a
te
d
th
re
e
ti
m
e
s
.
(a
)
F
M
O 0
.8
6
%
W
T 8
2
.3
%
9
0
.8
%
IL
-1
3
-/
-
(c
)
F
M
O
W
T
IL
-1
3
-/
-
0
.8
6
%
2
7
%
7
1
%
TGF-b1
F
S
C
-A
IL-13Ra2
F
S
C
-A
% IL-13Rα2+ cDCs % TGF-b1+ cDCs
(b
)
(d
)
W
T
IL
-1
3-/-
0
3
0
6
0
8
0
9
0
1
0
0
**
**
W
T
IL
-1
3-/-
0
3
0
6
0
8
0
9
0
1
0
0
**
F
ig
u
re
4
.1
8
.
E
v
a
lu
a
ti
o
n
o
f
IL
-1
3
R
a
2
a
n
d
T
G
F
-b
1
o
n
lu
n
g
c
D
C
s
in
IL
-1
3
-/
-
a
n
d
W
T
m
ic
e
.
(a
a
n
d
b
)
in
d
ic
a
te
IL
-1
3
R
a
2
a
n
d
(c
a
n
d
d
)
in
d
ic
a
te
T
G
F
-b
1
e
x
p
re
s
s
io
n
o
n
lu
n
g
c
D
C
s
fr
o
m
u
n
im
m
u
n
is
e
d
IL
-1
3
-/
-
a
n
d
W
T
B
A
L
B
/c
m
ic
e
(n
=
3
p
e
r
g
ro
u
p
).
E
rr
o
r
b
a
rs
re
p
re
s
e
n
t
S
ta
n
d
a
rd
E
rr
o
r
o
f
m
e
a
n
(S
E
M
)
a
n
d
p
v
a
lu
e
s
w
e
re
c
a
lc
u
la
te
d
u
s
in
g
p
a
ir
e
d
S
tu
d
e
n
t’s
t-
te
s
t.
*p
<
0
.0
5
,
**
p
<
0
.0
1
,
**
*p
<
0
.0
0
1
,
**
**
p
<
0
.0
0
0
1
.
T
h
e
s
e
e
x
p
e
ri
m
e
n
ts
w
e
re
re
p
e
a
te
d
tw
o
ti
m
e
s
.
 154 
the percentage of cDCs expressing intracellular IL-13Ra2 was significantly 
elevated compared to extracellular IFN-gR (p=0.0228) (Figure 4.19a-b). 
Alternatively, extracellular IL-13Ra2 was significantly elevated compared to 
intracellular IFN-gR (p<0.0001), demonstrating an inverse correlation of the two 
receptors (Figure 4.19a-b). When analysis was performed to evaluate whether 
lung cDCs co-expressed IL-13Ra2 together with IFN-gR following i.n. rFPV 
vaccination, flow cytometry data revealed that the majority of the cDCs were 
double positive for the two receptors (85%) (Figures 4.20a-b). This was further 
substantiated by confocal imaging on lung CD11c+ DCs where ~75% of cells co-
expressed IL-13Ra2 and IFN-gR (Figures 4.21a-b). 
 
4.4.6 rFPV, rMVA and Adenovirus 5 (Ad5) vaccinations differentially 
regulated IL-13 receptors, STAT3/STAT6 and IFN-gR on cDC 24 h post 
vaccination 
Knowing that different viral vectors can induce different ILC2-derived IL-13 levels 
and DC subsets at the vaccination site, which were associated with different 
vaccine specific adaptive immune outcomes 367, next the IL-4/IL-13 receptor 
expression and regulation on lung cDCs post i.n. rMVA and Ad5 delivery were 
compared to i.n. rFPV vaccination. Interestingly, even though all three 
vaccinations induced significantly elevated intracellular and extracellular 
expression of IL-13Ra2 on lung cDCs (95–98%), elevated IL13Ra1 and IL-4Ra  
(intracellular) were only detected in cDCs, following rMVA and Ad5 viral vector 
vaccination (Figure 4.5a-b and 4.22a-b). It was noteworthy that, both 
intracellular and extracellular expression of the latter two receptors was 
significantly lower (rFPV 1-12%, rMVA 1-58% and Ad5 2-30% respectively) 
compared to IL-13Ra2 (95 – 100%) (Figure 4.5a-b and 4.22a-b).   
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Interestingly, although lung cDCs obtained from rFPV, rMVA and Ad5 vaccine 
groups showed expression of Stat6, Stat3, tgfb1 and Ifngr1 genes at a single cell 
level as well as at the protein level (pSTAT3, pSTAT6, TGF-b1 and IFN- gR) 
(Figures 4.23 and 4.24), the expression profiles were significantly different 
between the three vaccine groups. Specifically, the expression of both pSTAT3 
and pSTAT6 were found to be in the order of rFPV > rMVA > Ad5 (Figure 4.23a-
b). The expression of TGF-b1 was similar in rFPV and rMVA, but significantly 
lower in Ad5 (Figure 4.23a-b). In contrast, in the context of IFN-gR expression, 
the order was found to be rMVA > rFPV > Ad5 (Figure 4.23a-b). At the mRNA 
level, rMVA and Ad5 cDCs showed a greater probability of Stat3 and Stat6 co-
expression (79% and 76% respectively) compared to the rFPV group (Figures 
4.24a-b). The probability of Stat3 or Stat6 co-expression together with Ifngr1 was 
found to be in the order of rFPV (30%, 46%) < Ad5 (64%, 60%) < rMVA (71%, 
83%) (Figures 4.13b and 4.24a-b). The probability of Stat3 and Tgfb1 co-
expression was found to be very similar between rFPV (75%) and Ad5 (77%) 
cDCs (Figures 4.13b and 4.24b). However, Stat6 and tgfb1 co-expression profile 
was in the order of Ad5 > rMVA > rFPV (93%, 70%, 42% respectively) (Fig. 4.13b 
and 4.24a-b). 
 
To investigate differential regulation of Stat3 and Stat6 under different IL-13 
conditions, a PCA was performed with respect to Stat3, Stat6, Tgfb1 and Ifngr1 
(Figures 4.3 and 4.24c). Distinct gene clusters with different combinations of the 
four genes were analysed as described in methods and Figure 4.3. The 
proportion of each co-expression combination was represented as a stacked bar 
graph for each vaccine vector (Figure 4.24c), rFPV vaccination induced the 
highest proportion of cDCs expressing Stat3 and Stat6 together with Tgfb1 
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(rFPV 30% vs rMVA 8%, Ad5 21%). Additionally, rFPV vaccinated cDCs 
expressing Stat6 only (21%) and enhanced Stat3 co-expression with other 
genes, indicated that the rFPV response was STAT3 dominant. Following rFPV 
vaccination, much lesser proportion of cDCs expressed Stat3 and Stat6 together 
with either Ifngr1 (rFPV 6%, rMVA 20%, Ad5 0%) or Tgfb1 and Ifngr1 (rFPV 15%, 
Ad5 42%) (Figure 4.24c). In contrast, rMVA induced the highest proportion of 
cells expressing Stat3 and Stat6 together with either Tgfb1 and Ifngr1 (44%) or 
Ifngr1 only (rMVA 20%, rFPV 6%, Ad50%). Compared to rFPV, rMVA induced 
lower proportion of cDCs expressing Stat3/Stat6 in combination with Tgfb1 (rMVA 
8%, rFPV 30%). Following Ad5 vaccination, the majority of the cDCs expressed 
Stat3 as well as Stat6 along with Tgfb1 and Ifngr1 (Ad5 42%, rFPV 15%), 
comparable to the response exhibited with rMVA (44%). However, the proportion 
of Ad5 cDCs expressing Stat3 as well as Stat6 together with Tgfb1 expression 
was intermediary to that of rFPV and rMVA, however much higher proportion of 
Ad5 cDCs co-expressed Stat6 and Tgfb1 (Ad5 10%, rMVA 8%, rFPV 3%). Also, 
Ad5 vaccinated cDCs exhibited a more predominant co-expression of other 
genes with Stat6 compared to Stat3, indicating that unlike rFPV, the Ad5 
response was STAT6 dominant (Figure 4.24c). 
 
4.5. Discussion 
Asthma, allergy and vaccination studies have shown that lung cDCs are highly 
responsive to IL-13 361,367,375. Interestingly, this study demonstrated that, IL-
13Ra1 and IL-13Ra2 were differentially regulated on lung DCs in an IL-13 
concentration and time dependent manner. At the steady-state (prior to 
immunization) significantly higher percentage of lung cDCs expressed IL-13Ra2 
compared to IL-13Ra1. Furthermore, both these receptors were rapidly up-
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regulated on lung DCs upon IL-13 stimulation in vitro or 24h post viral vector-
based vaccination. Specifically, IL-13Ra2 expression was maintained under both 
low and high IL-13, whilst IL-13Ra1 was only observed under high IL-13 
conditions, suggesting, in lung cDCs IL-13Ra2 was the primary sensor and 
mediator (master regulator) of IL-13 responses. Moreover, this was further 
substantiated by the presence of elevated stable IL-13Ra2 protein and minimal 
mRNA expression at 24 h post rFPV vaccination, elucidating a distinct inverse 
protein-mRNA regulation, unlike IL-13 mediated inflammatory conditions 
288,309,376-378. Non-linear protein-mRNA regulation of other proteins 379,380, 
cytokines, including IL-13 381 specifically, elevated protein and rapid mRNA 
degradation associated with protein stability have been previously documented 
382-384. Moreover, presence of minimal Il13ra2 transcript levels in most mouse 
tissue types at steady-state 278,376-378,385 (NCBI Gene ID: 16165) and in human 
cancers post-transcriptional regulation of IL-13Ra2 by alternative epigenetic 
pathways have also been reported 386. Knowing that lung is continuously exposed 
to many environmental invasions (pathogens and allergens), the elevated stable 
IL-13Ra2 protein on lung DC may support the notion that, at the first line of 
defence (the lung mucosae), high affinity IL-13 receptor, IL-13Ra2 acts as the 
primary IL-13 sensor to mediate early IL-13 regulation/homeostasis and 
dysregulation of IL-13Ra2 could most likely be the cause of IL-13 mediated 
inflammatory disease.  
 
Previous studies in our laboratory have shown that transient inhibition of IL-4/IL-
13 signalling via STAT6 (using an rFPV based IL-4R antagonist adjuvanted HIV 
recombinant viral i.n. rFPV prime/i.m. rMVA or rVV boost vaccination strategy) or 
transient sequestration of IL-13 at the vaccination site (using IL-13Ra2 
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adjuvanted HIV recombinant viral i.n. rFPV prime/i.m. rMVA or rVV boost 
vaccination strategy) can induce high avidity/poly-functional mucosal and 
systemic T cells with better protective efficacy 122,124, which was associated with 
elevated cDC recruitment 99,124. These studies also showed that IL-13 was 
necessary for effective antibody differentiation 122, which was regulated via a 
STAT6 independent pathway 302. When trying to unravel how IL-13 modulated 
these different vaccine-specific outcomes current study revealed that, i) under 
low IL-13 conditions /rFPV vaccination (which induced low IL-13 at the lung 
mucosa), IL-13Ra2 expression was up-regulated on DC; ii) under low IL-
13/STAT3 inhibition IL-13Ra2 expression was up-regulated whilst TGF-b1 was 
down-regulated on lung DCs, as opposed to STAT6 inhibition; iii) Moreover, up-
regulation of phosphorylated STAT3 and TGF-b1 was detected on STAT6-/- cDCs 
post rFPV vaccination. There findings collectively suggested that, under low IL-
13 environments, cDCs most likely mediated IL-13 activity exclusively via IL-
13Ra2 by promoting STAT3/TGF-b1 activation, which was consistent with other 
findings 299,309. Also, the intriguing enhanced phosphorylated STAT6 expression 
on lung cDCs under low IL-13 signified a co-regulation of STAT3/STAT6 during 
this process. However, performing vaccination studies in IL-13Ra2-/- mice, to 
establish the ‘direct’ association of IL-13Ra2 signalling via STAT3 to induce TGF-
b1 would have added great value to our findings and this warrants further 
investigation.  
 
Under high IL-13, in addition to our study reconfirming the well-characterised IL-
13Ra1/IL-4Ra  signalling via STAT6 278, we also showed regulation of IL-13Ra2 
and co-expression of both IL-13Ra1 and IL-13Ra2 on lung DCs. These 
observations suggested that i) unlike low IL-13 conditions, DCs responded to high 
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IL-13 predominantly via IL-13Ra1/STAT6 pathway and ii) under high IL-13 
conditions, IL-13Ra2 likely regulated IL-13 in a STAT3 dependent manner. 
Moreover, the unexpected up-regulation of IL-13Ra2 under high IL-13 and dual 
STAT3/STAT6 inhibition also suggested the possible involvement of STAT3-
independent IL-13Ra2 signalling mechanisms, similar to IL-4 signalling via 
STAT1 and STAT5 387 (redundancies built into the system to regulate IL-13). In 
inflammatory diseases and high IL-13 conditions, IL-13Ra2 is recognized to be a 
decoy receptor that sequesters excess IL-13 376,377. Interestingly, rMVA and Ad5 
vaccination, which promoted high IL-13 367, expressed Stat6 mRNA and 
phosphorylated STAT6 on lung cDCs, associated with IL-13Ra1 signalling 
together with Stat3 and phosphorylated STAT3 activation. Knowing that IL-
13Ra2 can regulate IL-4Ra/STAT6 388, promote TGF-b1 expression and latter 
can also regulate STAT6 389, we propose that elevated IL-13 in the milieu post 
viral vector vaccination i) can activate IL-13Ra1/STAT6 signalling whilst 
promoting IL-13 sequestration by IL-13Ra2 in a STAT3 dependent manner on 
lung cDCs and ii) IL-13Ra2 can also regulate STAT6 in a STAT3 dependent 
manner, to prevent excessive IL-13 signalling on lung cDCs to maintain 
homeostasis at the lung mucosae (Figure 4.25).  
 
Studies have shown that STAT6 and STAT3 can be differentially regulated, 
according to the state of viral infection/vaccination. Specifically, in the context of 
viral vector-based vaccination whilst IL-13/STAT6 signalling has been shown to 
dampen effective antiviral immunity 132,302, however in acute and primary viral 
infections, it has shown to improve antiviral immunity 263,277. This study showed 
that viral vector induced IL-13 “level” in the cell milieu significantly altered the  
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STAT3/STAT6 equilibrium. Specifically, rFPV vaccination, associated with low 
ILC2-derived IL-13 at the vaccination site 366,390, exhibited enhanced STAT3  
expression (both at mRNA protein levels), which correlated with TGF-b1 on lung 
cDCs, suggesting a positive regulation of IL-13Ra2/STAT3 by TGF-b1. In 
contrast, a negative association of Stat3 with Ifngr1, was confirmed by the inverse 
correlation and co-expression pattern of IFN-gR with IL-13Ra2 on cDCs, 
suggesting that IL-13Ra2 could be negatively regulated by IFN-g, under low IL-
13 conditions, which is in agreement with studies by Daines et al. 286.  
 
Data revealed that as opposed to rFPV vaccinated lung cDCs, rMVA vaccinated 
lung cDC (associated with high ILC2-derived IL-13 at the vaccination site 367), 
exhibited both STAT3 and STAT6 expression, associated with an IFN-gR 
expression bias (both at the mRNA and protein levels). Interestingly, Ad5 
vaccinated lung cDC, (associated with moderate ILC2-derived IL-13, 
intermediate of rFPV and rMVA 367), showed higher association of STAT3 with 
IFN-gR compared to TGF-b1 (both the mRNA and protein levels). Knowing that 
IFN-g  can regulate IL-13 responses 371, these observations indicated that 
following viral vector-based vaccination, at the cDC level the differential 
environmental immune responses to IL-13 are not only determined/regulated by 
STAT3/STAT6, but also by TGF-b1 and IFN-g either collaboratively or 
independently, which was consistent with cancer/inflammation studies 391-394. 
Interestingly, rapid STAT3 activation has shown to control some viral infections 
277,395,396 whilst, STAT6 independent mechanisms have also been associated with 
effective antibody differentiation 302. Moreover, IL-13 mediated enhanced IFN-g 
signalling has been shown to exacerbate respiratory viral infections 311,397. 
Collectively, our findings propose the notion that in the context of viral vector-
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based vaccination and recruitment of DCs, vectors that promote low ILC2-derived 
IL-13, induce IL-13Ra2 signalling and STAT3/TGF-b1 activation, are associated 
with effective T and B cell immune outcomes. In contrast, vectors that promote 
high ILC2-derived IL-13 induce IL-13Ra1/STAT6 signalling and elevated IFN-g 
activity, lead to suboptimal vaccine-specific T cell outcomes. This may explain 
why in a prime-boost vaccine modality, choice of viral vector or adjuvant used in 
a ‘prime’ can crucially impact the vaccine-specific functional CD8 T cell avidity 
133, (knowing that booster vaccination mainly expands the initial high or low avidity 
T cell subset generated during priming) 124. 
 
In conclusion, our current study demonstrated a dual role of IL-13Ra2/STAT3 in 
IL-13 regulation of lung cDCs at the lung mucosae. Specifically, under viral 
vaccination-induced low IL-13, IL-13Ra2 functioned as a signalling receptor on 
lung cDCs, whilst, under high IL-13, mediated homeostasis by sequestration of 
excess IL-13 in the cell milieu, both involving STAT3 activation and co-regulation 
of STAT3 and STAT6 (Figure 4.25). Hence, fully understanding these IL-13, 
STAT3/STAT6 regulatory paradigms, have high potential to help design more 
efficacious vaccines against chronic pathogens and also therapies against other 
IL-13 related diseases. 
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Chapter 5 
 
Differential IL-13 receptor regulation on lung dendritic 
cells likely governs the unique pox viral vector-based 
vaccine immune outcomes. 4 
  
 
 
 
4 Experiments related to ILCs was performed by Dr. Zheyi Li. 
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5.1 Abstract 
Current study revealed that following intranasal poxviral vector-based 
vaccination, IL-13Ra2 and IL-13Ra1 were differentially regulated on lung DCs, in 
a viral vector and time dependent manner, where IL-13Ra2 was the immediate 
IL-13 sensor. Following recombinant fowlpox (rFPV) vaccination, known to 
induce low ILC2-derived IL-13 at the lung mucosae, IL-13Ra2 whilst being the 
immediate IL-13 mediator on lung cDCs, low affinity Type II receptor complex IL-
13Ra1/ IL-4Ra regulated responses 48-72h post delivery. In contrast, replication 
competent recombinant vaccinia virus (rVV), which induced high ILC2-derived IL-
13, exhibited sustained elevated expression of IL-13Ra2 together with IL-
13Ra1/IL-4Ra on lung cDC. Latter indicating that, in the context of rVV 
vaccination, IL-13Ra2 likely was involved in sequestration of excess IL-13 in the 
milieu, whilst signalling via the low affinity IL-13Ra1/IL-4Ra complex, resembling 
IL-13 regulation under chronic inflammation conditions. Interestingly, cDC 
obtained from replication abortive, recombinant Modified Vaccinia Ankara 
(rMVA), known to induce moderate ILC2-derived IL-13, showed an intermediary 
IL-13 receptor regulation profile to rFPV and rVV. Moreover, the deletion variant 
of rMVA, rMVADIL-1bR vaccination depicted a unique IL-13 regulatory profile 
where IL-13Ra2/IL-4Ra antagonism was likely at play. These findings 
demonstrated that the host tropism, replication status and presence or absence 
of immunomodulatory genes in a viral vector considerably impacted IL-4/IL-13 
receptor regulation on lung DCs. The differences observed may explain how and 
why despite encoding the same vaccine antigens, different viral vectors yield 
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vastly different immune outcomes (eg. rFPV priming induce highly poly-functional 
cytotoxic CD8 T cells compared to rVV and/or rMVA vaccination). Taken together 
our findings imply that fate of a vaccine is influenced by the balanced and timely 
regulation of IL-13 by IL-13Ra2 and IL-13Ra1 on lung DCs, at the early stages 
(24-72h) of vaccination. 
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5.2 Introduction  
Cytokine IL-13 can be characterized as a double edge sword, as under different 
disease conditions the ‘level’ of IL-13 can promote vastly different immune 
outcomes. Specifically, although overproduction, has been associated with 
allergic asthma 255,269, fibrosis 264,265, tumor progression 267,268, atopic dermatitis 
257,266, lack of IL-13 has been linked to susceptibility to helminth, parasitic and 
some bacterial infections (eg. K. Pneumonia) 252,275,276. Moreover, in some acute 
and primary viral infections, whilst IL-13 has been associated with improved 
antiviral immunity 263,277, in the context of viral vector-based vaccination, 
presence of IL-13 has been detrimental for the induction of effective T cell 
immunity whilst being crucial for effective antibody formation 132,302. 
 
Our recent studies have demonstrated that following viral vector vaccination 
Innate Lymphoid Cell 2 (ILC2) are the major source of IL-13 at the vaccination 
site 24 h post delivery 306 and ILC2-derived IL-13 level can significantly alter the 
DC recruitment 367, responsible for uniquely different immune outcomes 99. 
Specifically, low ILC2-derived IL-13 induced by recombinant fowlpox virus 
(rFPV), preferentially recruited cDCs not pDC to the lung mucosae unlike 
recombinant modified vaccinia Ankara (rMVA) or Vaccinia Virus (rVV) 367 and, 
the specific nature of a virus also significantly modulated this activity (eg. rMVA 
vs rMVADIL-1bR) 367. 
 
It is well established that during IL-13 signalling, low affinity receptor IL-13Ra1 
(KD = 30 nM) heterodimerizes with IL-4Ra to form the functional IL-13Ra1/IL-
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4Ra Type II receptor complex, which signals via STAT6 278. However, the exact 
signalling mechanism of the high affinity IL-13Ra2, (KD = 440 pM) 378,398, is 
currently not well characterized, although deemed functional in humans 278,293,399. 
Interestingly, these two receptors have been defined to have unique functions 
under different IL-13 conditions. For example, whilst, increased IL-13 production 
following asthma and allergy has shown to be regulated by IL-13Ra1 262, under 
reduced IL-13 conditions, IL-13Ra1 has also shown to maintain homeostasis and 
lung repair 312. Interestingly, the lesser-known IL-13Ra2 has been implicated in 
promoting lung and intestinal fibrosis, secondary methicillin resistant during 
staphylococcus aureus (MRSA) infection and liver pathology during some chronic 
infections 309-311. Moreover, over-expression of IL-13Ra2 has been associated 
with poor prognosis of several cancer types 288,293. 
 
Our recent intranasal viral vector-based vaccine studies have revealed that on 
lung DCs IL-13Ra2 acts a major IL-13 sensor and plays a dual role at the lung 
mucosae (Roy et al. (submitted)). Specifically, under low IL-13, IL-13Ra2 
performs as the primary signalling receptor, whilst under high IL-13, helps to 
maintain homeostasis. Knowing that different viral vectors can induce variable 
ILC2-derived IL-13 levels at the lung mucosae 367, in this study we have 
attempted to unravel how IL-4 and IL-13 receptors get regulated on cDCs and 
pDCs 24-72h post pox viral vector vaccination.  
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5.3 Materials and Methods 
 
5.3.1 Mice.  
Pathogen-free 6–8 weeks old female BALB/c mice were purchased from the 
Australian Phenomics Facility, The Australian National University (ANU). The 
mice were maintained, monitored daily and euthanized using Australian NHMRC 
guidelines within the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes and in accordance with guidelines approved by the ANU 
Animal Experimentation and Ethics Committee (AEEC), protocol number 
A2014/14 and A2017/15.  
 
5.3.2 Viral vector based vaccination.  
BALB/c mice were intranasally immunised with 1 X 107 plaque forming units (pfu) 
of FPV-HIV, MVA-HIV, MVA-ΔIL-1bR-HIV, VV-HIV, as described previously 367. 
rFPV, rMVA, rMVA-ΔIL-1bR and rVV were sonicated thrice for 15 seconds on ice 
at 50% capacity using Branson Sonifier 450 immediately prior to vaccination. 
Mice were vaccinated with a volume of 10 µl per nostril (total 20 µl) under mild 
isofluorane anaesthetic. 
 
5.3.3 Evaluation of lung ILC2s and corresponding IL-13 expression using 
flow cytometry. 
Lung tissues were harvested 24 h post vaccination in complete RPMI and single 
cell suspensions were prepared as described previously 306,367. Briefly, lungs 
were cut into small pieces, enzymatically digested with digestion buffer containing 
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1 mg/ml collagenase (Sigma-Aldrich, St Louis, MO), 1.2 mg/ml Dispase (Gibco, 
Auckland, NZ), 5 Units/ml DNase (Calbiochem, La Jolla, CA) in complete RPMI. 
Samples were filtered using 100µm falcon cell strainers followed by red cell lysis 
and cells were re-suspended in complete RPMI, rested overnight at 37°C under 
5% CO2 as per our previous studies prior to staining 306,367. Lung cells were 
stained with lineage markers (FITC-conjugated anti-mouse CD3 (clone 17A2), 
CD19 (clone 6D5), CD11b (clone M1/70), CD11c (clone N418), CD49b (clone 
HMα2), FcεRIα (clone MAR-1)), PE-conjugated anti-mouse ST2/IL-33R (clone 
DIH9), APC/Cy7-conjugated anti-mouse CD45 (clone 30-F11), Brilliant Violet 
421-conjugated anti-mouse CD335 (NKp46) (clone 29A1.4) obtained from 
Biolegend and PE-eFluor 610-conjugated anti-mouse IL-13 (clone eBio13A) 
purchased from eBioscience as previously described 306. Briefly, following 
treatment with Brefeldin A for 5 hours, cell surface staining was performed 
followed by intracellular staining after fixing and permeabilising the cells. All 
samples were fixed with 0.5% paraformaldehyde and 1.4 x 106 events from each 
lung sample were acquired on a BD LSR Fortessa. Data were analysed using 
Tree Star FlowJo software (version 10.0.7) using gating strategies previously 
described 306,367. 
 
5.3.4 Evaluation of IL-4 and IL-13 receptor expression on lung cDCs and 
pDCs using flow cytometry.  
Lung tissues were harvested and prepared into single cell suspensions from 
mice, following 24, 48 or 72h post vaccination in complete RPMI. 2 X 106 cells 
from each sample were blocked with anti-mouse CD16/CD32 Fc Block antibody 
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(BD Biosciences, USA) for 20 min at 4°C and cells were stained with DC markers, 
APC-conjugated anti-mouse MHCII I-Ad (e-Biosciences, USA), biotin-conjugated 
anti-mouse CD11c (N418 clone, Biolegend, USA), followed by streptavidin 
Brilliant violet 421 (Biolegend, USA), anti mouse CD11b AlexaFluor 700 (M1170 
clone, Biolegend, USA), anti-mouse CD103 FITC (2E7 clone, e-Biosciences, 
USA) and anti-mouse B220 PercpCy5.5 (RA3-6B2 clone, e-Biosciences, USA) 
for 30 min on ice. To evaluate IL-4 and IL-13 receptors, cells were also 
extracellularly either stained with anti-mouse IL-4Ra (CD124) PE (I015F8 clone, 
Biolegend, USA), anti-mouse IL-13Rα1 (CD213a) PE (13MOKA clone, e-
Biosciences, USA), Biotin-conjugated anti-mouse IL-13Rα2 (110815 clone, R&D 
systems, USA), followed by streptavidin PE (Biolegend, USA), anti mouse gc 
(CD132) PE (TUGm2 clone, Biolegend, USA). Cells were further fixed using 1.5% 
paraformaldehyde followed by resuspension in PBS and analysed using BD 
LSRII flow cytometer Becton Dickinson, San Diego, CA). 5 x105 events per 
sample were acquired and results were analyzed using FlowJo software v10.0.7 
and gating strategies described in Figure 5.1a-c.  
 
5.3.5 Statistics. 
IL-4 and IL-13 receptor proportions were calculated as a percentage of parent 
MHC-II+ CD11c+ CD11b+ CD103- cDC and MHC-II+ CD11c+ CD11b- B220+ pDC 
population. Please note that less than 10 receptor expressing cells were reported 
as undetectable expression. The p-values were calculated using either unpaired 
non-parametric Student’s t-test or Two-way ANOVA with Tukey’s multiple 
comparison post-test. All experiments were repeated minimum 2-3 times. 
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5.4 Results 
5.4.1. rFPV and rVV vaccinated lung cDCs exhibited uniquely differential IL-
4/IL-13 receptor expression profiles 24h-72 h post delivery.  
We have previously shown that the nature and replication status of a viral vector 
can significantly alter the ILC2-derived IL-13 level at the vaccination site 367. 
Moreover, under low and high IL-13 conditions, IL-13 receptors can be 
differentially regulated (Roy et al. (submitted)), Therefore, in this study we have 
further evaluated the cDC associated IL-4/IL-13 receptor kinetics 24-72 h post 
rFPV and rVV vaccination as per described in methods. Results indicated that 
compared to rFPV which does not replicate in mammalian cells, replication 
competent rVV induced considerably elevated ILC2-derived IL-13 at the lung 
mucosae by an ST2/IL-33R- ILC subset at 24h post vaccination (p<0.0001) 
(Figure 5.2). Moreover, there was also a significant regulation of the different IL-
4/IL-13 receptors on cDC where the number of cells that expressed IL-13Ra2 
were much greater than IL-13Ra1 and IL-4Ra.  Interestingly, although the 
percentage of cDCs expressing IL-13Ra2 was much greater at 24 - 48h (90%) 
compared to 72 h post rFPV delivery (~80%) (p<0.0001) (Figure 5.3a), the IL-
4Ra and IL-13Ra1 on cDC were significantly up-regulated at 48 and 72 h (24 vs 
48 h and 24 vs 72 h p<0.0001) (Figure. 5.3b-c). In contrast, post rVV vaccination 
significantly elevated and sustained IL-13Ra2 expression (99%) was detected 
over time (Figure 5.4a), whilst the IL-13Ra1/IL-4Ra  expression trends were 
found to be very similar to rFPV vaccination (Figure 5.4b-c). Unlike the other 
receptors, the expression of gc, which heterodimerises with IL-4Ra to form the  
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IL-4 type I receptor complex (IL-4Ra/gc), was not significantly 
expressed/regulated on cDC at 72 h post vaccination post vaccination (Figure 
5.5a-b). 
 
In the context of receptor densities (mean fluorescence intensity), 24 to 72 h post 
rFPV vaccination, the IL-13Ra2, showed a downward trend (Figure 5.6a), where 
as an upward trend was observed with IL-13Ra1 and IL-4Ra  (Figure 5.6b-c). In 
contrast, post rVV vaccination down-regulation of both IL-13Ra2 and IL-13Ra1 
densities were detected at 48h (24 vs 48 h p<0.0001), followed by an up- 
regulation at 72 h, comparable to 24 h was observed (Figure 5.7a-b). However, 
IL-4Ra  densities on rVV vaccinated cDC were gradually but significantly 
increased overtime (24 vs 48 h p= 0.0127, 48 vs 72 h and 24 vs 72 h p<0.0001) 
(Figure 5.7c). In general, the IL-13Ra2 receptor densities on cDC following rFPV 
and rVV were approximately ten times greater than that of IL-13Ra1 and IL-4Ra.   
 
5.4.2 rMVA and rMVADIL-1bR vaccination induced vastly different IL-13Ra2, 
IL-13Ra1 and IL-4Ra expression profiles on lung cDCs 24-72 h post 
delivery. 
We have previously shown that a single deletion of virokine IL-1bR from rMVA 
(rMVADIL-1bR) could promote significantly lower ILC2-derived IL-13 expression 
and enhanced cDCs at the lung mucosae, compared to parental rMVA 367. Thus, 
next the IL-4/IL-13 receptor expression profiles were assessed 24 - 72 h post 
delivery of these two vectors using flow cytometry as per indicated in methods. 
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Specifically, data revealed that compared to 24 and 48 h post rMVA vaccination 
significantly lower percentage of cDCs expressed IL-13Ra2 at 72 h (~95% vs 
~50%) (p<0.0001) (Figure 5.8a), where as IL-4Ra and IL-13Ra1 expression was 
significantly enhanced at 48h compared to 24h (~1 vs 3 and ~3 vs 6%) 
(p<0.0001) with no detectable expression at 72 h post delivery (48 vs 72 h 
p<0.0001) (Figure 5.8b-c). Although, with rMVADIL-1bR, similar IL-13Ra2 and 
IL-13Ra1 expression profiles to rMVA were detected (Figure 5.9a-b), vastly 
different IL-4Ra expression profile was observed at 72 h, not only between the 
two vaccination groups (rMVA 0%, rMVADIL-1bR ~20%) but also during 24 - 72 
h post rMVADIL-1bR delivery (24 vs 48 h and 24 vs 72 h p<0.0001) (Figure 5.9c). 
Once again the gc was not expressed on cDCs 72 h  following rMVA and 
rMVADIL-1bR vaccination (Figure 5.10a-b). 
 
In the context of receptor densities, IL-13Ra2 densities following rMVA and 
rMVADIL-1bR were also ~10 times greater than that of IL-13Ra1 and IL-4Ra.   
On rMVA and rMVADIL-1bR vaccinated cDC, although the IL-13Ra2 and IL-
13Ra1 receptor densities tracked similar to that of the proportion of cDCs 
expressing each receptor (Figure 5.11a-c and 5.12a-b), the IL-4Ra  densities 
showed significant up-regulation at 72 h post rMVADIL-1bR vaccination, unlike 
rMVA, (rMVA vs rMVADIL-1bR p<0.0001) (Figure 5.12c).  
 
5.4.3 Following pox viral vaccination lung pDCs exhibited differential IL-
13Ra2/IL-13Ra1 expression profiles to cDCs  
  
 
194 
Knowing that pDCs can modulate antibody differentiation by induction of type I 
interferons 336,400, plus our recent studies showing that IL-13 is necessary for 
effective antibody differentiation 122,257 and also viral vector induced ILC-derived 
IL-13 significantly impacted the pDC recruitment to the lung mucosae 367, we next 
evaluated the IL-4/IL-13 receptor regulation on pDCs post poxviral vaccination. 
Surprisingly, data revealed that although rFPV and rVV vaccinations showed 
regulation of IL- 13Ra2, IL-13Ra1, IL-4Ra and gc, post rMVA and rMVADIL-1bR 
vaccination no detectable expression of the latter three receptors was found on 
lung pDC even though elevated expression of IL-13Ra2 was detected 24 and 48 
h post delivery (24 vs 48 h p<0.0001) (Figure 5.13a-b). The IL-13Ra2 expression 
on pDCs post rFPV vaccination was found to be in the order of (24 > 48 < 72 h) 
(24 vs 48 h and 48 vs 72 h p<0.0001) (Figure 5.14), where as rVV showed a 
significant up-regulation of IL-13Ra2, both at 48 and 72 h, compared to 24h post 
delivery (24 < 48 ≤ 72 h) (24 vs 48 h and 24 vs 72 h p<0.0001) (Figure 5.15). 
Interestingly, very low number of rFPV vaccinated pDCs expressed IL-4Ra, IL-
13Ra1 and gc at 24 h and 48 h (≥ 3%) and no detectable expression was 
observed at 72h post delivery (Figure 5.14 and 5.16a). In contrast, significant up 
regulation of IL-4Ra  and   IL-13Ra1 were detected on rVV vaccinated lung pDCs 
48 to 72 h post delivery (20 - 80%) where very high proportion of pDCs expressed 
IL-13Ra1 (24 vs 48 and 24 vs 72 h p<0.0001) and IL-4Ra (24 vs 48 p<0.0001 
and 24 vs 72 h p=0.0003) compared to 24h (≥ 2%) (Figure 5.15). Moreover, less 
than 2% of rVV vaccinated pDCs expressed gc at 24 h and no detectable 
expression was found at other time points (Figure 5.15 and 5.16b).  
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rFPV vaccinated pDCs showed significant decrease in IL-13Ra2 (24 vs 48 h p = 
0.0002; 24 vs 72 h p = 0.0003), IL-13Ra1 (24 vs 48 h and 24 vs 72 h p = 0.0284) 
and IL-4Ra densities (24 vs 48 h and 24 vs 72 h p = 0.0277) over time (Figure 
5.17). In contrast, rVV vaccinated pDCs showed significantly elevated IL-13Ra2 
density at 72 h (24 vs 72 h p<0.0001), IL-13Ra1 (24 vs 48 h p=0.0002; 24 vs 72 
h p<0.0001) and IL-4Ra  densities (24 vs 48 h and 24 vs 72 h p<0.0001) over 
time (Figure 5.18). Similar to cDCs, the expression/regulation of gc on pDCs were 
also not very significant (Figure 5.16). Interestingly, the expression densities of 
IL-13Ra2 on rVV vaccinated pDC were also found to be approximately 10 times 
greater than that of IL-13Ra1 and IL-4Ra. 
 
5.5. Discussion 
The enhanced IL-13Ra2 expression unlike IL-13Ra1, detected on lung cDCs and 
pDCs 24 h following pox viral vector vaccination, have strengthened our previous 
findings that IL-13Ra2 may be the early sensor/mediator of IL-13 responses at 
the first line of defense, the lung mucosae (Roy et al. (submitted)). Moreover, the 
dissimilar expression of IL-4 Type I receptor complex (IL-4Ra  and gC) on cDCs, 
further substantiated that at early stages of vaccination, IL-13 performed a more 
predominant role in shaping the vaccine-specific immune outcomes, than IL-4, 
which was also consistent with our previous findings 122,302. Specifically, where, 
we have shown that pox viral vector-based vaccines, that have transiently 
inhibited IL-13 at the vaccination site by significantly dampening ILC2-derived IL-
13 activity at the lung mucosae, 24h post delivery 306 have been associated with  
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enhanced lung cDC recruitment 99 and induction of high avidity T cells 123,367. In 
this study the replication abortive (in mammalian cells) rFPV and replication 
competent rVV yielded uniquely different ILC2-derived IL-13 and IL-13 receptor 
regulation on lung cDCs. rFPV vaccination, which was linked to low ILC2-derived 
IL-13, showed up-regulation of IL-13Ra2 on cDC 24 h and down-regulation 72 h 
delivery, whist the opposing was observed with Type II receptor complex (IL-
4Ra/IL-13Ra1) (Figure 5.19). This once again indicated that on lung cDCs the 
high affinity IL-13Ra2 was most likely associated with IL-13 signalling at the early 
stages (24 h) of rFPV vaccination, whilst, low affinity IL-13Ra1 gained function at 
later stages of delivery. In contrast, post rVV vaccination (under high ILC2-
derived IL-13), constantly elevated IL-13Ra2 expression 24-72 h (Figure 5.19) 
suggested that, under this condition IL-13Ra2 was likely involved in sequestration 
of the excess IL-13, produced by the replication competent vector (specifically 
48-72 h) whilst signalling was mainly controlled by the low affinity Type II receptor 
complex (IL-4Ra /IL-13Ra1). These uniquely different early events may explain 
‘how and why’ i) in a prime-boost vaccination modality, rFPV prime can generate 
high avidity T cells, unlike rVV 133 and ii) the order of vector delivery significantly 
impact vaccine-specific adaptive immune outcomes. 
 
Recently, we have shown that rMVA vaccination can induce much higher IL-
33R/ST2+ILC2-derived IL-13 and reduced cDC recruitment at the lung mucosae 
compared to rFPV vaccination. 367. Moreover, the level of IL-13 induced by these 
vectors were in the order of rFPV < rMVA < rVV (rMVA 2x higher and rVV 7x 
higher than rFPV) 367. Interestingly, in this study early (24 to 48 h) post vaccination 
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IL-13/IL-4 receptor regulation was very similar between rMVA and rVV, indicative 
of the two vectors possessing similar IL-13 regulation mechanisms (sequestration 
of IL-13 by IL-13Ra2 and signaling via IL-13Ra1/IL-4Ra). Nevertheless, 72 h 
post rMVA delivery exhibited significantly reduced IL-4/IL-13 receptor activity 
compared to the replication competent rVV (Figure 5.19), potentially associated 
with the continuous ILC2-derived IL-13 production at the vaccination site by rVV 
continuously activating IL-13Ra2, unlike the replication abortive rMVA.  
 
Interestingly, unlike parental rMVA, the IL-1bR deletion variant rMVADIL-1bR 
vaccination, which showed similar ILC2-derived IL-13 levels and lung cDC activity 
at the lung mucosae to rFPV, 367 also exhibited down-regulation of IL-13Ra2 (and 
also IL-13Ra1) and an up-regulation of IL-4Ra, 72 h post vaccination (Figure 
5.19). Given that, IL-13Ra2 can inhibit IL-4Ra activity 401, these observations 
inferred that, rMVADIL-1bR most likely regulated the vaccine-derived IL-13 
responses 24 - 72 h post vaccination by IL-13Ra2 signalling and regulation of IL-
4Ra by IL-13Ra2 antagonism, with no IL-4Ra/IL-13Ra1 (Type II receptor 
complex) signaling, unlike rFPV or rMVA. Interestingly,  we have recently shown 
that compared to rFPV, rMVADIL-1bR vaccination generated not only significantly 
lower ILC2-derived IL-13 but also ILC1/ILC3-derived IFN-g, (likely due to the 
residual viral IL-18 binding protein neutralizing host IL-18 preventing host IFN-g 
production). Thus, in the context of rMVADIL-1bR, we postulate that the 
imbalance of IL-13/IFN-g expression may be linked to the differential IL-13Ra1/IL-
13Ra2 regulation compared to rFPV.   
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Figure 5.19. Comparison of IL-4/ IL-13 receptor expression on lung cDCs and pDCs between 24 - 72 h following
viral vector vaccination. IL-4/IL-13 receptor expression obtained from Fig 1-6 have been summarised to compare and
contrast receptor expression between lung cDCs and pDCs between 24 – 72h hours post viral vector vaccination. Line
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Analogous to the cDCs, IL-13Ra2 and IL-13Ra1/IL-4Ra expression on lung 
pDCs were found to be significantly different 24 - 72 following different pox viral 
vector-based vaccination. Interestingly, rFPV, that induced low IL-13 at the 
vaccination site, showed significantly elevated cDC and moderate pDC 
recruitment to the lung mucosae, where as the opposing was true with rVV 306,367. 
In the context of rFPV vaccinated lung pDC, enhanced IL-13Ra2 expression and 
no significant IL-13Ra1/IL-4Ra regulation over time (Figure 5.19), once again 
highlighted an association of IL-13Ra2 signalling under low IL-13 unlike rVV. 
pDCs have long been associated with effective antibody maturation and 
development 336,400 and recently we have shown that following pox viral 
vaccination, the presence of IL-13 was crucial for effective antibody 
differentiation, via an STAT6 independent manner 302,402. Intriguingly, our current 
findings further corroborate that in the context of pDC, IL-13 signaling/regulation 
via IL-13Ra2 may be involved in this process. Furthermore, rFPV primed pDCs, 
which exhibited enhanced IL-13Ra2 and minimal IL-13Ra1/IL-4Ra regulation on 
pDCs, has also shown to induce modest antibody responses in mice and 
macaques 122,123. Whilst, rVV vaccination, which was associated with enhanced 
IL-13Ra2 and IL-13Ra1/IL-4Ra activity, has shown robust neutralizing antibodies 
in mice and humans 403-405. In contrast, rMVA vaccination which has shown to 
induce much lower magnitude of antibody responses compared to rVV 
137,266,406,407, interestingly, showed reduced lung pDCs compared to rVV, and 
down-regulation of IL-13Ra2 by 72 h post vaccination with no IL-13Ra1/IL-4Ra 
activity. These observations insinuate that, the ability of different viral vectors to 
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induce effective antibodies responses may also be governed by IL-13 regulation 
of IL-13Ra2 and IL-13Ra1/IL-4Ra on lung pDCs, at early stages of vaccination. 
 
Moreover, rVV vaccination has shown to induce enhanced pDCs and cross-
presenting DCs 367, associated with induction of greatly elevated VV-specific 
antibody as well as T cells responses both in mice and humans 403-405,408,409. 
However, when rVV has been used as a vaccine vector, the quality of T cell 
responses induced to the encoded vaccine antigens have been much inferior 
compared to rFPV 133. These observations, together with our current findings 
suggest that, in the context of viral vector-based vaccines, more attenuated and 
unrelated the vector to the host it may have the capacity to induce more 
efficacious and high quality vaccine-specific immune outcomes. This may also 
explain why, in a prime-boost vaccination modality, rFPV or canarypox vector 
prime have shown to induce more effective immune outcomes than other pox 
viral vectors 121,123,131,133, specifically, given that priming creates the initial 
antigen-specific T cell population, which gets expanded during the booster 
vaccination 122,124.  
 
Collectively, our findings reveal that the host tropism, replication status as well as 
presence or absence of immunomodulatory genes in a viral vector can 
significantly impact the IL-4/IL-13 receptor regulation on lung DCs. These findings 
may elucidate why despite encoding the same vaccine antigens, different viral 
vectors yield vastly different vaccine-specific immune outcomes. Taken together 
our observations evoke the notion that efficacy/fate of a vaccine is likely governed  
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by the early effective regulation and balance of IL-13 by IL-13Ra2/IL-13Ra1 on 
DC at the vaccination site. 
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Chapter 6 
 
General Discussion 
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6.1 Synopsis 
Designing a successful vaccine against any chronic pathogen frequently poses 
many challenges. Specifically, in the context of HIV, high epitope variability, 
which leads to immune evasion and immune recognition 410,411, existence of 
different HIV clades in different geographic locations 412,413 have made designing 
an effective vaccine that can induce long lasting adaptive immunity, which 
recognizes the broad breadth of HIV antigens, extremely difficult. Whilst an HIV 
vaccine with cross-reactive or broadly neutralizing antibody responses remain 
elusive 414, studies have also established that cytotoxic CD8+ T cells are crucial 
in preventing viral replication and pathogenecity 415-418. Two decades of work in 
our laboratory have established that the route of vaccination, choice of viral 
vaccine vector and the vaccination induced cytokine milieu (IL-4/IL-13) critically 
influenced the fate of a vaccine 122-124,130-133. Studies by Wijesundara et al. 
showed that in a heterologous poxvirus vector-based HIV prime-boost 
vaccination modality, the priming vector crucially impacted the functional avidity 
of HIV-specific CD8+ T cells 133. Specifically, rFPV prime was shown to induce 
CD8+ T cells of higher functional avidity compared to rMVA or rVV 133. 
Furthermore, novel recombinant poxviral vector-based HIV vaccines co-
expressing IL-4/IL-13 inhibitors, which transiently blocked IL-13 or STAT6 
signalling at the vaccination site, was shown to significantly influence cellular and 
humoral immune responses 122-124. Specifically, i.n. rFPV/ i.m. rMVA or rVV 
poxvirus prime-boost vaccination strategy, that transiently inhibited STAT6 
signalling at the lung mucosae was shown to induce both high avidity/poly-
functional cytotoxic T cells as well as effective antibody responses in mice and 
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non-human primates 122,123 (Li et al. in preparation). In comparison, transient 
sequestration of IL-13 from the milieu only improved the functional avidity of T 
cells 124. These studies clearly demonstrated that, IL-13 at the vaccination site, 
whilst being detrimental to functional avidity of T cells, was essential for effective 
humoral immunity. Trivedi et al. using these novel vaccines, also showed that 
reduced IL-13 levels at the vaccination site promoted cDC recruitment to the 
vaccination site associated with high avidity T cell induction 99. Furthermore 
investigating which cells expressed IL-13 at the vaccination site 24h post viral 
vector, Li et al. for the first time established that ILC2 were the major producer of 
IL-13 306. This PhD project sought to unravel some of the fundamental 
mechanisms by which IL-13 modulated DC activity at the vaccination site. The 
major findings of this project were:  
1. Viral vector-induced IL-13 levels at the vaccination site differentially 
regulated DC recruitment to the vaccination site, 24 h post delivery. 
2. Enhanced expression of IL-13Ra2 detected on lung DCs was regulated in 
a vector-dependent manner (according to the level of IL-13 induced). 
3. Following viral vector vaccination, low IL-13 conditions induced IL-13Ra2 
signalling via STAT3 in lung cDCs, governed by TGF-b1 regulation, whilst 
high IL-13 conditions induced IL-13Ra1 signalling, where IL-13Ra2 
regulated IL-13 homeostasis at the lung mucosae.  
4. On lung cDCs, the densities of IL-13Ra2 and IFN-gR co-expression, 24 h 
post viral vector delivery, were found to be linked to different vaccine-
specific T cell outcomes (observed in previous studies). 
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6.2. Viral vectors have not only their own ILC2-derived IL-13 profiles but 
also their own DC signature. 
Findings in this thesis for the first time demonstrated that different viral vector-
based vaccines expressing the same vaccine antigen can not only crucially 
impact the recruitment of different ILC and ILC2-derived IL-13 levels, but also the 
DC recruitment to the vaccination site, 24 h post delivery. Specifically, each viral 
vector exhibited its own ILC2-derived IL-13 profile as well as a DC signature. 
These findings further substantiated our previous findings, eliciting the 
importance of the priming vector, in a prime-boost modality. Previous studies 
have shown that the priming vaccination generates the initial vaccine-specific T 
cell pool, which gets expanded by the booster, responsible for the final T cell 
outcomes 122,124. Specifically, in this study, i.n. rFPV priming which induced low 
ILC2-derived IL-13, showed enhanced cDC recruitment to the lung mucosae. 
Whilst i.n. rMVA and rVV priming which induced high ILC2-derived IL-13, 
recruited enhanced cross-presenting DCs. Using the novel IL-4/IL-13 inhibitor 
vaccines, adoptive transfer studies by Trivedi et al. have clearly shown that in a 
prime-boost modality, whilst cDCs were involved in the induction of high avidity 
T cells, cross-presenting DCs were associated with induction of low avidity T cells 
133. Moreover, recent studies by Li et al. have also shown that different ILC2-
derived IL-13 levels in the lung and muscle correlated with varying T cell 
outcomes following viral vector-based vaccination 306. Taken together, these 
current findings have further unravelled some of the fundamental IL-13 related 
mechanisms at the innate immune cell level, specifically how ILC-DC cross talk 
at the vaccination site shape the downstream adaptive immune outcomes.  
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Chapter 3 studies also demonstrated that manipulation of the inherent properties 
of the viral vector can significantly impact the ILC2-derived IL-13 as well as 
associated DC profiles at the vaccination site. For example, a single deletion of 
virokine IL-1bR from rMVA vector significantly reduced the ILC2-derived IL-13 
levels at the vaccination site, compared to the parental rMVA and lead to 
enhanced cDC recruitment to the lung mucosae, similar to rFPV. In the context 
of rMVA, deletion mutants of immune evasive genes such as IL-18 binding 
protein or C6L and F1L have also been tested 183-185,419. Interestingly, although 
the T cell outcomes of these mutant variants have been established, underlying 
mechanisms leading to the differential quality or magnitude of these T cell 
responses have not yet been characterized. These findings further lead into one 
of the major caveats in the current vector-based vaccine design, where the nature 
of the viral vector is often overlooked when designing vaccine against different 
pathogens. This study, for the first time, has demonstrated i) how a viral vector 
critically influenced the fate of a vaccine, and ii) how characterizing the IL-13 
associated DC profiles, specifically unraveling the mechanisms of ILC-DC cross 
talk at the vaccination site may hold the key to better vector-based vaccine design 
in the future.  
 
6.3. Viral vector-based vaccination, lung cDC and dual role of IL-13Ra2.  
Chapter 4 and 5 studies for the first time unraveled one of the mechanisms by 
which lung DCs shape different cellular and humoral immune outcomes, 24 h 
post intranasal viral vector-based vaccination, where IL-13Ra2 was the main IL-
  
 
227 
13 regulator on lung cDCs and pDCs. Specifically, how cDCs modulate high 
avidity T cells 99,124 and pDCs regulate antibody differentiation 97,420, via IL-
13Ra2/STAT3. Interestingly, studies by Hamid et al. also pointed towards the 
involvement of a STAT6 independent mechanism (likely IL-13Ra2 related), 
involved in the latter process 302. These finding clearly showed that according to 
the vector-specific IL-13 level, IL-13Ra2/STAT3 performed a dual role at the 
vaccination site (at the lung mucosae), where under low IL-13, IL-13Ra2/STAT3 
lead to TGF-b1 activation, whilst, under high IL-13, the receptor performed a 
sequestration role to maintain homeostasis, similar to inflammatory conditions 
295,296. These observations were further corroborated by other vaccination studies 
where TGF-b1 was linked to enhanced protection associated with CD4+ T cells 
421,422, whilst, early STAT6 signalling was associated with poor vaccine-specific T 
cell outcomes 122,132. Collectively, these observations, indicated that promoting 
low IL-13 production, leading to early enhanced IL-13Ra2/STAT3/TGF-b1 
expression, as opposed to IL-13Ra1/STAT6/IFN-gR by cDCs may be a useful 
strategy when designing effective T cell-based vaccine strategies in the future.  
 
One of the most unexpected findings of this thesis was the elevated expression 
of IL-13Ra2 not only on vaccinated cDCs, but also naïve lung cDCs (even though 
vaccination further up-regulated the expression). Knowing that the lung is 
constantly exposed to air-borne impurities and pathogens, and IL-13 is 
profoundly involved in lung inflammation, taken together these findings 
suggested that elevated IL-13Ra2 expression on lung cDCs could be an inherent 
mechanism by which lung DCs at the first of defence regulate IL-13 mediated 
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lung inflammation. Furthermore, given that IL-13Ra2 is known to play different 
roles in immune protection 295,296 as well as disease (cancer) progression 291, 
current findings suggested that this may occur via how effectively different 
environmental factors regulate cDC/IL-13Ra2. Findings of this thesis also 
advocated the notion that dysregulation of IL-13Ra2/IL-13Ra1 balance leading 
to STAT3/STAT6 malfunction may be the main cause of allergy/asthma, including 
exacerbation of certain IL-13 mediated disease conditions, specifically certain 
cancers.  
 
6.4. Viral vector-specific IL-13Ra2/IFNgR co-expression profiles on lung 
cDCs likely influence vaccine-specific T cell outcomes. 
Chapter 4 studies also revealed that each viral vector-specific IL-13 level can also 
influence the relative expression of IL-13Ra2 and IFN-gR on lung cDCs, 24 h post 
delivery. Interestingly, rFPV vaccination, which induced low ILC2-derived IL-13 
and elevated ILC1/ILC3 derived IFN-g at the lung mucosae, 24 h post delivery, 
was associated with co-expression of enhanced IL-13Ra2 and low IFN-gR on 
lung cDCs (Figure 6.1). In contrast, rMVA, which induced opposing ILC-derived 
IL-13 and IFN-g levels at the lung mucosae, showed elevated IL-13Ra2 
expression and IFN-gR response bias on lung cDCs (Figure 6.1). The moderate 
ILC-derived IL-13 and IFN-g producer, rAd5 vector showed an intermediary IL-
13Ra2/IFN-gR profile to rFPV and rMVA (Figure 6.1). Remarkably, in this study 
the cDC recruitment to the lung mucosae was in the order of rFPV > Ad5 > rMVA. 
Ad5 showed reduced cDC and elevated pDC recruitment to the lung mucosae. 
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Interestingly, cDCs have been associated with high avidity T cell induction 99, and 
pDCs with effective antibody immunity 97,420. Also, recent findings have shown 
that although rAd26 HIV vaccination induced enhanced HIV Env-specific 
antibody and ADCC responses in animal models and Phase 1 trials 232,233,423,424, 
did not induce effective HIV-specific CD8+ T cell immunity. Knowing that i.n. rFPV/ 
i.m. rMVA vaccination can induce both high avidity/poly-functional 
mucosal/systemic CD8+ T cells, ADCC and effective Env-specific antibody 
responses in non-human primates 123 (Li et al. in preparation), taken together the 
findings in this thesis, knowing that rFPV induced cDCs leading to high quality T 
cells 130-132, data suggested that in the future an i.n. rFPV/i.m.rAd26 booster 
strategy may have high potential to induce more effective balanced T and B cell 
vaccine outcomes . Collectively, these findings also propose the notion that the 
IL-13Ra2/IFN-gR co-expression patterns on lung cDCs may also reflect the 
different avidities/qualities of vaccine-specific T cells, following viral vector 
vaccination.  
 
6.5. Viral vectors, IL-13 and DC profiles and how can these factors be 
modulated for better vaccine design.  
Studies in our laboratory have shown that mucosal vaccination induced high 
avidity T cells associated with low IL-13 expression, whilst systemic vaccination 
induced low avidity T cells associated with high IL-13 expression by vaccine-
specific T cells 130-132. Li et al. have also shown that mucosal rFPV vaccination 
induced low ILC2-derived IL-13 compared to systemic vaccination 306. Also, the 
chapter 3 related ILC studies substantiated Li et al.’s findings. Thus, extrapolating 
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the ILC-derived IL-13 and related DC profiles with different viral vectors 24h post 
i.n. delivery (low IL-13 associated with cDC, high IL-13 with cross presenting DC), 
data suggested that intramuscular vaccination which induced high IL-13 in the 
muscle, may have high potential to lead to recruitment of enhanced cross-
presenting DCs, associated with low avidity T cell induction. Interestingly, this 
may explain why for over two decades, systemic HIV vector-based vaccination 
strategies have yielded extremely poor outcomes in HIV Phase I clinical trials 
144,204.  
 
For many years, immune potentiating adjuvants (4-1BBL), chemokines and 
cytokines (IL-2, IL-12, IL-18, type I and III interferons), have been co-expressed 
together with vaccine antigens, to improve vaccine-specific immunity 206-
209,212,213,425-427. Although majority of these vaccines have elicited “enhanced T 
cell immunity, measured by IFN-g production”, have not improved the “quality of 
T cell immunity” in animal models and most have shown poor immune outcomes 
in humans 204,214. In contrast, vaccines antagonizing cytokine signaling at the 
vaccination site (such as IL-4R antagonist, IL-13Ra2), have shown to induce 
higher quality T cell immunity in mice and non-human primates 122-124,131. Why 
sequestration of cytokines yield better quality T cells compared to overexpression 
were recently corroborated by Mahboob et al., where they showed that 
overexpression of cytokines (e.g. IL-13, IFN-g, ) had no impact on the ILC2-
derived IL-13 or ILC1/ILC3-derived IFN-g expression at the vaccination site  
(Mahboob thesis 2016), whilst Li et al. showed that vaccines sequestering IL-25 
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at the vaccination site, which altered ILC activity can differentially modulate ILC2-
derived IL-13 expression 24 h post i.n. or i.m. vaccination 428. Taken together 
these findings indicated that, rather than over-expression of cytokines, 
antagonism (e.g. IL-4R antagonist, IL-13Ra2 and IL-25 binding protein) 122,124,428, 
which alters ILC/DC profiles at the vaccination site could be of more value in the 
context of inducing high quality T cells and protective efficacy against chronic 
viral pathogens. Knowing that IL-6, IL-10 and VEGF can alter DC function with 
respect to STAT3 activity in cancer therapy 429, co-expression of “DC targeted 
molecules” in viral vector-based vaccines, may warrant further investigation. 
 
Unlike HIV-1 infection, in the context of bacterial pathogens such as 
Mycobacterium tuberculosis and Chlamydia trachomatis, CD4+ T cells have been 
associated with host protection 430-436. Studies have shown that cross-presenting 
DCs effectively present bacterial and fungal antigens to CD4+ T cells 437,438. Thus, 
taken together the findings of the current study, a prime-boost vaccination 
approach, using rMVA prime, which induces high ILC2-derived IL-13 and 
elevated cross-presenting DCs followed by a relevant booster (rFPV, rAd or 
protein), have high potential to yield effective antigen-specific CD4+ T cell 
outcomes against these pathogens. In summary, these findings further 
highlighted that understanding the route and vector-specific ILC and DC profiles 
at the vaccination site may help tailor pathogen-specific vaccine design, to yield 
desired protective immune outcomes. 
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In conclusion, this study for the first time demonstrated that the viral vector-
specific ILC2-derived IL-13 at the vaccination site crucially impacted the DC 
subsets recruited to the lung mucosae. The fate of a viral vector-based vaccine 
was determined by how the IL-13-driven IL-13Ra2 on lung cDCs was regulated, 
specifically by STAT3/TGF-b1 or STAT6/IFN-gR, where the former lead to high 
avidity T cell induction unlike the latter. Hence, not only the encoded antigens, 
but also the viral vector-associated IL-13 and DC regulation profiles should be 
carefully taken into consideration when designing viral vector-based vaccines 
against chronic pathogens. Vaccine strategies that can manipulate STAT3 and/or 
STAT6 activity may have high potential to yield exciting and different adaptive 
immune outcomes against different pathogens, in the future. 
 
6.6 Limitations:  
• One of the main limitations of this study was the unavailability of IL-13Ra2 
and STAT3 knock out mice on the BALB/c background, which would have 
helped to confirm the ‘direct relationship’ of IL-13Ra2, STAT3 and TGF-
b1 under low IL-13 conditions. 
• Knowing that viral vector-based vaccination induced much greater ILC2-
derived IL-13 in muscle than lung, a comparative study using i.m. delivery 
of different viral vectors to evaluate lung DC subsets recruited to the 
muscle, 24h post delivery would have added value to the work.  
• Establishing the ‘direct’ cross-talk between ILC2-derived IL-13 and lung 
DCs using ILC2-/- mouse model on BALB/c background would have been 
useful to further confirm findings of the thesis.  
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6.7 Future directions: 
• Designing a database denoting the ILC profiles (e.g. ILC2-derived IL-13, 
ILC1/ILC3-derived IFN-g and IL-17 levels) and DC profiles with expression 
patterns of IL-13Ra2, STAT3, STAT6, TGF-b1, IFN-gR levels, 24h post 
delivery, for commonly used viral vectors as well as adjuvants following 
intranasal and intramuscular vaccination could be a powerful reference 
library/repository, which may help design more effective vector-based 
vaccine strategies, according to the pathogen of interest in the future. This 
may help restrain/prevent the current notion that, when designing vaccines 
“same vector or adjuvant would fit every pathogen”.  
• Knowing that in addition to DCs, macrophages and monocyte-derived DCs 
also polarize Th1 and Th2 immunity, it would be of value to test whether 
these cells have any association with the IL-13 levels at the vaccination 
site, or the observed outcomes are DC-specific. 
• Now, knowing that in the context of viral vaccination DCs play a key role 
in governing the fate of the vaccine, it would be also of interest to further 
unravel other underlying mechanisms, specifically how different lung DCs 
selectively present antigens to activate specific T cell clones to induce 
mucosal homing.  
• Perform pull-down assays to assess whether there are any other receptors 
that complex with IL-13Ra2 to initiate STAT3 signalling or IL-13Ra2 
remodeling post IL-13 binding to initiate signalling.  
• This study demonstrated that following viral vector vaccination, STAT3/ 
STAT6 play an important role in lung cDC regulation. Hence, it would be 
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of interest to characterize how these molecules also regulate cross-
presenting DCs and pDCs following viral vector vaccination.  
• In the future, following viral vector based vaccination, subjecting sorted 
DCs to parallel RNA single cell sequencing (MARS-seq) 439 may also help 
to generate a viral vector-specific genetic signature (find molecules other 
than the observed regulatory elements), which may help design better 
vaccines strategies in the future.  
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